|
Eight International Congress on Drug Therapy in HIV InfectionGlasgow, UK - 12-16 November 2006 |
Cite as: Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P40
| Plenary Sessions |
|
| KL1 - Keynote Lectures (Past, Present and Future) |
|
| KL1 | [KL1] WHERE DID IT ALL BEGIN? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. KL1 Paul M Sharp The numbers of examples of SIVcpz and SIVsmm characterized have been extremely limited. To learn more about these viruses, and the origins of HIV-1 and HIV-2, non-invasive techniques have been developed and used to greatly increase the number of strains sampled from wild populations of sooty mangabeys and chimpanzees. We have found the closest SIVsmm relatives of the two epidemic forms of HIV-2 in Cote dIvoire. The closest SIVcpz relatives of HIV-1 infect one particular subspecies of chimpanzees, Pan troglodytes troglodytes, in West Central Africa. We have now found widespread endemic infection in these apes, with SIVcpz prevalence rates over 20% in some communities. SIVcpz strains exhibit a local phylogeographic clustering, allowing us to trace the origins of pandemic (group M) and non-pandemic (group N) HIV-1 to distinct, geographically isolated chimpanzee communities in southern Cameroon. Thus, 25 years into the AIDS epidemic, the origins of this newly emerged disease have been elucidated. |
| KL2 | [KL2] WHERE ARE WE WITH ART IN 2006? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. KL2 Roy M Gulick Other areas of active investigation offer promise in relation to newer diagnostic tests, newer treatment strategies and a number of investigational antiretroviral agents, including HIV integrase inhibitors and HIV maturation/gag processing inhibitors. Acknowledging our substantial progress with ART to date, additional gains may be anticipated. |
| KL3 | [KL3] WHERE ARE WE GOING WITH HIV PREVENTION, TREATMENT AND CARE AT A GLOBAL LEVEL? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. KL3 Kevin M De Cock As increased numbers of people access treatment, resource requirements for HIV/AIDS will also increase, highlighting the need for effective prevention and innovative financing methods. How HIV/AIDS will fare in global prioritization in the coming decade will depend on epidemiologic trends as well as programmatic performance, in a complex world with other emerging threats. |
| PL1 - Treatment Strategies |
|
| PL1.1 | [PL1.1] CLINICAL USE OF VARIOUS HIV TREATMENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL1 Manuel Battegay Potent antiretroviral therapy (ART) has dramatically and increasingly reduced long-term morbidity and mortality since the mid-1990s. With the advent of many new drugs in recent years, multiple options have become available for initiating ART. Regimen design considerations include efficacy, durability, tolerability and long-term adverse effects, convenience, and drug-interactions, as well as the potential for salvaging the initial regimen (IAS USA and DHHS guidelines). |
| PL1.2 | [PL1.2] Antiretroviral therapy for prevention of transmission of HIV-1 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL1.2 Myron S Cohen Substantial limitations for ART for prevention include the treatment of the right people at the right time(s), viral resistance, and the potential inspiration of risky sexual behavior. |
| PL1.3 | [PL1.3] New treatment paradigms for experienced patients Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL1.3 David Cooper Abstract not available. |
| PL1.4 | [PL1.4] Antiretroviral treatment strategies for the next decade Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL1.4 Mark Harrington Abstract not available. |
| PL2 - Open Papers |
|
| PL2.1 | [PL2.1] HIV-associated renal disease Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.1 John Connolly HIV is associated with a wide spectrum of renal disease. Viral infection gives rise to a collapsing glomerulopathy (HIVAN) in susceptible patients which may be responsive to antiretroviral therapy (ART). HIV is also associated with a variety of immune complex glomerular diseases in which the role of ART is less clear. |
| PL2.2 | [PL2.2] Susceptibility of a protease inhibitor (PI) treatment-experienced UK clinical cohort to TMC-114 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.2 C Loveday, E MacRae, on behalf of the ICVC Clinical Collaborative Research Group In this PI treatment-experienced clinical cohort, the majority had very low frequency of TMC-114 related mutations. Only 10 patients had ≥10 PR mutations with 2 patients including 4 HI mutations. Based on these data TMC-114 should be of benefit to PI treatment-experienced patients in a UK clinical cohort. |
| PL2.3 | [PL2.3] INDUCTION-MAINTENANCE ANTIRETROVIRAL THERAPY WITH TRIZIVIR PLUS EITHER EFAVIRENZ OR LOPINAVIR/R: RESULTS OF A MULTICENTRE RANDOMIZED CLINICAL TRIAL AT 72 WEEKS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.3 J Mallolas, M Penaranda, P Domingo, H Knobel, E Pedrol, F Gutierrez, P Barrufet, J Peraire, D Dalmau, E Ribera, A Ocampo, MA Muniain, C Alonso, V Estrada, JR Blanco, J Cucurull, J Pich, E De Lazzari, A Leon ARV-naïve patients undergoing induction with TZV + EFV or LPV/r followed by maintenance with TZV achieved adequate immunological and virological response at W72. The study shows a trend to an increased VF in EFV arm. |
| PL2.4 | [PL2.4] WIDE DISPARITY IN SWITCH TO SECOND-LINE THERAPY IN HIV-INFECTED CHILDREN IN CHIPS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.2 K J Lee, H Lyall, A S Walker, M Sharland, A Judd, D M Gibb CD4 and VL, and timing of switch in relation to different VL thresholds vary widely in children across all ages. There is urgent need for evidence on which to base switching. |
| PL2.5 | [PL2.5] Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD in ARV-naïve HIV-1 infected patients: GEMINI Study Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.5 J. Slim, A. Avihingsanon, K. Ruxrungtham, M. Schutz, S. Walmsley At Wk 24, SQV/r appears comparable to LPV/r in terms of efficacy and tolerability. Non-inferiority of the regimen and lipid differences will be evaluated in the final 48-wk analysis. |
| PL3 - New Challenges in Providing ART [IAS Session] |
|
| PL3.1 | [PL3.1] NEW CHALLENGES OF PROVIDING HAART: LESSONS FROM THE FRONTLINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.1 Elly T Katabira Providing ART in resource-limited settings requires a dedicated and robust team of health professionals, administrators and community leaders. Team members should be flexible and highly innovative. They should be able to work with their patients more closely and support each other at all times in order to realise the rewards of ART that have been seen in the developed world. |
| PL3.2 | [PL3.2] HOW EFFECTIVE IS THE 'WHO MONITORING SYSTEM' FOR PATIENTS ON ANTIRETROVIRAL TREATMENT? LESSONS LEARNT DURING THE ROLL-OUT OF ANTIRETROVIRALS IN THE WESTERN CAPE PROVINCE, SOUTH AFRICA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.2 Peter Bock, Andrew Boulle, Meg Osler Patient retention and viral load suppression rates are highly comparable with data from other studies; indicating the feasibility of an antiretroviral program in the public health sector in South Africa. The monitoring system had proved effective; however experience in the field has shown that improvements to its design and implementation need to be made. |
| PL3.3 | [PL3.3] GLOBAL RESISTANCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.3 Luis Soto-Ramirez The availability of HAART that suppresses replication of HIV-1, has dramatically improved the prognosis of HIV-infected patients. Unfortunately, HAART does not durably suppress HIV replication in 20 to more than 50% of treatment-naïve patients and in up to 50-70% of treatment-experienced patients. |
| PL3.4 | [PL3.4] HIV-1 SUBTYPE C VIRUSES RAPIDLY DEVELOP K65R RESISTANCE AGAINST ddI AND TENOFOVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.4 Mark A Wainberg, Florence Doualla-Bell, Tendani Gaolathe, Madisa Mine, Max Essex, Bluma Brenner K65R may emerge at higher frequency in individuals infected with subtype C viruses who experience treatment with certain NRTIs, establishing the need to monitor for the presence of this mutation and its possible transmission. |
| PL3.5 | [PL3.5] THE NEED FOR PHARMACOVIGILANCE IN THE RESOURCE-LIMITED SETTING: AN INDUSTRY PERSPECTIVE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.5 Didier Lapierre Traditionally clinical research has been mainly performed in the “Western World” where medical infrastructures are available. Drug development in resource poor setting was limited by lack of capacities but also by ethical and access challenges. Globalisation of the R&D is a new reality firstly to fulfil the unmet medical needs of 80% of the world population and of the HIV patients in particular but it is also attractive from a drug development point of view. |
| PL3.6 | [PL3.6] NEW CHALLENGES IN ART ROLL-OUT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.6 Charles Gilks The main donors are all committed to (as close as possible) universal access to ART by 2010. To come close to this noble goal, major challenges and constraints will have to be identified and overcome:... |
| PL4 - Clinical Pharmacology and Resistance |
|
| PL4.1 | [PL4.1] ANTIRETROVIRAL THERAPY AND PHAMACOGENOMICS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL4.1 David Haas Pharmacogenomics also holds promises to suggest novel targets for drug development. This is highlighted by the discovery that a non-functional variant of the HIV receptor gene CCR5 protected against HIV infection, prompting development of therapeutic CCR5 antagonists. |
| PL4.2 | [PL4.2] THE PLACE FOR THERAPEUTIC DRUG MONITORING Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL4.2 Marta Boffito The potential for undesirable drug interactions is the main reason for interest in therapeutic drug monitoring (TDM): important drug interactions may occur among antiretrovirals (ARVs) belonging to the same or to different classes or between ARVs and drugs received by HIV patients for the treatment of co-existing medical conditions, the treatment and prevention of opportunistic infections, for supportive care or for the management of adverse events caused by ARVs. |
| PL4.3 | [PL4.3] THE PLACE OF DRUG RESISTANCE TESTING IN THE CLINICAL MANAGEMENT OF HIV Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL4.3 Annemarie Wensing In most European countries, drug resistance testing has become part of routine clinical management of HIV infection, particularly at the time of antiretroviral therapy failure. Genotypic testing is performed most frequently because of its relatively low cost, technical convenience and virological benefit shown in clinical trials. |
| PL4.4 | [PL4.4] DRUG RESISTANCE TESTING AND THERAPEUTIC DRUG MONITORING IN HIV-1 INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL4.4 Daniel R Kuritzkes Drug resistance testing has become an essential tool for the management of antiretroviral therapy. Increasing rates of transmission of drug-resistant virus in the United States and cost-effectives analyses support the use of drug resistance testing as an essential part of initial patient evaluation, prior to starting antiretroviral therapy. |
| PL5 - Oral Papers |
|
| PL5.1 | [PL5.1] USE OF TMC114 IN COMBINATION WITH OTHER DRUGS: GUIDANCE FROM PHARMACOKINETIC STUDIES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.1 D Back, V Sekar, E Lefebvre, M De Pauw, E De Paepe, T Vangeneugden, R Hoetelmans TMC114/r can be combined with many drugs with no TMC114/r dose adjustments. Some co-administered drugs may require dose adjustments (SIL, AVS, KTZ and IDV). Combining TMC114/r with LPV/r or SQV/r is not recommended. Additional contraception should be used when OC are combined with TMC114/r. Current evidence shows that DIs between TMC114/r and drugs commonly used in HIV-infected patients are well characterised and manageable. |
| PL5.2 | [PL5.2] TMC125 IN COMBINATION WITH OTHER MEDICATIONS: SUMMARY OF DRUG-DRUG INTERACTION STUDIES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.2 Thomas N Kakuda, Monika Schöller-Gyüre, Brian Woodfall, Goedele De Smedt, Monika Peeters, Kati Vandermeulen, Richard M Hoetelmans TMC125 can be combined with most of the drugs studied without dosage adjustment. Dose adjustments may be required for FPV and SIL. It is not recommended to combine TMC125 with TPV/rtv. Drug interactions between TMC125 and medications commonly used in HIV therapy are well characterized and manageable. |
| PL5.3 | [PL5.3] INVOLVEMENT OF URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE POLYMORPHISMS (UGT) IN ATAZANAVIR TOXICITY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.3 Ulrike Moebius, T O Lankisch, M Wehmeier, G M Behrens, M P Manns, R E Schmidt, C P Strassburg GD-associated jaundice in ATV-treated patients is a phenotype associated with a novel UGT1A gene haplotype encompassing four genetic variants with altered glucuronidation activity of the affected genes. In normal individuals these variants do not occur in linkage dysequilibrium. The detection of variants at the UGT1A gene locus is a potentially powerful pharmacogenetic tool contributing to prediction and identification of drug-associated toxicity and disease susceptibility. |
| PL5.4 | [PL5.4] THE ASSESSMENT OF MULTI-LOCUS GENE EFFECTS UPON LOPINAVIR PHARMACOKINETICS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.4 A Owen, T Mahungu, C Cook, M Youle, M Johnson, D Back, S Khoo These data are preliminary but suggest that cumulative scoring algorithms can be developed to assess multi-locus genetic effects influencing LPV pharmacokinetics. |
| PL5.5 | [PL5.5] DECLINING INCIDENCE OF MULTIDRUG-RESISTANT HIV-1 OVER TIME (2001-2006): WHICH NEW DRUGS DO WE REALLY NEED? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.5 J Vercauteren, K Theys, M Debruyne, A P Carvalho, A M Vandamme, R Camacho The incidence of MDR is decreasing over time in Portugal, reflecting the increasing efficiency of HAART. We anticipate that, in a near future, activity against resistant viruses will not be the primary target for the design of new drugs. Better tolerability, ease of use or less toxicity may instead be favored. |
| PL5.6 | [PL5.6] IMPACT OF NNRTI AND NRTI RESISTANCE ON THE RESPONSE TO THE REGIMEN OF TMC125 PLUS TWO NRTIS IN STUDY TMC125-C227 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.6 B Woodfall, J Vingerhoets, M Peeters, I Peeters, G De Smedt, GD Miralles, M.P. de Béthune In this study, in PI-naïve patients having failed a first-line NNRTI regimen, the level of NNRTI and NRTI resistance was higher than expected. Since patients were PI naïve, these higher levels of baseline resistance probably account for the difference in outcome between the TMC125 and PI arms. Given the demonstrated long-term virological benefit of TMC125 in patients with NNRTI and PI resistance, evaluation of TMC125 in NNRTI and PI experienced patients continues in ongoing Phase III trials. |
| PL6 - HIV-related Infections, Co-infections and Malignancies I |
|
| PL6.1 | [PL6.1] NEW TREATMENTS IN HEPATITIS C AND B CO-INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL6.1 Jürgen Rockstroh HIV has been shown to accelerate the progression of hepatitis C and B, and to result in higher liver disease related mortality and morbidity, thereby clearly underlining the importance of treating HIV patients for underlying hepatitis. A number of important clinical studies were able to show that the introduction of pegylated interferon plus ribavirin combination therapy has significantly improved treatment outcome and that sustained virological response rates (SVR) over 40% in HIV/HCV co-infected individuals seem achievable. |
| PL6.2 | [PL6.2] INFLUENCE OF THE STAGE OF LIVER FIBROSIS ON PLASMA LEVELS OF ANTIRETROVIRAL DRUGS IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL6.2 C Pablo Barreiro, Sonia Rodriguez-Novoa, Pablo Labarga, Andres Ruiz-Sancho, Carol Castellares, Marina Nuñez, Inmaculada Jimenez-Nacher, Luz Martin-Carbonero, Juan Gonzalez-Lahoz, Vincent Soriano Liver clearance of NNRTI, particularly of EFV, seems to be impaired in cirrhotics, what translates into higher plasma drug levels. These patients might benefit from therapeutic drug monitoring to avoid drug overexposure. No similar effect was seen for PI. LF assessment by non-invasive tools may identify HCV/HIV patients that warrant antiretroviral dose adjustments in order to minimize toxicities. |
| PL6.3 | [PL6.3] ORGAN TRANSPLANTATION IN HIV-INFECTED PATIENTS – MANAGEMENT AND OUTCOME EXPERIENCES FROM EUROPE AND NORTH AMERICA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL6.3 José M Miró With the recent advent of highly active antiretroviral therapy (HAART), those patients infected with HIV are now living longer and dying from illnesses other than acquired immunodeficiency syndrome (AIDS). Liver disease due to chronic hepatitis B and C is now a leading cause of mortality among HIV-infected patients in the developed world. |
| PL6.4 | [PL6.4] THE MANAGEMENT OF TB IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL6.4 Stephen D Lawn The management of tuberculosis (TB) in HIV-infected patients remains a clinical challenge, especially for those working in resource-limited settings with high TB incidence. In this talk, the burden of TB among patients accessing antiretroviral treatment (ART) in both high-income and resource-limited settings will be described, and the long-term impact of treatment on risk of TB will be reviewed. |
| PL7 - HIV-related Infections, Co-infections and Malignancies II |
|
| PL7.1 | [PL7.1] HUMAN PAPILLOMAVIRUS INFECTION – WHERE ARE WE? HPV VACCINATION LAUNCHES PROMOTION OF SEXUAL HEALTH IN POPULATION-BASED COHORTS OF THE YOUNG Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL7.1 Matti Lehtinen The most effective way of controlling common sexually transmitted diseases (STD) is inclusion of efficacious preventive measures into national vaccination/screening programmes directed to the young in a coordinated and evaluable, i.e., randomized manner. Our trial is a proof of principle on how population-based cohorts and biobanks can provide new knowledge on implementation and evaluation of these programmes. Improved understanding from molecular epidemiology of the common STDs to cost-effectiveness of the interventions against the common STDs is gained, and propects for eradication of both the infectious causes and the diseases are evaluated. |
| PL7.2 | [PL7.2] THE RISK OF NON-AIDS DEFINING MALIGNANCIES IN THE ERA OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL7.2 Alexandra M Levine The use of highly active anti-retroviral therapy (HAART) has resulted in a dramatic decrease in AIDS-defining Kaposi’s sarcoma and non-Hodgkin’s lymphoma, while its impact has been less clear for invasive cervical cancer. Nonetheless, the incidence of several additional cancers, the non-AIDS defining cancers, has also increased statistically in Human Immunodeficiency Virus (HIV) infected individuals. |
| PL7.3 | [PL7.3] IMPACT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON THE OUTCOME OF HIV-ASSOCIATED NON-HODGKIN LYMPHOMA AND HODGKIN’S DISEASE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL7.3 M Simcock, M Blasko, U Karrer, M Pless, P Tarr, B Hirschel, H Furrer, M Rickenbach, H Guenthard, P Sendi, E Bernasconi, P Vernazza, M Battegay, The Swiss HIV Cohort Study HAART increased OS by 22 months in HIV-related NHL and HD, with increased PFS also. Use of CHOP chemotherapy greatly reduces the risk of lymphoma progression and ultimately death. |
| PL8 - HIV-related Infections, Co-infections and Malignancies II |
|
| PL8.1 | [PL8.1] TREATMENT INTERRUPTIONS: WHERE ARE WE? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL8.1 Bernard Hirschel In conclusion, SMART’s results imply that STIs will always be associated with a slightly increased risk of AIDS-defining events and death. It stands to reason, however, that the shorter the STI, and the higher the CD4 count, the lower the excess risk. At some point, the cost of continuing treatment at high CD4 counts counterbalances the increased risk of interrupting it. Where is that point? Economical, political and psychological, rather than medical arguments will decide. |
| PL8.2 | [PL8.2] ACCEPTABILITY OF A STRUCTURED TREATMENT INTERRUPTION (STI) STRATEGY OF 12 WEEK CYCLES ON AND OFF ART IN PATIENTS IN THE DART TRIAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL8.2 D Tumukunde, G Lillian, S Mutsai, R Nalumenya, J Komunyena, D Nsibambi, M Machingura, A Burke, on behalf of the DART Trial Team Although the STI strategy in DART was associated with a 2.6-fold increase in disease progression compared to CT, the absolute rate was low with the majority (92%) able to take ART intermittently without developing WHO 4 events. Around 40% of patients reported problems with STI: but a sizeable minority (around 30%) perceived fixed cycle STIs as having some advantages. Identification of predictors of poor response to STI and strategies with lower risks remains important. |
| PL8.3 | [PL8.3] ARE TREATMENT INTERRUPTIONS ASSOCIATED WITH HIGHER VIRAL REBOUND RATES IN PATIENTS WITH VIRAL SUPPRESSION? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL8.3 L K Bansi, A A Benzie, C A Sabin, A N Phillips Previous episodes of treatment interruptions do not appear to be associated with viral rebound. Analyses are underway to determine whether the type of regimen interrupted and restarted has impact on viral rebound. |
| PL8.4 | [PL8.4] NEW PARADIGMS OF CARE: CUTTING CORNERS AND MAINTAINING STANDARDS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL8.4 Paul Benn The re-evaluation of existing roles of health care providers within HIV services, including developing extended roles and non-medical prescribing, has been key. In addition, the successful implementation of several service innovations, including telephone consultations and e-mail communication, has afforded individuals more choice and have proven to be effective without compromising quality of care. |
| PL9 - Adverse Events I |
|
| PL9.1 | [PL9.1] DRUG HYPERSENSITIVITY IN THE SETTING OF HIV: PATHOGENESIS AND MANAGEMENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.1 Simon Mallal Abstract not available. |
| PL9.2 | [PL9.2] HLA-B5701 TESTING AND ABACAVIR HYPERSENSITIVITY: A SINGLE CENTRE EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.2 Laura Waters, Andrea Gritz, Desmond Maitland, Mark Nelson Prospective HLA-B5701 testing has proven to be useful in reducing the rate of ABC discontinuation secondary to suspected HSR; historically approximately 7% have discontinued therapy for possible HSR reduced to 1.8% since the introduction of prospective HLA testing. Our results highlight the necessity for maintaining clinical suspicion despite negative HLA testing. |
| PL9.3 | [PL9.3] SEXUAL DISSATISFACTION IN ASSOCIATION WITH COMBINATION ANTIVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.3 Bob Colebunders Sexual dissatisfaction (SD), especially loss of libido, is present in a very high number of men and women with HIV infection. HIV-discrimination and disturbing adverse events such as lipodystrophy due to HIV-treatment have been reported to be associated with SD. |
| PL9.4 | [PL9.4] Predict, avoid and manage side-effects and adverse events of ART: the needs of people living with HIV/AIDS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.4 Luis Mendao Treatments for HIV/AIDS continue to have a prevalence of associated adverse events (AE) and side-effects (SE) that negatively impact on the adherence, quality of life of patients and health of affected people. We need to improve the reporting, knowledge and spread of information to doctors and patients using a range of processes. |
| PL9.5 | [PL9.5] Relationship between use of stavudine and diabetes mellitus Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.5 S De Wit, CA Sabin, R Weber, SW Worm, P Reiss, R Thiebaut, W El-Sadr, A D'Arminio Monforte, E Fontas, MG Law, AN Phillips, N Friis-Moeller, JD Lundgren Stavudine is significantly associated with DM after adjustment for risk factors for DM and lipids. Adjustment for lipodystrophy did not modify the relationship, suggesting that stavudine potentially directly contributes to insulin resistance, rather than through lipodystrophy. |
| PL9.6 | [PL9.6] MITOCHONDRIAL DNA (mtDNA) DEPLETION IS PRESENT IN OOCYTES OF HIV-INFECTED ANTIRETROVIRAL-TREATED INFERTILE WOMEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.6 G Garrabou, O Coll, M Durban, S Lopez, R Vidal, A Suy, S Hernandez, F Cardellach, D Mataro, O Miro Oocytes of infertile HIV-infected ARV-treated women show decreased mtDNA and this could explain their poor reproductive outcome. |
| PL10 - Paediatric Infection |
|
| PL10.1 | [PL10.1] HIV+ teenagers: transfer to adult clinics Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL10.1 Alexandra Peltier Early disclosure (if possible before puberty), support groups and specific counseling should be offered to teenagers. Training and reference centers should supervise and study more deeply special needs for an effective transition between pediatric and adult clinics and between teenage and adult life in order to avoid failure to treatment and loss for follow up. |
| PL10.2 | [PL10.2] FORMULATION, DOSING AND ART STRATEGIES FOR CHILDREN WITH HIV INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL10.2 Diana Gibb Effective prevention of mother-to-child HIV transmission, including testing, perinatal ARV prophylaxis, and safe alternatives to breastfeeding, have resulted in few births of vertically HIV-infected babies in well-resourced countries since 2000. Thus, in Europe and US, paediatric HIV-infected cohorts are older children entering adolescence who have either received previous mono and dual ART prior to HAART, or are newly diagnosed having recently moved to live in these countries. |
| PL12 - Adverse Events II |
|
| PL12.1 | [PL12.1] REDUCING CARDIOVASCULAR RISK IN THE SETTING OF HIV INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL12.1 Judith Currier Data from observational studies suggest that HIV infection, and to some extent HIV treatments, may contribute to increasing cardiovascular risk. Although the specific contributions of traditional risk factors and HIV therapy to cardiovascular risk remain incompletely defined, it is critical that providers determine the optimal means to reduce long-term cardiovascular risk in this population. |
| PL12.2 | [PL12.2] EFFECT OF INTERVENTIONS TO IMPROVE DYSLIPIDAEMIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL12.2 M vd Valk, N Friis-Møller, C Sabin, F Dabis, A D'Arminio Monforte, R Weber, S Worm, W El-Sadr, S de Wit, C Pradier, O Kirk, M Law, A Philips, J Lundgren, P Reiss At 1 year, reductions in TC, LDL, TG and TC/HDL were significant for both the LLT and SWITCH groups, whereas a significant HDL rise was only seen in those switching. The effect of the interventions on TC/HDL ratio was similar. Changes were also observed in controls, suggesting some regression to the mean effect, or possible selection of those in whom intervention was withheld in view of declining lipid values. |
| PL12.3 | [PL12.3] THE MANAGEMENT OF LIPOATROPHY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL12.3 Jussi Sutinen For any patient with signs of LA, a thymidine analogue (stavudine, zidovudine) should be replaced either by abacavir or tenofovir if the switch is considered virologically safe. Switching away from a protease inhibitor does not correct LA. |
| PL13- Hot Topics and Late Breakers |
|
| PL13.1 | [PL13.1] THE PRESCO TRIAL: ROLE OF EXTENDED DURATION OF THERAPY WITH PEGYLATED INTERFERON ALFA-2A PLUS WEIGHT-BASED RIBAVIRIN DOSE IN 389 HCV/HIV CO-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL13.1 Marina Nuñez, Celia Miralles, Miguel A Berdún, Elena Losada, Koldo Aguirrebengoa, Antonio Ocampo, Piedad Arazo, Manuel Cervantes, Ignacio de los Santos, Isabel San Joaquín, Santiago Echeverria, María J Galindo, Victor Asensi, Pablo Barreiro, Julio Sola, Juan J Hernandez-Burruezo, Josep M Guardiola, Vincent Soriano, on behalf of the PRESCO Study Group PRESCO is the largest trial conducted so far in coinfected patients using pegIFN plus RBV. The use of 1000-1200 mg/day of RBV was relatviely safe and provided SVR in nearly half of HCV/HIV-coinfected patients, twice higher in HCV-2/3 than HCV-1/4 carriers. Both the use of higher RBV doses and extended duration of therapy most likely explained the better responses in this study compared to prior trials conducted in coinfected patients. |
| PL13.2 | [PL13.2] PREDICTORS OF CREATININE (CR) INCREASE AND DRUG DISCONTINUATION IN PATIENTS RECEIVING TENOFOVIR DF (TDF) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL13.2 M Harris, R Joy, N Zalunardo, R Werb, B Yip, R Hogg, J Montaner Among patients taking TDF, Cr elevation and TDF discontinuation are associated with concomitant use of ddI (but not boosted PIs), and with lower CD4, as previously shown. |
| PL13.3 | [PL13.3] IMPACT OF A LOPINAVIR/RITONAVIR (LPV/r) MONOTHERAPY ON SELF-REPORTED SIDE EFFECTS AND GLOBAL HEALTH PERCEPTION AMONG ANTIRETROVIRAL-NAÏVE PATIENTS: 48-WEEK ANALYSIS OF THE MONARK TRIAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL13.3 B Spire, F Marcellin, I Cohen Codar, B Knysz, C Lascoux, M A Valantin, M Norton, P NgoVan, J F Delfraissy Patients’ quality of life, estimated by the number of self-reported side effects and perception of global health was better with LPV/r monotherapy when compared with a triple regimen of LPV/r+AZT/3TC. Further exploration of LPV/r monotherapy is warranted. |
| PL13.4 | [PL13.4] EFFICACY AND SAFETY OF TWO DOSES OF TIPRANAVIR/RITONAVIR VERSUS LOPINAVIR/RITONAVIR-BASED THERAPY IN ANTIRETROVIRAL-NAÏVE PATIENTS: RESULTS OF BI 1182.33 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL13.4 D Cooper, R Zajdenverg, K Ruxrungtham, R L Chavez The TPV-200 arm was closed due to higher rate of G3/4 ALT elevations. While non-inferiority was achieved with data collected up to Week 48 in all arms, TPV-100 was no longer non-inferior using Week 60 data from all patients due to a higher discontinuation rate based on a less favourable tolerability profile. |
| Posters |
|
| Treatment Strategies - Naïve |
|
| P1 | [P1] ONCE-DAILY BOOSTED FOSAMPRENAVIR (FPV/r) OR ATAZANAVIR (ATV/r) WITH TENOFOVIR (TDF)/EMTRICITABINE (FTC) IN ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS: 24-WEEK RESULTS FROM COL103952 (ALERT) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P1 K Smith, W Weinberg, E DeJesus, M Fischl, Q Liao, L Ross, K Pappa, T Lancaster Both regimens studied demonstrated a high rate of virologic suppression with similar lipids through 24 wks. |
| P2 | [P2] EFFICACY AND SAFETY OF ONCE-DAILY BOOSTED FOSAMPRENAVIR/RITONAVIR (FPV/r) WITH ABACAVIR (ABC)/LAMIVUDINE (3TC) FIXED DOSE COMBINATION IN ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS: 24-WEEK RESULTS FROM COL100758 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P2 C Hicks, E DeJesus, L Sloan, M Sension, D Wohl, Q Liao, I Gray, T Lancaster Data suggest a high rate of virologic suppression through 24 wks for FPV/r 1400mg/100mg QD. These results should be interpreted with caution until full data through 48 wks are available. |
| P3 | [P3] DOES GENDER OR ETHNICITY INFLUENCE TREATMENT OUTCOMES IN ANTIRETROVIRAL NAÏVE PATIENTS COMMENCING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) BASED HAART? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P3 NT Annan, S Mandalia, M Bower, BG Gazzard, MR Nelson We have shown in a large NNRTI-experienced cohort that although in the univariate analysis females commencing HAART containing NVP are more likely than males to achieve VS, this association was not reproduced in the multivariable model. We found no association between ethnicity and either VS or TF. |
| P4 | [P4] EFAVIRENZ (EFV) VS. LOPINAVIT/RITONAVIR (LPV/R)-BASED COMBINED ANTIRETROVIRAL THERAPY IN ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS FROM THE SPANISH VACH COHORT: THE SUSKA STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P4 Pere Domingo, Ramon Teira, Ignacio Suarez-Lozano, Jose Lopez-Aldeguer, Enric Pedrol Our study suggests that EFV-based cART has a longer durability than a LPV/r-based regime in naïve HIV and VHC co-infected patients. |
| P5 | [P5] LONG-TERM FOLLOW-UP OF IMANI I: PILOT STUDY OF THE SAFETY AND EFFICACY OF LOPINAVIR/RITONAVIR (LPV/R) AS SINGLE AGENT THERAPY (SAT) IN HIV-1 ANTIRETROVIRAL (ARV)-NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P5 Joseph C Gathe, Jr., Carl Mayberry, Bernie Miguel, John Nemecek Follow-up of IMANI I, the longest followed cohort of ARV-naïve pts. on SAT therapy, reveal: 17/18 pts. on SAT had VL <50 at last evaluable time point, no genotypic/phenotypic resistance in any subject at any time point, intensified pts. (n=2) both remained virologically suppressed VL<50, one failing pt. was due to lack of LPV/r access, no significant toxicity was seen/no lipid lowering agents were prescribed, and continued success with switch to LPV/r tablets. These promising long-term results strongly support larger study of LPV/r as an option to triple therapy HAART in ARV-naïve pts. |
| P6 | [P6] EFFICACY AND SAFETY OF TENOFOVIR DF (TDF), EMTRICITABINE (FTC) AND EFAVIRENZ (EFV) COMPARED TO FIXED DOSE ZIDOVUDINE/LAMIVUDINE (CBV) AND EFV THROUGH 96 WEEKS IN ANTIRETROVIRAL TREATMENT-NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P6 A Pozniak, J Gallant, E DeJesus, J Arribas, B Gazzard, D McColl, J Enejosa, A Cheng Through Wk 96, significantly more pts on TDF+FTC+EFV achieved HIV RNA<400 c/mL and had higher CD4 cell increase from baseline. More pts in CBV arm discontinued study regimen due to adverse events. Limb fat was significantly higher in TDF+FTC arm. |
| P7 | [P7] SIMILAR ANTIVIRAL EFFICACY AND TOLERABILITY BETWEEN EFAVIRENZ AND LOPINAVIR/RITONAVIR, ADMINISTERED WITH ABACAVIR/LAMIVUDINE (KIVEXA), IN NAÏVE PATIENTS: A MULTICENTRE, RANDOMIZED STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P7 Patricia Echeverria, Giampiero Carosi, Juan Galves, Isabel Bravo, Raquel Lopez, Bonaventura Clotet EFV demonstrated comparable antiviral efficacy and safety to LPV/r over 24 wk administered with ABC/3TC (Kivexa). Hypersensitivity reaction was higher in EFV-group, probably due to the ABV and EFV combination. |
| P8 | [P8] STUDY OF THE EVOLUTION AND SURVIVAL RATE OF A COHORT (COHORT OMEGA) OF PATIENTS WITH A LATE STAGE OF HIV INFECTION. EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY (4 YEARS LATER) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P8 Rosario Palacios, Mercedes Gonzalez, Josefa Ruiz, Manuel Marquez In spite of the advanced stage of HIV infection at diagnosis, the outcome of this cohort is very good and the long-term survival is high. Mortality mainly occurs in the first months. The immunovirologic response is very good, with few new opportunistic events, few adverse events and few virologic failure. |
| P9 | [P9] SIMILAR VIROLOGIC AND IMMUNOLOGIC RESPONSE TO EFAVIRENZ OR LOPINAVIR/RITONAVIR-BASED HAART IN A LARGE COHORT OF ANTIRETROVIRAL-NAÏVE PATIENTS WITH ADVANCED HIV INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P9 F Pulido, J Arribas, S Moreno, J Gatell, B Vendrell, O Serrano After adjusting for differences in BL characteristics in this retrospective cohort study, EFV showed similar efficacy to LPV/r in Tx naïve severely immunodepressed Pts with less D/C due to intolerance. |
| P10 | [P10] ONCE-DAILY (QD) ABACAVIR (ABC)/LAMIVUDINE (3TC) AND RITONAVIR-BOOSTED ATAZANAVIR (ATV/R) IN ANTIRETROVIRAL NAÏVE HIV-1 INFECTED SUBJECTS: 24-WEEK ANALYSIS FROM COL102060 (SHARE) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P10 R Elion, E DeJesus, M Sension, D Berger, W Towner, G Richmond, L Yau, B Ha A high rate of virologic suppression was observed through 24 weeks. The development of hypertriglyceridemia was observed possibly due to ritonavir-boosting. |
| P11 | [P11] EFFECTIVENESS OF DIDANOSINE, LAMIVUDINE, EFAVIRENZ AND ZIDOVUDINE, LAMIVUDINA, EFAVIRENZ IN NAIVE HIV-INFECTED PATIENTS FROM THE SPANISH VACH COHORT (QUOVIDES STUDY) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P11 Ignacio Suarez-Lozano, Esteban Ribera Our data suggest that, in real clinical practice, ddI and 3TC, as a backbone in Efavirenz based cART, has the same durability than the recommended backbone of ZDV and 3TC in HIV-infected and in HCV co-infected naïve patients. |
| P12 | [P12] RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN NAÏVE PATIENTS: THE NEWCASTLE EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P12 B Payne, J Matthew, A Foster, D Burns, A Tromans, D Price, M Schmid, M Snow, E Ong Our study confirms the potency and tolerability of HAART, particularly NNRTI based regimes, for antiretroviral naïve patients. Excellent virological suppression, comparable with clinical trial outcomes, is achievable in the clinic setting. |
| P13 | [P13] SUSTAINED VIROLOGIC AND IMMUNOLOGIC RESPONSE OVER 180 WEEKS IN ANTIRETROVIRAL THERAPY (ART)-NAÏVE SUBJECTS RECEIVING FOSAMPRENAVIR/RITONAVIR (FPV/R) QD Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P13 N Bellos, N Clumeck, G Bleiber, S Tomkins, F Xu, H Garges Long-term treatment with FPV/r QD in ART-naïve subjects resulted in sustained virologic suppression, continued immunologic improvement, few subjects with new drug-related AEs and rare development of resistance. |
| P14 | [P14] COST-EFFECTIVENESS ANALYSIS OF TENOFOVIR/EMTRICITABINE AND ABACAVIR/LAMIVUDINE IN THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P14 John Borrill, Ruairi A O'Donnell, Claudio Avila, Francois Everhard, Michelle E Orme TDF/FTC is cost-effective compared to CBV and offers more convenient dosing. ABC/3TC is unlikely to be cost-effective versus CBV given that it was not shown to be more efficacious than CBV. |
| P15 | [P15] COMPARISON OF SINGLE AND BOOSTED-PROTEASE-INHIBITOR (PI) VERSUS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING REGIMENS IN PREVIOUSLY ANTIRETROVIRAL NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P15 A Mocroft, O Kirk, A Horban, N Clumeck, H J Stellbrink, A d'Arminio Monforte, K Zilmer, J Gatell, A N Phillips, J D Lundgren, the EuroSIDA study group Compared to patients starting a NNRTI regimen, patients starting a single-PI regimen were less likely to be virologically suppressed at 3 years after starting cART. These results from an observational setting are consistent with those from INITIO, a randomised trial. Ultimately, clinical outcome will be the measure of efficacy of cART regimens, which requires the follow-up of large numbers of patients over many years. |
| P16 | [P16] ABC/3TC IN COMBINATION WITH A BOOSTED PI IN CLINICAL PRACTICE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P16 Andreas Carganico, Stephan Dupke, Bettina Hintsche, Frank Schlote The combination of ABC/3TC and a boosted PI is a potent and safe treatment option in therapy naïve patients in a clinical setting. |
| P17 | [P17] FOSAMPRENAVIR BOOSTED WITH A SINGLE 100 MG CAPSULE OF RITONAVIR AS PART OF A ONCE DAILY FIRST LINE REGIMEN IN NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P17 Stephane De Wit, Benedicte Poll, Coca Necsoi, Nathan Clumeck The combination of Fosamprenavir boosted with a single 100 mg dose of Ritonavir +Tenofovir + Lamivudine (or Emtricitabine) is a convenient, highly effective, well tolerated once daily first line regimen, with little impact on lipid profile. The use of Fosamprenavir boosted with a single daily Ritonavir capsule should be further evaluated. |
| P18 | [P18] INDUCTION/MAINTENANCE STRATEGY WITH ATAZANAVIR/RITONAVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P18 Douglas J Ward, Charles Fiorentino An induction / maintenance strategy of ATV/r going to ATV provides a potent, well tolerated treatment regimen with high rates of long term viral suppression and minimal toxicity in treatment naïve and select treatment experienced patients. |
| P19 | [P19] SUCCESS OF AN INDUCTION-MAINTENANCE STRATEGY USING BOOSTED FOSAMPRENAVIR PLUS ZIDOVUDINE AND LAMIVUDINE FOR TREATING HIV-1 INFECTED DRUG-NAÏVE SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P19 P Di Vincenzo, O Viganò, M Galazzi, L Meroni, M Moroni, M Galli, S Rusconi Induction-maintenance therapy with FPV/RTV resulted in sustained viral suppression and continued immunological benefit. CD4/CD8 apoptosis decreased over-time mirroring an amelioration of the immune system. Antiretroviral therapy including an induction phase with a potent PI followed by a maintenance simplified therapy with EFV has been well tolerated in naïve patients. |
| P20 | [P20] NNRTIs-BASED HAART IN CLINICAL PRACTICE. A RETROSPECTIVE STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P20 Benedetto M Celesia, Luciano Nigro, Sergio Mavilla, Rosario La Rosa, Arturo Montineri, Monica Nicotra, Rosario Russo EFV seems to induce better immunoreconstitution and higher rate of VL suppression than NVP although at baseline subjects treated with EFV are more immunocompromised. In naïve subjects the two drugs show similar metabolic and hepatotoxic profile. |
| P21 | [P21] THE VeLLA STUDY: VIH EN LATINOS/LATINAS EN LOS ANGELES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P21 Daniel D Pearce, Felix F Carpio, Bill Guyer, Debra Johnson In this small pilot study, a once-daily regimen of TVD and ATV/r was safe, well tolerated and associated with positive virologic and immunologic effects in treatment-naïve Latino patients. Concerns about the efficacy or renal toxicity of this regimen were not supported in this trial. |
| Treatment Strategies - Experienced |
|
| P22 | [P22] VIROLOGIC RESPONSE FOLLOWING DISCONTINUATION OF LAMIVUDINE (3TC) AMONG PATIENTS WITH 3TC-RESISTANT HIV AND WITH ≥ 2 ACTIVE DRUGS IN THE HAART REGIMEN (CTN 189) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P22 M Harris, R Sandre, E Yu, A Thorne, J Singer, J Montaner Our preliminary results indicate that discontinuing 3TC in the setting of M184V/I is not associated with a loss of VL control among patients receiving ≥3 other ARVs of which ≥2 were active (excluding 3TC). |
| P23 | [P23] COMBINED ANALYSIS OF RESIST 96 WEEK DATA: DURABILITY AND EFFICACY OF TIPRANAVIR/R IN TREATMENT EXPERIENCED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P23 B Gazzard, A Antinori, C Cheli These 96 week results confirm the durable superiority of TPV/r vs. CPI/r regimens in HTE patients. Combining TPV/r with an active ARV, e.g. ENF, resulted in a greater virologic response rate. |
| P24 | [P24] WEEK 48 EFFICACY OF TPV/R TREATMENT IS ENHANCED IN PATIENTS WITH HIGHER NUMBERS OF GENOTYPICALLY AVAILABLE BACKGROUND DRUGS IN RESIST 1 AND 2 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P24 A Lazzarin, J Feinberg, M Kraft, D Hall TPV/r provides superior efficacy compared with CPI/r through 48 weeks. Treatment responses to TPV/r regimens improved with increasing numbers of active OBR ARVs. |
| P25 | [P25] HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF PATIENTS TREATED IN RESIST Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P25 A W Wu, I Huang, H Thijs, H W Finnern, M Kraft, J C Gathe, D L Fairclough Despite a higher incidence of treatment-related AEs, HRQOL in TPV/r patients was stable or improved in comparison to treatment with CPI/r. |
| P26 | [P26] ARV-EXPERIENCED PATIENTS RECEIVING TDF + ddI IN THE RESIST STUDIES HAD A REDUCED CD4 RESPONSE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P26 B Clotet, E Negredo, PM Girard, M Youle, D Neubacher, J Leith RESIST patients receiving TDF and ddI had similar virologic responses but reduced CD4 responses versus patients taking TDF without ddI. |
| P27 | [P27] RESPONSE TO MONO-CLASS NUCLEOSIDE REGIMEN OF TENOFOVIR DF + TRIZIVIR IN ANTIRETROVIRAL-EXPERIENCED PATIENTS: 48 WEEK RESULTS AND PREDICTORS OF RESPONSE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P27 B Dauer, P Khaykin, P Gute, S Klauke, M Stuermer, S Staszewski Pts on a failing NRTI-only regimen showed virologic response after TDF-intensification. Patients who failed virologically did so early. BSL VL <5000 copies was a significant predictor for response. Mono-class TDF+TZV therapy showed increasing efficacy even after 24 weeks which was maintained out to 48 weeks. |
| P28 | [P28] TMC114/r HAS TOLERABILITY AND EFFICACY BENEFITS FOR TREATMENT-EXPERIENCED PATIENTS COMPARED WITH CONTROL PIS: OVERVIEW OF THE POWER TRIALS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P28 J Rockstroh, N Clumeck, S Spinosa-Guzman, E De Paepe, E Lefebvre TMC114/r shows an improvement in gastrointestinal tolerability compared with CPIs. This may be of benefit to treatment-experienced pts. |
| P29 | [P29] TMC114/r PROVIDES GREATER EFFICACY BENEFITS VERSUS CONTROL PROTEASE INHIBITOR(S), REGARDLESS OF THE PROTEASE INHIBITOR OR SENSITIVITY TO THE PROTEASE INHIBITOR: POWER 1 AND 2 TRIALS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P29 E Lefebvre, S De Meyer, E De Paepe, A Hill TMC114/r 600/100mg bid showed efficacy benefits over each CPI used, regardless of the sensitivity to the PI. |
| P30 | [P30] A PILOT 48 WEEK STUDY OF ONCE DAILY (180MG QD) VS TWICE DAILY (90MG BID) ENFUVIRTIDE (ENF) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P30 D Wright, A Rodriguez, E Godofsky, S Walmsley, E Labriola-Tompkins, A Shikhman, E Tucker, Y-Y Chiu, J Chung, L Rowell, N Graham, M Salgo Despite somewhat better adherence on QD, both ENF QD and BID appeared similar, although the study was not designed or powered to assess non-inferiority of QD dosing. Further studies are warranted. |
| P31 | [P31] DURABILITY OF HIV RNA ENDPOINTS IN TREATMENT EXPERIENCED PATIENTS – ANALYSIS OF POWER, RESIST AND TORO TRIALS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P31 Andrew Hill, Diego Miralles, Tony Vangeneugden, Eric Lefebvre Although 1 log HIV RNA log reduction endpoint has been used to evaluate efficacy in patients with poor therapeutic options, the HIV RNA 50 copy endpoint is more likely to be sustained in longer-term follow-up, and should become the primary efficacy parameter for new pivotal trials of both treatment naïve and experienced patients. |
| P32 | [P32] SIMPLIFICATION TO EFAVIRENZ + ABACAVIR/LAMIVUDINE (KIVEXA) IN PREVIOUSLY SUPPRESSED HIV-INFECTED PATIENTS COMPARED WITH OTHER CONVENTIONAL REGIMENS OF 2 NUCLEOSIDES + EFAVIRENZ: 6-MONTHS OF FOLLOW-UP Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P32 Patricia Echeverria, Javier de la Torre, Juan Pasquau, Jose Sanz, Isabel Bravo, Raquel Lopez, Bonaventura Clotet, Eugenia Negredo The combination ABC/3TC(Kivexa)+EFV is a good alternative as a simplification regimen due to its virological and immunological effectiveness and good tolerability. |
| P33 | [P33] COMBINATION ANTIRETROVIRAL THERAPY WITHOUT A NUCLEOSIDE ANALOGUE: EXPERIENCE FROM 334 PATIENTS IN THREE COHORTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P33 A Calmy, K Petoumenos, C Lewden, M Law, F Bocquentin, K Hesse, D Cooper, A Carr, F Bonnet In these antiretroviral-experienced patients, NRTI-sparing therapy appeared to have satisfactory virological and immunological efficacy. However, hyperlipidemia was frequent and requires monitoring of cardiovascular risk-factors. |
| P34 | [P34] TENOFOVIR PLUS DIDANOSINE BACKBONE IN HIV-PATIENTS FAILING HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P34 M Bongiovanni, N Gianotti, E Chiesa, P Nasta, A Capetti, P Cicconi, P Marconi, G Rizzardini, T Quirino, A Antinori, A Matti, C Torti, A Castagna, A d'Arminio HAART containing TDF/ddI are associated with a good virologic and immunologic outcome when their choice is driven by a genotypic resistance test. |
| P35 | [P35] SAQUINAVIR IN DOUBLE PROTEASE INHIBITOR REGIMENS BOOSTED WITH RITONAVIR (R) – RESULTS OF THE AROMA-COHORT: COMPARISON OF SAQUINAVIR/ATAZANAVIR/r VERSUS SAQUINAVIR/LOPINAVIR/r Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P35 Axel Baumgarten Both saquinavir containing double PI regimens were effective and well tolerated. Subgroup analyses did not indicate an additional benefit of the optimized background. The data support the use of SQV in boosted double PI regimens. |
| P36 | [P36] CLINICAL EXPERIENCE WITH NEVIRAPINE: A COHORT ANALYSIS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P36 Franco Maggiolo, Claudio Arici, Monica Airoldi, Veronica Ravasio, Diego Ripamonti NVP-based therapies are still widely used and are a cornerstone of HAART in developing Countries. Our data indicate that these regimens may be effective for a long period of time and that tolerability of this drug is high. |
| P37 | [P37] NEVIRAPINE TWICE-DAILY VERSUS ONCE-DAILY AS A SIMPLIFICATION STRATEGY AFTER A SUCCESSFUL PROTEASE INHIBITORS-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P37 Massimo Giola, Daniela Dalla Gasperina, Cristina Basilico, Leonardo Tomasello, Laura Lazzaroni, Paolo Grossi Our study, at the interim analysis at 24 weeks, did not show a statistically significant difference between NVP BID and OD in the setting of simplification after a successful PI-based HAART. However, a trend towards a better tolerability of NVP BID needs to be confirmed at 48 weeks and probably in larger studies. |
| P38 | [P38] ATAZANAVIR/RITONAVIR IN COMBINATION WITH NEVIRAPINE AS A NUCLEOSIDE-SPARING STRATEGY IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED SUBJECTS (NEVATA STUDY) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P38 A M Cattelan, M Trevenzoli, S Cavinato, I Cerbaro, F Salin, F Adorni, S G Parisi, G Palu Dual therapy with ATV/RTV plus NVP is potent and safe as standard-of-care HAART at week 24 of follow-up. These preliminary data suggest a significant improvement in triglyceride profile and in HDL-cholesterol level in the nucleoside-sparing regimen. |
| P39 | [P39] EFFICACY AND SAFETY OF TELZIR™ IN HIV PATIENTS: RESULTS FROM THE SPANISH EXPANDED ACCESS PROGRAM (EAP) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P39 M Sanchez-Conde, MJ Prez-Elias, F Blanco, J Mallolas, B Clotet, C Alonso, J Galindo, I Luque, F Rodriguez-Alcantara In this EAP, fosamprenavir/ritonavir BID was well tolerated and provided therapeutic benefit to ART-experienced subjects including those heavily pre-treated, with high degree of co-morbidities and/or inmunosuppression. |
| P40 | [P40] INTER-COUNTRY VARIATION IN PHYSICIAN PERSPECTIVES OF ENFUVIRTIDE (ENF) PRESCRIBING Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P40 R Horne, V Cooper, G Gellaitry Significant inter-country differences exist in physician attitudes to Rxing injectable ARVs. The country-specific barriers identified may assist in designing targeted interventions to help optimize use of injectable ARVs in ARV-experienced patients. |
| P41 | [P41] PATIENTS' AND PHYSICIANS’ PERCEPTIONS TOWARDS SUBCUTANEOUS TREATMENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P41 H Knobel, C Fumaz, A Segador, A Lorenzo, J Gonzalez, M Garcia Pulgar, N Perulero Physicians perceive that SC may affect daily life situations and psychological patient’s life in greater extent than patient himself. |
| P42 | [P42] EFFICACY AND SAFETY OF LOPINAVIR/R AND ATAZANAVIR WITHOUT A NUCLEOSIDE BACKBONE IN ANTIRETROVIRAL THERAPY EXPERIENCED HIV-INFECTED SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P42 David A Parks, Harold C Jennings, Christopher W Taylor, Jean M Tschampa The combination of LPV/r 400/100mg bid + ATV 300mg qd was shown to be efficacious and well tolerated. There were no virologic failures and the mean CD4+ T-cells increased. No subjects experienced grade III/IV adverse events. Although the study population was small, these results suggest that this dual PI combination is a safe and effective nucleoside sparing regimen, further studies are warranted. |
| P43 | [P43] STUDY ON THE EFFICACY OF REDUCED-DOSE STAVUDINE IN PATIENTS RECEIVING RESCUE THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P43 Enric Pedrol, Alex Almuedo, Esther Ferrer, Pedro García, Elisabet Deig In this study, reduced-dose stavudine used in rescue therapy does not compromise immuno-virological efficacy and its safety profile is good. |
| P44 | [P44] CHARACTERISTICS OF HIV INFECTED PATIENTS ELIGIBLE TO PARTICIPATE IN THE SMART STUDY IN GLASGOW Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P44 L McLean, R Fox Our results show that there are important differences between patients who are participating in the SMART study and those who are not. These differences and the reasons identified for non-participation would be helpful in designing any future similiar study. |
| P45 | [P45] TREATMENT OF ANTIRETROVIRAL EXPERIENCED, ENFUVIRTIDE NAÏVE, ADVANCED HIV PATIENTS WITH A BOOSTED TIPRANAVIR – ENFUVIRTIDE BASED REGIMEN IN CLINICAL PRACTICE: 24-WEEK RESULTS OF AN ITALIAN COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P45 Giustino Parruti, Augusta Consorte, Giuseppina Placido, Alessandro Pieri, Adriana Agostinone, Luciana Alterio, Rocco V Graziani, Giuseppe D'Amico Our experience adds evidence that TPV/r-ENF based regimens may induce remarkable benefits in ordinary clinical settings. Lower TPV mutation scores were associated with better and prompter control of viral replication. |
| P46 | [P46] A STUDY ON THE PERFORMANCE OF COMBINATION OF KALETRA® AND SAQUINAVIR TWICE-DAILY REGIMEN ON A GROUP OF ANTIRETROVIRAL THERAPY EXPERIENCED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P46 Kaveh Manavi, Collette Burns, Alexander McMillan Kaletra®/ saquinavir may result in viral suppression and significant increase in CD4+ T-cell count in the majority of patients without PI mutations. Further investigation on the potency and the frequency of all possible side effects of this regimen is required. |
| P47 | [P47] ENFUVIRTIDE + NRTIs FOR THE TREATMENT OF HIV INFECTED PATIENTS WITH CONCURRENT ACTIVE MYCOBACTERIAL INFECTION: A PILOT EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P47 Clotilde Allavena, Charlotte Biron, Marie Pierre Cossevin, David Boutoille, Pascale Bemer, Francois Raffi, Eric Billaud Given the high prevalence of active mycobacterial infection at low CD4 cell counts, and the need to include rifamycin in the treatment regimen, controlled studies to assess cost-benefit of ARV therapy with or without ENF are needed. |
| P48 | [P48] CD4+ T-CELL EVOLUTION AFTER TENOFOVIR/DIDANOSINE BACKBONE (TDF/ddI) IN PRESENCE OF UNDETECTABLE HIV-RNA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P48 C Torti, G Lapadula, P Barreiro, V Soriano, S Mandalia, A De Silvestri, F Suter, F Maggiolo, A Antinori, F Antonucci, R Maserati, I El Hamad, P Pierotti, L Sighinolfi, G Migliorino, N Ladisa CD4+ T-cell loss was not seen in patients on TDF-ddI (low dose) for up to 24 months, after excluding the possible influence of positive HIV-RNA. Factors explaining inter-individual variability could explain blunted CD4 recoveries and/or paradoxical declines in former studies using higher doses of ddI and/or longer follow-ups. In the meantime, our results are reassuring about the safety of this combination in treatment simplification strategies. |
| P49 | [P49] CLINICALLY STABLE TREATMENT-EXPERIENCED ADULTS RECEIVING TENOFOVIR AND DIDANOSINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P49 Andrea Beltrame, Daniela Fenoglio, Paola Costa, Antonio Di Biagio, Francesco Vitale, Giovanni Cenderello, Giuseppe Ferrea, Claudio Viscoli, Andrea De Maria In HAART-experienced pts, the administration of ddI+TDF compared to ddI+3TC didn’t increase adverse effects or decreased efficacy, in the presence of conserved CD4+ T cell function. |
| P50 | [P50] STUDY OF CHANGES IN CD4 CELLS COUNT AFTER SWITCHING TENOFOVIR TO ABACAVIR OR TDF AND DIDANOSINE TO ABC+LAMIVUDINE IN PATIENTS WITH A ddI+TDF CONTAINING REGIMEN AND VIRAL SUPPRESSION (EUROPA STUDY): PRELIMINARY ANALYSIS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P50 E Pedrol, E Negredo, P Domingo, V Estrada, A Ocampo, J Flores, S Echevarria, A Terron, E Deig After 12w of treatment no statistically significant differences were found between arms, except for those pts that were treated with ABC+3TC. Then a longer follow-up will probably reveal if these differences exits between groups and decide what is the most suitable regimen in these pts. |
| P51 | [P51] COST-EFFECTIVENESS OF TMC114 (DARUNAVIR)/RITONAVIR COMPARED WITH CURRENTLY AVAILABLE PROTEASE INHIBITORS IN TREATMENT-EXPERIENCED HIV PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P51 J Mauskopf, A Brogan, E Smets, G Nuyts, S Martin TMC114/r is predicted to be a cost-effective therapy vs other currently available PIs and yields an average of 0.4 additional QALYs per treatment-experienced patient over 5 years. |
| P52 | [P52] COST-EFFECTIVENESS OF LOPINAVIR/R TABLETS COMPARED TO ATAZANAVIR + RITONAVIR IN ANTIRETROVIRAL EXPERIENCED PATIENTS IN THE UK, SPAIN, ITALY, AND FRANCE BASED ON RESULTS FROM BMS AI424-045 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P52 Kit N Simpson, Walter Jones, Rukmini Rajagopalan, Brigitta Dietz The survival benefit of LPV/r is due to the differences in patients with VL suppressed to 50 copies/mL or below, while the economic benefit is due to both the lower cost of LPV/r and the savings incurred by slower rates of disease progressions. These estimates are robust to large variations in costs, but very sensitive to assumptions related to the viral rebound for patients with suppression to VL below 400 and below 50 copies/mL. |
| Treatment Strategies - Switch |
|
| P53 | [P53] IMPACT OF SWITCHING VIROLOGICALLY SUPPRESSED, HIV-INFECTED PATIENTS FROM FIXED-DOSE ZIDOVUDINE/LAMIVUDINE (CBV) TO FIXED-DOSE TENOFOVIR DF/EMTRICITABINE (TVD) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P53 Edwin DeJesus, Sheetal Sharma, Roberto Corales, Ramin Ebrahimi, Alvan Fisher, John Flaherty Pts switched to TVD+EFV maintained virologic suppression, and the regimen was well tolerated. Other benefits (↑Hb,CD4, ↓lipids) were noted. Pt satisfaction and adherence with the regimen were high. |
| P54 | [P54] SIMPLIFICATION FROM PROTEASE INHIBITOR (PI) TO EFAVIRENZ (EFV) BASED HAART IN VIROLOGICALLY SUPPRESSED HIV-INFECTED SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P54 Calvin Cohen, Edwin DeJesus, Rafael Campo, Kristy Porter, Jen-Fue Maa, Daniel Seekins, Rozina Khanna Viral suppression was maintained and FAHI/IIRS-based QoL improved in subjects simplifying from PI to EFV-based HAART. EFV-based HAART was well tolerated, with few treatment-limiting AEs. |
| P55 | [P55] IMMUNOLOGICAL IMPROVEMENT IN PATIENTS WITH SUSTAINED LOW LEVEL VIREMIA-SLLV WHO SWITCH OR MAINTAIN A PARTIAL EFFECTIVE HAART (IMPROVE-MASTER STUDY) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P55 P Nasta, A Matti, F Gatti, F Castelnuovo, G Cocca, G Zoboli, MC Nigro, MC Colombo, C Calzetti, F Barchiesi, G Carosi, IMPROVE-Master Group CD4 cells decline was more pronounced in SLLV pts who switched HAART without obtain viral suppression, than in pts who maintain a partial effective regimen. The HAART switch in SLLV pts with stable CD4 cell count, should be consciously individualized. |
| P56 | [P56] SWITCHING A TOXICITY-CAUSING ANTIRETROVIRAL (ARV) TO ENFUVIRTIDE (ENF) IN PATIENTS WITH TREATMENT-LIMITING TOXICITIES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P56 M Stoll, M Muller, S Staszewski, M Gorgolas, J Portilla, A Streinu-Cercel, L Rowell, E Labriola-Tompkins, E Waalberg, M Salgo Med Hochschule, Hannover, Germany; Stuttgart, Germany; JW Goethe Substituting ENF for an ARV associated with a treatment-limiting toxicity led to toxicity improvements or resolution in the majority of these extensively pretreated patients with maintenance of viral suppression in many and immunological improvement in most. |
| P57 | [P57] COMPARING TREATMENT-SIMPLIFICATION STRATEGIES IN LONG-TERM OBSERVATION. PRELIMINARY RESULTS FROM SIMPLEF STUDY OF MASTER DATABASE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P57 A Antinori, P Lorenzini, M Zaccarelli, F Suter, F Maggiolo, G Cologni, F Castelnuovo, S Lo Caputo, L Sighinolfi, S Novati, G Migliorino, N Ladisa, G Carosi All simplification strategies showed similar efficacy in long-term. IDU and HCV+ predicted failure. Increasing risk of viral rebound by switch at high CD4 count could concern adherence. Simplifying to ABC from a potent PI, such as LPV/r, may increase the risk of failure. |
| P58 | [P58] THE RAINBOW COHORT: SUCCESSFUL INITIATION/SWITCH WITH/FROM THE NEW SAQUINAVIR 500MG FORMULATION – FIRST RESULTS FROM GERMANY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P58 H Knechten, T Lutz, G Knecht, A Haberl, A Carganico, F Glaessl, H Jaeger, A Tappe, E Wellmann, J Steinmueller These data suggest that patients can take advantage from switching to the convenient 500mg SQV FCT formulation without compromising virological and immunological control. The data support the use of boosted SQV as a first-line PI. |
| P59 | [P59] FINAL SAFETY AND EFFICACY ANALYSIS OF A RANDOMISED PILOT STUDY EVALUATING EARLY VERSUS LATE SWITCH FROM EFAVIRENZ TO NEVIRAPINE AS PART OF HAART: THE BI SWITCH STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P59 M Youle, U B Dragsted, D Podlekareva, C Smith, A Caroll, F Turner, M Johnson In this open-label, randomised, pilot study significant improvement in EFZ-related CNS AEs was seen at week 8 in pts switching to NVP at bl. No differences were seen in viral suppression, CD4 count or AEs between the study arms through week 24. |
| P60 | [P60] FTC IN AN OUTPATIENT GROUP: SWITCH OF A STABLE VIRUS-CONTROLLED ART TO A FTC-CONTAINING REGIMEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P60 Stefan Fenske, Thomas Buhk FTC as part of a combination therapy is a well tolerated and safe drug. There are no virological failures during the observation period. |
| P61 | [P61] VIROLOGIC SUPPRESSION IS MAINTAINED IN ANTIRETROVIRAL EXPERIENCED ADULTS WHO CHANGE FROM TENOFOVIR AND LAMIVUDINE TO TRUVADA, A ONCE DAILY FIXED-DOSE COMBINATION TABLET OF TENOFOVIR AND EMTRICITABINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P61 Amy E Colson, Calvin J Cohen, Claudia Martorell, Robert C Stevens, Karen McLaughlin Changing TDF and 3TC to Truvada maintained virologic suppression. Four wks after the change, 100% of participants found Truvada to be more convenient. |
| P62 | [P62] TOLERABILITY AND PREFERENCE OF LOPINAVIR/RITONAVIR (KALETRA) CAPSULES VERSUS TABLETS AS SINGLE AGENT THERAPY (IMANI-2) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P62 Joseph Gathe, Bryan Lipman, Bernie Miguel, Carl Mayberry, John Nemecek This is the first study to compare tolerability of LPV/r tablets to SGC in HIV + patients. Results indicate high tolerability, satisfaction and tablet preference. Low grade diarrhea on SGCs was absent post-switch. The absence of other ARVs allows direct measure of LPV/r tolerability without confounding therapy. |
| P63 | [P63] PROTEASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY SWITCH TO EFAVIRENZ-BASED REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P63 Pavel Khaykin, Schlomo Staszewski, Brenda Dauer, Amina Carlebach, Axel Mueller, Annette Haberl, Peter Gute, Gaby Knecht Modification of the HAART could achieve viral suppression if EFV was substituted for a PI or PI/r. However, some patients demonstrated adverse events or virologic failure. Most of patients who discontinued EFV had 2- or 3-class resistance in the treatment history. EFV is a proven component of standard-of-care in first-line HIV. Further investigation of EFV in patients after therapy failure of PI / PI/r containing regimens is warranted. |
| P64 | [P64] SWITCH TO A COMPLETELY ONCE DAILY REGIMEN CONTAINING EMTRICITABINE/TENOFOVIR-FIXED DOSE COMBINATION PLUS THIRD QD PARTNER: 24 WEEKS INTERIM ANALYSIS OF THE SONETT TRIAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P64 Lutwin Weitner, Stefan Fenske, Birger Kuhlmann, Matthias Freiwald, Ramin Ebrahimi, Lothar Gallo, Britta Ranneberg, Thomas Mertenskoetter, Keikawus Arasteh Results support switching from a stable CBV-containing HAART to a completely qd regimen of TVD plus third divergent partner given that virologic (< 50 c/mL) and immunologic control were maintained with the additional benefit of Hb increasing significantly. |
| Treatment Strategies - Treatment Interruptions |
|
| P65 | [P65] HIGH ACTIVITY ANTIRETROVIRAL THERAPY INTERRUPTIONS UNDER SUPERVISION: 5 YEARS FOLLOW UP Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P65 Marcial Delgado-Fernandez, Felipe Diez-Garcia, Ana Belen Lozano, Clara Natera-Kindelan, Joaquin Salas-Coronas, Rafael Cotos-Canca Drug holidays are feasible in concrete patients. |
| P66 | [P66] MORPHOLOGIC CHANGES 42 MONTHS AFTER ANTIRETROVIRAL TREATMENT INTERRUPTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P66 Eva Martinez, Carla Estany, Eugenia Negredo, Raquel Lopez, Ana Canton, Ana Sanmarti, Bonaventura Clotet HAART interruption was associated with a significant increase of weight and due to an increase of fat mass, mainly in trunk. The mild improvement of femur BMD with this strategy could suggest a negative impact of ARV therapy on bone metabolism. |
| P67 | [P67] A RANDOMIZED TRIAL OF CD4-GUIDED HAART INTERRUPTION IN PTS RECEIVING MOSTLY NNRTI-BASED REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P67 M Olmo, D Podzamczer, L Ruiz, M Penaranda, F Gutierrez, J Niubo, J Romeu, M Larrousse, P Domingo, J Oteo, P Sanchez, I Ruiz, JL Aldeguer, J Iribarren Although minor HIV related conditions were observed, progression to AIDS or CD4 < 200 was not observed in TI pts. TI strategy allowed a therapy saving of 84%. Nadir and baseline CD4 influenced the need and timing of HAART reinitiation. |
| P68 | [P68] NO BENEFIT OF TREATMENT INTERRUPTIONS ON HIV-RELATED NEUROCOGNITIVE FUNCTIONING IN PATIENTS TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P68 Jose A Muñoz-Moreno, Carmina R Fumaz, Anna Prats, Maria J Ferrer, Eugènia Negredo, José Moltó, Raquel López-Blázquez, Maria T Garolera, Bonaventura Clotet TI may be a non-recommendable strategy for NF. Unexpected differences on NF exist when pts are assessed according to the existence of HAART interruptions. |
| P69 | [P69] ANTIRETROVIRAL TREATMENT AFTER CONTROLLED INTERRUPTIONS: A COMPARISION BETWEEN NON-NUCLEOSIDE AND PROTEASE INHIBITORS GROUPS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P69 Jose Perez-Silvestre, Francisco Garcia-Gonzalez, Roberto Oropesa, Victor Gonzalez-Valles, Vicente Abril, Miguel Garcia-Deltoro, Enrique Ortega We haven’t found significative differences between the rates of viral suppression at three months, although there is a tendency to greater suppression in NNRTI group. Six months and one year after there aren’t significative differences between NNRTI and PI groups. |
| P70 | [P70] ACUTE RETROVIRAL SYNDROME AFTER INTERRUPTION OF ANTIRETROVIRAL TREATMENT. DESCRIPTION OF 4 CASES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P70 Ana Guelar, Luisa Sorli, Milagro Montero, Alicia González, Jordi Mercadal, Hernando Knobel Only a minority of patients developed acute retroviral syndrome after treatment interruption, but it can be life threatening. In most cases the patients presented a significant increase in viral load and a pronounced reduction of CD4 cell count. The predictive factors associated with this evolution are unknown. |
| P71 | [P71] STRUCTURED TREATMENT INTERRUPTIONS (STI) IN ACUTE HIV INFECTION IN TWO PATIENTS: A NEW APPROACH Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P71 Israel Yust, Nurith Vardinon, Irena Zeldis, Vered Hadas, Boaz Avidor, Dan Turner, Michael Burke The first patient demonstrates the possibility that multiple STI over a prolonged period may permit a decrease in duration of drug administration, without affecting immune or viral parameters. The second patient shows that stopping therapy after STI of brief duration did not prevent viral rebound and CD4 count fall shortly afterwards. There is no uniformity nor are there guidelines for STI. These preliminary results may encourage controlled STI studies to determine dose frequency vis a vis response. |
| Treatment Strategies - Other |
|
| P72 | [P72] DIFFERENT INFLUENCE OF ANTIRETROVIRAL DRUGS ON NEUROCOGNITIVE AND MOTOR FUNCTIONING IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P72 Jose A Muñoz-Moreno, Carmina R Fumaz, Maria J Ferrer, Eugènia Negredo, Anna Prats, Maria T Garolera, Bonaventura Clotet In our study, NVP-based regimens were associated with a better NF compared with EFV- and LPV/rtv-based regimens. Antiretroviral therapy may produce a different impact on NF in HIV-infected people. |
| P73 | [P73] EFFICACY OF LOPINAVIR/RITONAVIR (LPV/R) IN CLINICAL PRACTICE: AN 18-MONTH OBSERVATIONAL PROSPECTIVE COHORT OF 1315 PATIENTS (KALEOBS COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P73 Jean-Michel Livrozet, Michel Dupon, Laurence Morand-Joubert, François-André Allaert, Alain Lafeuillade These results confirm the virological efficacy of LPV/r-containing regimens in ARV- or PI-naïve and PI-exp patients. Immune restoration was noted in all 3 populations. The benefit of LPV/r-based therapy was sustained, as demonstrated in patients followed up to M18. |
| P74 | [P74] THE EFFICACY OF NEVIRAPINE IN COMBINATION WITH TWO NUCLEOSIDE ANALOGUES IN THE TREATMENT OF HIV PATIENTS: 240 WEEK RETROSPECTIVE MULTICENTRE STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P74 A Jayasuriya, J Arumainayagam, K Yoganathan, V Harindra, S Das, S Allan In this cohort, those who remained on Nevirapine maintained long-term viral suppression. A large proportion, however, discontinued nevirapine. Further work is needed to see if this drop-off rate lessens as clinicians become more confident in the recognition and management of nevirapine side-effects. |
| P75 | [P75] LONG-TERM SURVIVORS TREATED WITH DIFFERENT ANTIRETROVIRAL REGIMENS – RESIDUAL VIREMIA AND MODERATE LEVELS OF VIRAL LOAD Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P75 Loredana Manolescu, Paul Marinescu, Camelia Sultana, Simona Ruta In this study achieving higher levels of viral suppression did not confer greater CD4 cell count increases and higher levels of viral suppression did not predict reduced rates of virologic failure. Long-term studies are needed to determine whether the differences in immunological response seen here translate into differences in the risk of clinical disease taken into account the evolution of drug resistance and drug sequencing. |
| P76 | [P76] RITONAVIR BOOSTED SAQUINAVIR ONCE DAILY – AN INDIAN EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P76 Satish Kadappa, Bhimasena RS Rao, G V Mallesh, K N Praveenkumar Boosted PI regimens increase the potency and efficacy of the drug and lead to regimen simplification. Our cohort of patients who were on once daily ritonavir boosted saquinavir in a dose of 1600mg/100mg have experienced immunological benefits. The limitation of the present study is the small number of patients evaluated. For now, we cannot ignore the obvious benefits once daily ritonavir boosted saquinavir in HAART. |
| Adverse Effects - non-specific |
|
| P77 | [P77] TOLERABILITY OF BOOSTED PROTEASE INHIBITOR THERAPY IN CLINICAL PRACTICE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P77 David V Condoluci, Maryann Andrews, Paulette Dawn Slowinski, Marlene Folino, Kelly L Rand, Katherine Gallagher, William C Woodward In this retrospective analysis, BPI therapy was generally well tolerated with few significant adverse events or discontinuations for AEs. |
| P78 | [P78] TREATMENT WITH EFV+DDI+3TC IS AN EFFECTIVE, GENERALLY WELL TOLERATED AND WELL PERCEIVED COMBINATION IN INITIAL (I), SIMPLIFICATION (S) AND RESCUE (R) THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P78 H Knobel, J Hernandez-Quero, E Ribera, P Domingo, B Vendrell, O Serrano, J Perez-Molina H. del Mar, H. San Cecilio, H. Vall de Hebron, H. San Pau In the real-life conditions of this study, EFV+ddI+3TC was generally well tolerated and effective. G-3/4 liver toxicity was <2% and lipid parameters improved slightly. The most common AR were CNS-related not leading to Tx D/C in most cases. |
| P79 | [P79] EVALUATION OF THE LOCAL TOLERANCE AND QUALITY OF LIFE IN 60 HIV-1 INFECTED PATIENTS TREATED WITH AN ARV REGIMEN CONTAINING ENFUVIRTIDE: SURCOUF COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P79 Clotilde Allavena, Thierry Prazuck, Gwenael Le Moal, Thomas Jovelin, Fabienne Sauser, Veronique Reliquet, Francois Raffi During the study, more and more patients, especially self-injected ENF patients, get satisfied with ENF therapy. ISRs are frequent but mostly of minor or moderate intensity and do not prevent impovement in the QOL. |
| P80 | [P80] THE SAFETY AND THE EFFECTIVENESS OF ANTIRETROVIRAL THERAPY CONTAINING ATAZANAVIR/RITONAVIR (ATV/r) WITH OR WITHOUT TENOFOVIR (TDF) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P80 Ana Guelar, Milagro Montero, Aitziber Ullaro, Luisa Sorli, Gabriel Vallecillo, Hernando Knobel Antiretroviral therapy containing Atazanavir/ritonavir with Tenofovir showed similar effectiveness and safety compared with regimens that did not contain this drug. However, a tendency of a greater incidence of hyperbilirubinemia was observed in the tenofovir group. |
| P81 | [P81] CAN NEVIRAPINE WARNING PREVENTS ADVERSE EVENTS IN ALL CLINICAL SETTINGS? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P81 Ana Guelar, Milagro Montero, Alexia Carmona, Sonia Luque, Nuria Berenguer, Alicia González, Hernando Knobel In our clinical setting, application of the warnings about the use of nevirapine could not prevent development of adverse events. Rashes were more frequent in patients without warning criteria. Hepatotoxicity was infrequent and developed later. |
| P82 | [P82] HLA-B*5701 CARRIAGE FREQUENCY IN A LONDON COHORT – WILL PROSPECTIVE SCREENING BE OF USE IN OUR POPULATION? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P82 Christopher Collister, Brett Marret, Simon Portsmouth, Alan Winston, Nicola E Mackie The demographics of the patients tested reflect our diverse clinic population. The prevalence of HLA-B*5701 in Black patients is higher than has been previously reported and interestingly is not significantly different than our Caucasian population. These findings are not in keeping with historic data reporting reduced rates of ABC HSR in patients of African origin assuming similar associations exist between carriage of HLA-B*5701 and ABC HSR in this group. |
| P83 | [P83] INCIDENCE OF ANEMIA AMONG PATIENTS TREATED WITH ZIDOVUDINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P83 Suellen M Curkendall, James Richardson, Matthew F Emons Upon adjusting for other factors, ZDV use was associated with increased anemia risk in patients without baseline anemia and of worsening anemia in those with baseline anemia. Nearly 1/5 of new anemia cases among patients treated with ZDV required epo or blood transfusions. |
| P84 | [P84] DIRECT COSTS OF ANEMIA AMONG PATIENTS TREATED WITH ZIDOVUDINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P84 S M Curkendall, Q V Doan, M F Emons, J Richardson, R J Halbert Patients treated with ZDV who experienced anemia required significantly more medical care and reported higher medical cost than patients without anemia. |
| P85 | [P85] CHANGES ON ERYTHROCYTE AND LYMPHOCYTE PROPERTIES PARTIALLY REVERSED IN PATIENTS UNDERGOING ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P85 Nuno C Santos, J Martins-Silva, M Doroana, N Duarte, L Tavares, F Antunes, Carlota Saldanha Our data shows that the HIV-1 infection of a patient leads to biophysical changes on the membrane of lymphocytes (mostly non-infected) and erythrocytes, partially reversed by HAART. The observations are consistent with a process of facilitated propagation of the infection to new cells, stimulation of virion production and maintenance of a reservoir of erythrocyte-bound infectious virus. |
| P86 | [P86] DOES ANTIRETROVIRAL DRUG THERAPY ALTER THE CLINICAL OUTCOME IN HIV POSITIVE PATIENTS AFTER ORAL AND MAXILLOFACIAL SURGERY? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P86 Kishore Shetty HIV seropositive status was found to be an independent risk factor for complications of major oral surgical procedures. The most important risk factors for complication of surgery in HIV positive individuals were high viral load and absence of higly active antiretroviral treatment. |
| Adverse Effects - Bone |
|
| P87 | [P87] RISK FACTORS OF OSTEOPOROSIS IN HIV-INFECTED WOMEN: NO ROLE OF ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P87 A Libois, S Rozenberg, K Kabeya, M Gerard, B Poll, E Goudeseune, M Tondeur, N Clumeck In this population of HIV-infected women, mainly composed of African women, there was no association between antiretroviral therapy (containing PI or not) and BMD loss. |
| P88 | [P88] PREVALENCE AND RISK FACTORS FOR OSTEOPENIA/OSTEOPOROSIS IN SLOVENIAN HIV INFECTED MALE POPULATION; A NATIONAL SURVEY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P88 Janez Tomazic, Katja Ul, Gabriele Volcanek, Samo Gorenek, Mia Pfeifer, Ludvik Vidmar, Primoz Karner According to published data, the highest proportion of the national HIV-infected population was included. The prevalence of reduced BMD was significantly higher than the national prevalence among males. There was no association between reduced BMD and any specific ART. According to our results, reduced BMD was related to HIV itself. None of the multiple established risk factors turned out to predict reduced BMD. Screening and treatment of reduced BMD present a reasonable strategy for preventing reduced BMD in HIV-infected patients, but adjusting vitamin D could be an important component, as well. |
| Adverse Effects - Cardiovascular |
|
| P89 | [P89] CEREBRO- AND CARDIOVASCULAR EVENTS AND CARDIOVASCULAR MORTALITY IN HIV-INFECTED PATIENTS WERE SIGNIFICANTLY INCREASED AFTER THE INTRODUCTION OF HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P89 Paula Freitas, Davide Carvalho, Tiago Costa, Margarida Tavares, Joana Rema, Rui Marques, Fernando Lopes, António Mota-Miranda, José Luis Cerebro and cardiovascular events, as well as cardiovascular mortality, increased significantly after 1997, when HAART became available. |
| P90 | [P90] CARDIOVASCULAR RISK FACTORS IN HIV INFECTED WOMEN FROM THE SPANISH VACH COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P90 Maria Jose Galindo, Paloma Geijo, Maria Luisa Garcia-Alcalde, Ignacio Suarez-Lozano, Pere Domingo The HIV infected women on treatment are at higher risk of developing a coronary event than the Spanish population. This risk is lower than the HIV infected men of the VACH cohort. |
| P91 | [P91] USE OF FRAMINGHAM RISK SCORE AND DIAGNOSIS OF METABOLIC SYNDROME TO IDENTIFY HIV PATIENTS WITH A HIGH CARDIOVASCULAR RISK PROFILE IN CLINICAL PRACTICE: AN ITALIAN MULTICENTRIC EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P91 Giuseppe VL De Socio, Giordano Madeddu, Marzia Franzetti, Elena Rosella, Francesca Vichi, Carmela Grosso, Sara Melzi, Patrizia Marconi, Giustino Parruti, Paolo Bonfanti The combined use of the diagnostic criteria for Metabolic Syndrome and the Framingham-Risk Score may represent a simple clinical tool for identifying high-risk HIV infected patients, worth further diagnostic interventions. |
| P92 | [P92] PATIENTS’ AWARENESS OF ANTIRETROVIRAL-RELATED CARDIOVASCULAR RISK AND THEIR PREFERENCES ON HOW TO MANAGE IT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P92 Peio López de Munáin, Daniela Rojas, Jorge Del Romero, Alfredo Del Campo Patient’s preferences and declared treatment compliance reinforce the importance of switching strategy in HIV therapy to more convenient and potentially less toxic ARV regimens. Educational programs might improve patients’ attitudes towards prevention of CV risk. |
| P93 | [P93] CARDIOVASCULAR SCREENING IN HIV DISEASE IN THE UNITED KINGDOM – WHO DOES IT AND HOW? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P93 Clare Stradling UK clinics undertake baseline CV risk assessment and lifestyle advice as recommended by British HIV Association (BHIVA) Guidelines. A structured approach would be useful in many centres. Standards could be developed by DHIVA in association with BHIVA. |
| P94 | [P94] LIPID PROFILE USING OF THE NEW PROTEASE INHIBITORS IN ANTIRETROVIRAL TREATED HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P94 Eugenia Negredo, Patricia Echeverria, Jordi Puig, Raquel López-Blázquez, Anna Bonjoch, Bonaventura Clotet The use of the new PIs, FAPV/rtv, TMC 114/rtv and TPV/rtv, was associated with a good lipid profile in highly antiretroviral treated HIV-infected patients. The increase of TG levels observed after starting TPV/rtv was slight and transitory. ATV, even boosted by rtv, showed a higher improvement of TG than the other PIs. |
| P95 | [P95] EFFECT OF ATAZANAVIR (ATV) VERSUS OTHER PROTEASE INHIBITOR (PI)-CONTAINING ANTIRETROVIRAL COMBINATION THERAPY ON ENDOTHELIAL FUNCTION IN HIV-INFECTED PERSONS: RANDOMIZED CONTROLLED TRIAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P95 A Flammer, TTN Vo, B Ledergerber, A Gämperli, A Lahn, C Grube, J Evison, I Baumgartner, M Cavassini, D Hayoz, K Quitzau, T F Lüscher, G Noll, R Weber Treatment with ATV vs. cPI improved lipids but had no clear effect on endothelial function. Power calculations indicate 2×340 patients for a significant FMD difference between arms. |
| P96 | [P96] ROLE OF CIRCULATING THROMBOMODULIN LEVEL IN LATENT PROGRESSION OF ATHEROSCLEROSIS IN HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY WITH NELFINAVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P96 Iryna Korzh, Valeriya Nemtsova, Inga Fedotova These results suggest that circulating levels of thrombomodulin are elevated in HIV-infected patients as compared to control subjects and that the thrombomodulin level may be a molecular marker of the latent progression of atherosclerosis in HIV-infected patients receiving HAART containing nelfinavir. |
| P97 | [P97] SIGNIFICANCE OF NUMBER AND MIGRATORY ACTIVITY OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P97 Oleksii M Korzh, Sergiy V Krasnokutskiy, Genadiy I Kotchuev EPC biology, which is critical for neovascularization and the maintenance of vascular function, is altered in HIV-infected patients receiving HAART. Our data strongly suggest that dysfunction of circulating EPC has a role in the progression of cardiovascular disease in these patients. |
| P98 | [P98] ANATOMICAL AND FUNCTIONAL VASCULAR CHANGES IN HIV (+) PATIENTS: A CASE CONTROL STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P98 Ioannis Palios, Sotirios Tsiodras, Periklis Panagopoulos, Anastasia Antoniadou, Garyfalia Poulakou, Antonios Papadopoulos, Ignatios Ikonomidis, Loukianos Rallidis, John Lekakis, Dimitrios Kremastinos, Helen Giamarellou HIV pts had similar IMT compared to matched CAD pts. Hypertension, diabetes and dyslipidemia are important in the development of atherosclerosis and arterial stiffness in HIV pts. The role of HAART needs to be further explored. |
| P99 | [P99] BMI AND LONG-TERM NRTI TREATMENT ARE SIGNIFICANTLY ASSOCIATED WITH HYPERTENSION 10 YEARS AFTER PI-ART START Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P99 Goran Bratt, Sissela Liljeqvist, Carolina Ek, Thomas Nystrom, Ake Sjoholm Venhalsan Only a history of NRTI treatment before PI-ART and a BMI above the median 10 years after PI-ART start were of significant importance. Hypertension has multifactorial causes in HIV-infection. The contribution of long-term NRTI treatment needs to be further studied. |
| P100 | [P100] HIGH PREVALENCE OF PERIPHERAL VASCULAR DISEASE (PVD) IN HIV PATIENTS OLDER THAN 50 YEARS: TOBRA STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P100 Ana Hidalgo, Isabel Aguilar, Rosario Palacios, Mercedes Gonzalez, Josefa Ruiz, Manuel Marquez, Jesus Santos The prevalence of PVD in HIV pts ≥50 years is very high. CVRF are quite frequent in this population. PVD was not related with features of HIV infection nor with HAART, but with traditional factors such as male sex, time of hypertension, and use of OAD. |
| P101 | [P101] PREDICTORS OF HYPEROMOCYSTEINEMIA IN HIV-POSITIVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P101 M Bongiovanni, M Casana, M Pisacreta, F Tordato, P Cicconi, U Russo, A d'Arminio Monforte, T Bini HO is a quite frequent finding in HIV-pts. Low folate levels and older age are associated with such abnormality. The correlation between these results and an increased CVD risk remains to be assessed. |
| Adverse Effects - Gastrointestinal |
|
| P102 | [P102] UPPER GASTROINTESTINAL COMPLAINTS AND USE OF ACID REDUCING AGENTS ARE FREQUENT IN PATIENTS TREATED WITH ANTIRETROVIRALS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P102 E Toma, N Ackad, S Auger, J Sampalis Upper gastrointestinal complaints and use of ARA are highly prevalent among ARV-treated HIV positive patients. Those on LPV/r have a lower prevalence of UGC. Treatment regimens may impact UGC and treatment of UGC may impact ARV efficacy. |
| P103 | [P103] IMPROVEMENTS IN SELF-REPORTED ADHERENCE & GASTROINTESTINAL ADVERSE EFFECTS (AES) WITH LOPINAVIR/RITONAVIR (LPV/R) AFTER SWITCHING FROM SOFT-GEL CAPSULE (SGC) TO TABLET (TAB) VARIES BY ETHNICITY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P103 Shannon Schrader, Susan K Chuck, Laurie W Rahn, Katherine G Emrich, Paras S Parekh Significant improvements in tolerability, satisfaction, & AEs were reported in all groups switched from LPV/r SGC to TAB. Significant improvements in adherence were seen in AA & H pts, closing the gap observed prior to switching. |
| P104 | [P104] SIGNIFICANT IMPROVEMENTS IN SELF-REPORTED GASTROINTESTINAL (GI) TOLERABILITY, QUALITY OF LIFE (QoL), PATIENT SATISFACTION, AND ADHERENCE WITH LOPINAVIR/RITONAVIR (LPV/R) AFTER SWITCHING FROM BID SOFT-GEL CAPSULE (SGC) TO BID TABLETS (TAB) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P104 Shannon Schrader, Susan K Chuck, Laurie W Rahn, Katherine G Emrich, Paras S Parekh LPV/r TAB provide multiple benefits to pts relative to SGC with significant improvements in tolerability, GI AEs, satisfaction adherence when these 332 pts switched from LPV/r SGC to TAB. The TAB benefit most frequently liked by pts was lack of refrigeration. Additional study to further define the tolerability profile of LPV/r TAB is warranted. |
| P105 | [P105] TOLERABILITY OF LOPINAVIR/RITONAVIR (LPV/R) LIQUID IN HIV+ ADULTS SWITCHED FROM THE SOFT GELATIN CAPSULE (SGC) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P105 J Toy, M Harris, J da Silva, J Montaner Following a switch from LPV/r SGC to liquid, GI side effects improved in 26%, worsened in 24%, and 66% discontinued. Patients naïve to LPV/r were less likely to remain on the liquid formulation. Unpleasant taste, inconvenience and GI symptoms limited the use of this alternative dosage form. |
| Adverse Effects - Hepatic |
|
| P106 | [P106] LIVER TOLERANCE OF ANTIRETROVIRALS IS IMPROVED IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C THAT ATTAIN HCV CLEARANCE AFTER IFN-BASED THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P106 Pablo Barreiro, Pablo Labarga, Andrés Ruiz, Carol Castellares, Juan González-Lahoz, Vincent Soriano HCV clearance after IFN-based therapy is followed by a lower incidence of liver toxicity by HAART, as compared with patients with active HCV replication. The extent of liver fibrosis seems to be related also with the liver tolerance of antiretrovirals. |
| P107 | [P107] LOW INCIDENCE OF SEVERE LIVER EVENTS (SLE) IN HIV PATIENTS WITH AND WITHOUT HEPATITIS C OR B COINFECTION RECEIVING LOPINAVIR/RITONAVIR (LPV/r) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P107 Isabel Aguilar, Salvador Vergara, Antonio Rivero, Rosario Palacios, Juan Macias, Angela Camacho, Fernando Lozano, Maria Garcia, Juan A Pineda, Julian Torre-Cisneros, Manuel Marquez, Jesus Santos The incidence of SLE in HIV patients receiving a HAART regimen including LPV/r was very low, even in co-infected patients. HCV co-infection and baseline HT were the only factors associated with SLE. LPV/r can be considered a safe and well-tolerated option in HIV patients with hepatotropic virus coinfections. |
| P108 | [P108] FOSAMPRENAVIR/RITONAVIR (FPV/r): DECREASE OF LIVER ENZYMES IN PATIENTS CO-INFECTED WITH HEPATITIS C Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P108 Christine Koegl, Eva Wolf, Andrea Eberhard, Eva Jaegel-Guedes, Hans Jaeger In our cohort of pts treated with FPV/r, we observed relatively stable ALT values and a significant decrease in γ-GT in HIV/HCV-coinfected patients after switching to a FPV/r containing regimen. Our data confirm the safety of FPV/r in both HIV-mono and in HIV/HCV-coinfected pts. |
| P109 | [P109] NEVIRAPINE VS EFAVIRENZ IN 742 PATIENTS: THE LIVER TOXICITY OF NEVIRAPINE IS NOT LINKED TO THE FEMALE SEX AND A BASELINE CD4 COUNT ABOVE 250 CELLS/µL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P109 Roberto Manfredi, Leonardo Calza As assessed on 742 p who received a NNRTI for the first time in different baseline conditions, the female gender and a CD4 count >250 cells/µL do not prompt adjunctive hepatotoxicity. |
| P110 | [P110] CORRELATES OF RISK OF NEVIRAPINE (NVP) INTERRUPTION DUE TO LIVER TOXICITY (LT) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P110 Corvasce, F Adorni, M Franzetti, A Radice, M Moroni, M Galli LT observed on NVP was not life-threatening, not gender-associated and not strongly related to BL CD4 cell counts. The main correlates of LT interruptions were HCV coinfection and ALT levels at BL; about half of LT occurred after the first 6 months of treatment and can not be attributed to ‘acute’ hypersensitivity. |
| P111 | [P111] LOW-LEVEL TRANSAMINITIS IS ASSOCIATED WITH CURRENT OR PREVIOUS STAVUDINE/DIDANOSINE USE AND MAY INDICATE NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN HIV MONO-INFECTED SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P111 M Bongiovanni, C Smith, S Bhagani, F Lampe, M Tyrer, G Dusheiko, M Johnson, G Slapak Patients with LLT who are currently on or have previously used d4T and/or ddI, may have NASH and are at risk of progression to hepatic fibrosis. |
| P112 | [P112] SAFETY OF TIPRANAVIR IN HEAVILY ANTIRETROVIRAL-EXPERIENCED HIV-INFECTED PATIENTS WITH AND WITHOUT CHRONIC HEPATITIS B/C Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P112 P Garcia-Gasco, J Garcia, E Poveda, F Blanco, P Rivas, B Ramos, C Carapeto, A Alcolea, J G-Lahoz, V Soriano A mild-moderate increase in ALT, as well as in cholesterol and triglycerides, is frequently seen during TPV/r therapy. HBV/HCV co-infection does not seem to increase the risk of liver toxicity of TPV/r. A parallel increase in HDL-cholesterol could ameliorate the negative lipid profile of the drug. |
| P113 | [P113] NEW PROTEASE INHIBITORS RESCUE TREATMENT IN CO-INFECTED HIV-HCV PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P113 Isabel Lopez-Isidro, Sari M Arponen, Raquel Carrillo, Ignacio de los Santos-Gil, Jesus Sanz HAART including new PI leads to asymptomatic bilirubinaemia, higher with ATZ-r, but it only is statistically significant in 9 month control and does not mean to discontinue the treatment. There were no significant increase levels of ASAT, ALAT and GGT; neither do AF. Thus, LPV-r, FPV-r and ATZ-r are safety options to treat coinfected patients. |
| Adverse Effects - Hypersensitivity |
|
| P114 | [P114] ABACAVIR-ASSOCIATED DRUG HYPERSENSITIVITY IS STRONGLY ASSOCIATED WITH THE HUMAN LEUKOCYTE ANTIGEN B-57 ALLELE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P114 N Tesch, M Vogel, JC Wasmuth, M Schulz, E Althausen, JK Rockstroh Overall we found a striking association between the presence of HLA-B-57 and occurrence of ABC-related HSR. Clearly the definition of HSR still remains a clinical challenge. However, prospective screening of HLA-B-57 may be helpful to reduce the number of ABC-associated HSRs. |
| P115 | [P115] ABACAVIR HYPERSENSITIVITY REACTION IN EUROSIDA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P115 W Bannister, N Friis-Møller, A Mocroft, J-P Viard, J van Lunzen, O Kirk, P Gargalianos, D Banhegyi, A Chiesi, J Lundgren Within this heterogeneous population, ABC HSR was reported in 6.5% of patients. There were no regional differences. Crude analyses found a decrease in incidence of HSR after 1/04, which could be due to improved clinical management and/or related to a switch in genotype (less HLA-B*5701+) among patients under follow-up. |
| P116 | [P116] SCREENING FOR HLA B5701 IN A POPULATION OF HIV PATIENTS OF DIVERSE ETHNIC ORIGIN EXPOSED TO ABACAVIR IN FRANCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P116 D Zucman, P De Truchis, C Majerholc, S Stegmann, S Caillat In our population, HLA B5701 testing was a useful test to prevent ABC HSR, with high specificity. This at risk allele is very rare Blacks but seems to be frequent in populations of Mahgreb and Europe. |
| P117 | [P117] VALUE OF THE HLAB*5701 ALLELE TO PREDICT ABACAVIR HYPERSENSITIVITY IN SPANIARDS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P117 S Rodriguez-Novoa, P Garcia, G Gonzalez, C Castellares, V Moreno, I Jimenez, J Gonzalez, V Soriano HLAB*5701 testing may be useful to predict ABC-associated HSR in Spaniards. Although the specificity is excellent, the sensitivity might be lower than in other Caucasian groups. Although the role of concomitant medications or concurrent illnesses in producing symptoms which might mimic ABC-related HSR could not be ruled out completely in our study, our results suggest that other genetic factors could be involved in the HSR associated to ABC in Spaniards. |
| P118 | [P118] PREDICT1: A NOVEL RANDOMISED PROSPECTIVE STUDY DESIGN TO DETERMINE THE CLINICAL UTILITY OF PROGNOSTIC SCREENING FOR HLA-B*5701 (STUDY CNA106030) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P118 S Hughes, K Parry-Billings, N Givens, D Wong, E Loeschel, P Parada, D Zamoryakhin, C Goodwin, A Hughes, J Muir, L Curtis, D Thorborn This is the first randomised, blinded, prospective study designed to determine the clinical utility of screening for a specific pharmacogenetic marker, HLA-B*5701, in the management of HIV patients. This design could be adapted by others to assess the utility of pharmacogenetic screening and the use of other medicines. In the absence of definitive data from well designed clinical studies,GSK does not recommend routine use of prognostic screening for HLA-B*5701 outside of a clinical research setting. Pharmacovigilance remains the cornerstone of successful ABC risk management. |
| Adverse Effects - Lipodystrophy |
|
| P119 | [P119] PREVALENCE OF LIODYSTROPHY AND DYSLIPIDEMIA AMONGST PATIENTS TAKING 30 VS 40 MG STAVUDINE BASED HAART IN INDIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P119 Sanjay N Pujari, A Dravid, E Naik, J Nadler, J Sinnott Significant prevalence of lipodystrophy and dyslipidemia is seen amongst patients taking first line HAART. This prevalence is no different in patients taking 30 vs 40 mg of d4T-based regimes except for lipohypertrophy and low HDL levels. |
| P120 | [P120] SWITCH FROM STAVUDINE (D4T) TO TENOFOVIR DF (TDF) IN COMBINATION WITH LAMIVUDINE (3TC) AND EFAVIRENZ (EFV) RESULTED IN CONTINUED VIROLOGIC SUPPRESSION AND IMPROVEMENT IN LIPOATROPHY THROUGH 2 YEARS IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P120 J VR Madruga, I Cassetti, J MAH Suleiman, L Zhong, J Enejosa, A K Cheng In virologically suppressed patients, switching d4T to TDF in a once-daily regimen containing 3TC and EFV maintains virologic suppression and provides continued CD4 cell increases through 2 years. Significant continued improvement in limb fat was observed. |
| P121 | [P121] PATIENTS WITH HIV ASSOCIATED LIPODYSTROPHY HAVE AN INCREASED RISK OF CARDIOVASCULAR DISEASE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P121 Paula Freitas, Davide Carvalho, Flora Correia, Rui Marques, Rosário Serrão, António Mota-Miranda, José Luis Medina The CVD risk evaluated using Framingham score is increased in HIV-infected patients under ART, and is higher in those with lipodystrophy. |
| P122 | [P122] LIPODYSTROPHY IN HIV(+) CHILDREN IN POLAND Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P122 Jolanta Popielska, Magdalena Marczynska, Sabina Dobosz Lipodystrophy in observed group was frequent (clinical signs-46%, hyperlipidemia-73% of cases). The mixed form was dominant. The risk factor is treatment with d4T, ddI, RTV. The high risk of lipodystrophy in effective treated children changes opinion about therapeutical success and should require new therapeutical options. Measurement of skin folds is a diagnostic method, but body composition based on BIA is not useful test for diagnosis of lipodystrophy. |
| P123 | [P123] CHANGES IN BODY SHAPE OF HIV-HCV CO-INFECTED PATIENTS UNDER PEG-INTERFERON AN RIBAVIRIN TREATMENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P123 Eva Martinez, Carla Estany, Cristina Tural, Anna Salas, Nuria Perez, Ana Canton, Ana Sanmarti, Bonaventura Clotet The effect of peg-interferon and ribavirin treatment (PGRBV) on the nutritional state of HIV-HCV coinfected patients has been extensively studied. One of its main consequences is anorexia and weight loss. However, little is known about the impact of anti-HCV therapy on lipodystrophy. |
| Adverse Effects - Adverse Effects - Metabolic |
|
| P124 | [P124] THE METABOLIC SYNDROME AT BASELINE IN THE D:A:D STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P124 Signe Worm, C Sabin, W El-Sadr, P Reiss, A Monforte, M Rickenbach, R Thiébaut, S de Wit, E Fontas, M Law, O Kirk, J Lundgren, N Friis-Moller 24% had MS at baseline. Dyslipidemia and hypertension were the most common components. Treatment related factors associated with MS included Pis and lipodystrophy. Lipodystrophy might be phenotypically linked to MS with central fat accumulation and changed glucose metabolism. Pis are known to cause dyslipidemia and altered glucose homeostasis. Future analyses will investigate whether specific clusters of risk factors, as MS, provide predictive information for the risk of CVD in HIV-infected over and above the individual components. |
| P125 | [P125] METABOLIC SYNDROME IN BLACK AFRICAN HIV PATIENTS. WHICH CRITERIA SHOULD WE USE? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P125 A Jayasuriya, P Allan, A Wade, S Das Our Black African HIV cohort had a higher prevalence of metabolic syndrome by IDF compared to NCEP criteria. This may be due to differences in the waist circumference parameters. Further studies are needed to establish parameters specific to ethnicity and clarify which criteria we should use in clinical practice. |
| P126 | [P126] PREVALENCE OF METABOLIC SYNDROME IN HIV POSITIVE PATIENTS USING NCEP-ATPIII AND IDF DEFINITIONS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P126 Juan C Chuluyan, Laura B Palacios, Arnaldo D Casiro, Graciela S Guaragna, Rosana L Cuini, Graciela C Guzman, Mirta S Vivian, Sebastian Man Using IDF criteria, there seems to be higher prevalence of metabolic syndrome among these HIV-infected patients. As there is no universally accepted definition, more studies are needed to establish the best criteria of metabolic syndrome in HIV infected patients. |
| P127 | [P127] ATAZANAVIR HAS A BETTER IMPACT ON LIPID PROFILES THAN FOSAMPRENAVIR AND LOPINAVIR IN PATIENTS MATCHED FOR BASELINE TRIGLYCERIDES AND CHOLESTEROL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P127 Stephane De Wit, Benedicte Poll, Coca Nescoi, Nathan Clumeck In patients with similar baseline lipid profiles, boosted Fosamprenavir and Lopinavir, provided a comparable increase in triglycerides and total cholesterol while Atazanavir led to a reduction of these two parameters. Change in HDL cholesterol was similar for the 3 drugs. |
| P128 | [P128] IMPROVEMENT OF LIPIDIC METABOLISM DOES NOT CHANGE THE CARDIOVASCULAR RISK SCORE IN 13 MONTHS OF OBSERVATION OF PATIENTS SWITCHED TO ATAZANAVIR-BASED REGIMEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P128 M Colafigli, S Di Giambenedetto, L Bracciale, E Montuori, E Tamburrini, A De Luca, R Cauda Our data show that treatment switch to ATV caused significant reductions in TC, HDL and TG levels; nevertheless this did not translate into significant changes in a cardiovascular risk score based on the Italian population. Switch strategies should be accompanied by changes in other preventable cardiovascular risk factors. |
| P129 | [P129] IPANEMA COHORT: A COMPARISON OF LIPID AND HEPATIC PARAMETERS IN PATIENTS TREATED WITH SQV/r IN OD OR BID DOSING Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P129 E Ortega, J Sanz, I Suarez, JA Terron, P Arazo, F Pulido, M Amado, P Labarga, R Escayola After a mean of 1.4 years on SQV/r, benign lipids, hepatic and glucose levels were seen in patients treated with either OD or BID regimens. |
| P130 | [P130] IPANEMA COHORT: EVOLUTION OF LIPID AND HEPATIC PARAMETERS IN PATIENTS TREATED WITH SQV/r USED IN ITS 200MG AND 500MG FORMULATIONS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P130 J Sanz, E Pedrol, E Ortega, I Suarez-Lozano, F Lozano, A Collado, ML Garcia-Alcalde, M Fernandez, J Galindo, R Escayola Treatment with SQV/r 200 or 500 mg was well tolerated, with benign evolution of the lipid, hepatic and glucose parameters. |
| P131 | [P131] LIPIDS AND LIPOPROTEINS IN HIV-SUBJECTS TREATED WITH LOPINAVIR/RITONAVIR (L) OR ATAZANAVIR/RITONAVIR (A) BASED ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P131 Andreas Trein, Eiko Schnaitmann, Werner O Richter In this unselected group of patients we could not find a significant difference in triglycerides or VLDL-triglycerides between patients on L or A based antiretroviral drug therapy. After switching from L to A significantly higher triglyceride concentrations were measured. Our data provide no evidence for a general lipid-friendly effect of atazanavir. |
| P132 | [P132] EFFECT OF TOTAL CHOLESTEROL (TC) LEVELS ON CHOICE OF ART REGIMEN AND ART MODIFICATIONS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P132 C Smith, C Sabin, M Johnson, F Lampe, M Youle, A Phillips There is no evidence that TC influences choice of initial regimen or ART changes in the 1st year, suggesting other interventions (dietary advice, statins). Higher pre-ART TC levels were associated with smaller TC increases. |
| P133 | [P133] LIPID-PROFILE OF LOPINAVIR/RITONAVIR (LPV/r) IN AN 18-MONTH FRENCH OBSERVATIONAL PROSPECTIVE COHORT (KALEOBS COHORT) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P133 Michel Dupon, Jean-Michel Livrozet, Laurence Morand-Joubert, François-André Allaert, Alain Lafeuillade As previously reported after a M9 follow-up in this cohort, the impact of LPV/r on lipids, when it exists, occurs early after treatment initiation. Changes in TC and TG are moderate and remain stable up to M18. |
| P134 | [P134] TRIGLYCERIDES AND SMALL, DENSE LOW-DENSITY LIPOPROTEIN IN HIV INFECTED PATIENTS TREATED WITH LOPINAVIR/RITONAVIR AS A COMPONENT OF THE FIRST COMBINATION ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P134 L Magenta, W O Richter, M Opravil, M Flepp, O Keiser, H Bucher, H Drechsler, P Schmid, J M Evison, M Cavassini, B Bernasconi, E Bernasconi Despite a high prevalence of hypertriglyceridemia in LPV-ART treated patients, a significant elevation of sdLDL-apo B was only observed in two patients (3.3%). |
| P135 | [P135] ROSUVASTATIN IN THE TREATMENT OF DYSLIPIDAEMIA IN HIV PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P135 S Das, M Boothby, C Stradling Rosuvastatin appears to be safe and effective in this HIV cohort even when used with fibrate and other lipid lowering agents. |
| P136 | [P136] CHANGES IN BODY WEIGHT, ANTHROPOMETRIC MEASUREMENTS AND LIPID LEVELS IN TENOFOVIR CONTAINING ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P136 J Wembri, J Wotherspoon, M Snow, M Schmid, F McCorry, E Ong There was a significant improvement in fasting cholesterol/HDLc ratio and BIA showed significant increase in body fat mass. |
| P137 | [P137] A RANDOMIZED, PROSPECTIVE COMPARISON OF THREE HYPOGLYCEMIC AGENTS IN HIV-INFECTED PATIENTS RECEIVING PROTEASE INHIBITORS, WHO DEVELOPED INSULIN RESISTANCE AND GLUCOSE INTOLERANCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P137 Leonardo Calza, Roberto Manfredi A PI-based HAART may lead to a moderate risk of hyperglycemia-hyperinsulinemia. Either gliclazide metformin or rosiglitazone, proved equally effective. |
| P138 | [P138] Prevalence of hypertriglyceridemia in HIV-infected women Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P138 Andreas Trein, Eiko Schnaitmann, Werner O Richter Compared to the general population prevalence of elevated triglycerides is substantially higher in HIV-infected women without or with ART. Compared to men HIV-infected women on ART had significantly lower triglyceride concentrations, severe hypertriglyceridemia was rare. |
| P139 | [P139] PERSISTENT RISK OF LIFE-THREATENING LACTIC ACIDOSIS AFTER STOPPING ANTIRETROVIRALS. REPORT OF TWO CASES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P139 Lorena Abusamra, Pedro Cahn, Marisa Espina Peña, Isabel Casetti, Patricia Patterson, Omar Sued, Alejandro Krolewiecki The timing of the described events after stopping therapy underlines the increased risk of lactic acidosis in patients with hyperlactatemia even after stopping ARVs. Careful monitoring of patients with hyperlactatemia should be kept after stopping therapy at least until normalization of lactate levels. |
| Adverse Effects - Mitochondrial |
|
| P140 | [P140] MITOCHONDRIAL EFFECTS OF DIDANOSINE DOSAGE REDUCTION WHEN ADMINISTERED TOGETHER WITH TENOFOVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P140 G Garrabou, S Lopez, E Negredo, F Cardellach, J Casademont, B Clotet, O Miro Although reduction of ddI from 400 to 250 mg, when administered together with TDF, and mtDNA content recovery, other adverse effects on mitochondrial function persist, suggesting the existence of other side effects apart of the inhibition of γ-polymerase. |
| P141 | [P141] MITOCHONDRIAL DNA (mtDNA) CONTENT IN ENFUVIRTIDE-TREATED HEALTHY VOLUNTEERS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P141 G Garrabou, S Lopez, V Rodriguez, N Riba, E Martinez, MC Villarroel, M Manriquez, J Casademont, F Cardellach, O Miro T20 treatment for one week on healthy volunteers does not cause PBMCs mtDNA depletion confirming the theoretically low mitochondrial toxicity profile. |
| P142 | [P142] EFFECTS OF ZIDOVUDINE-BASED AND NRTI-SPARING REGIMENS ON MITOCHONDRIAL/NUCLEAR (MT/N) DNA RATIOS AND MITOCHONDRIAL GENE EXPRESSION (mtRNA) IN PERIPHERAL BLOOD Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P142 M Harris, H Cote, A Thorne, I Gadawski, J Singer, J Montaner 48 wks of treatment with either NVP/LPV/r or ZDV/3TC-based regimens did not affect mt/n DNA ratios in antiretroviral-naïve adults. However, although not statistically significant given the small number of patients, trends were observed towards increasing mtRNA in the NRTI-sparing arm compared to decreasing mtRNA in the ZDV/3TC arms. |
| Adverse Effects - Neurological |
|
| P143 | [P143] EARLY DETECTION OF HIV SENSORY POLYNEUROPATHY USING INTRAEPIDERMAL NERVE FIBER DENSITY QUANTIFICATION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P143 E Skopelitis, K Aroni, A N Kontos, K Konstantinou, P Kokotis, N Karandreas, T Kordossis Damage of the peripheral nervous system is diagnosed by means of IENFD in the majority of HIV(+) individuals and this is associated with the presence of advanced disease and the level of prior immunosuppression. IENFD is the only means of early diagnosis-before the onset of symptoms and abnormal electrophysiology-and constitutes an objective method for prospective evaluation. Secondary branching may reflect the severity of symptomatic neuropathy. |
| P144 | [P144] HIGH EFAVIRENZ TROUGH CONCENTRATIONS (ETC) AND CNS TOXICITY ARE ASSOCIATED WITH CYP2B6 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) IN BLACK AFRICANS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P144 Shalini Andrews, Salim Fredericks, Yalda Jamshdi, Lorna Tinworth, Derek Macallan, David W Holt, Nick Carter, Syed T Sadiq All our black African patients with CNS toxicity and high ETC carried 516TT/785GG or 516GT/785AG in 2B6 suggesting utility of pre-treatment screening. Complete 2B6 sequencing data with novel SNP and allelic frequency for a larger data set will be available shortly. |
| P145 | [P145] PERIPHERAL NEUROPATHY IN PATIENTS AT THE LIGHTHOUSE CLINIC, LILONGWE, MALAWI Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P145 Wendy I Beadles, Daniel Clutterbuck, Andreas Jahn, Ralf Weigel Peripheral neuropathy is common in this setting and poses significant challenges in assessment. Screening with checklists may over estimate the true prevalence. 1/3 of patients are currently reporting symptoms suggestive of PN and approximately 10% receive symptomatic or alternative treatment. Validation of the clinical diagnosis of PN, grading systems and randomised trials of the use of Amitriptyline and early versus late switch of therapy are required. |
| P146 | [P146] NO FREQUENT REPORTING OF NEUROLOGICAL OR PSYCHIATRIC EVENTS DURING TMC125 TREATMENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P146 B Woodfall, G De Smedt, C Berckmans, B Baeten, M Peeters The incidence and severity of neuropsychiatric events observed with the 800mg dose of TMC125 were similar to that seen with placebo in this study. Phase III trials with a new formulation of TMC125 with comparable exposure to the 800mg bid phase 2 formulation are ongoing. |
| Adverse Effects - Renal |
|
| P147 | [P147] EVALUATION OF RENAL FUNCTION IN 316 HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P147 F Tordato, P Cicconi, M Bongiovanni, L Gazzola, C Tincati, R Ranieri, T Bini, A Volpi, D Brancaccio, A Gori, A d'Arminio Monforte The high prevalence of impairment of renal function in HIV-infected pts suggests the need of a frequent monitoring of renal function in this population. Role of immune reconstitution and of ART needs to be further investigated. |
| P148 | [P148] TENOFOVIR-ASSOCIATED NEPHROTOXICITY IN THE FIRST YEAR OF THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P148 Sofia Rocha, Sandra Xerinda, Rui Marques, Antonio Prisca, Carmela Pineiro, Rosario Serrao, Jorge Soares, Catia Caldas During the first year of therapy with TDF 38.8% patients developed renal dysfunction, the majority beeing of a mild nature. Patients need an assessment of renal function before initiating TDF and should be monitored, as an adjustment of the dose interval may be needed in case of renal impairment. |
| P149 | [P149] TENOFOVIR-ASSOCIATED RENAL TOXICITY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P149 Clare Davies, Andrew M Hall, Ian G Williams, Sara Madge, Simon G Edwards, Margaret A Johnson, John O Connolly Renal toxicity remains a concern in patients treated with TDF. Clinical presentation may be with renal dysfunction, Fanconi syndrome or osteomalacia. Our investigations suggest proximal tubular toxicity as a common pathogenic mechanism. We have developed a screen to detect renal injury. Strategies for early detection and prevention of renal toxicity will be discussed. |
| P150 | [P150] COMPARISON OF EFFICACY AND TOXICITY PROFILE OF ABACAVIR (ABA) AND TENOFOVIR (TDF) CONTAINING REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P150 C Smith, M Nelson, M Fisher, C Sabin, B Gazzard, S Mandalia, M Johnson, G Moyle In this cohort ABA and TDF had similar efficacy profiles, but TDF was associated with increased creatinine levels and reduced GFR, although this was of a small magnitude. |
| P151 | [P151] RENAL SAFETY PROFILE OF TENOFOVIR PLUS DIDANOSINE CONTAINING REGIMENS. RESULTS FROM THE DIDITEN COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P151 Félix Gutierrez, Antonio Antela, Francisco Jiménez, Ignacio Santos, Luis López, Jose R Blanco, Juan Berenguer, Pedro Ferrer, Santiago Moreno The renal safety profile of the combination of TDF and ddI in this highly pretreated cohort showed no significant changes in the CrCl over time and a low rate of discontinuation due to renal events. |
| P152 | [P152] THE SAFETY AND EFFICACY OF TENOFOVIR DF (TDF) IN COMBINATION WITH LAMIVUDINE (3TC) AND EFAVIRENZ (EFV) THROUGH 5 YEARS IN ANTIRETROVIRAL-NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P152 I Cassetti, J VR Madruga, J MAH Suleiman, L Zhong, J Enejosa, A K Cheng Through 5 years of therapy, TDF+3TC+EFV demonstrated sustained antiretroviral activity with continued immunologic recovery and was not associated with limb fat loss or renal adverse events in antiretroviral-naïve patients. |
| P153 | [P153] TENOFOVIR (TDF)- VERSUS NON-TDF-CONTAINING ART: RENAL SAFETY IN DAILY PRACTICE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P153 E Wolf, G Gunturu, C Koegl, E Jaegel-Guedes, H Jaeger We observed mild renal impairment in both groups (25% of TDF pts, 21% of non-TDF pts). However, in the TDF group also cases of moderate to severe renal impairment occurred. Relationship with TDF could not be excluded, but other cofactors partially contributed to abnormalities in renal function. |
| P154 | [P154] NEPHROTOXICITY IN HIV PATIENTS RECEIVING COMBINATION ANTIRETROVIRAL THERAPY INCLUDING TENOFOVIR: RESULTS FROM THE SCOLTA PROJECT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P154 Giordano Madeddu, Elena Ricci, Giuseppe De Socio, Silvia Carradori, Carmela Grosso, Patrizia Marconi, Giovanni Penco, Elena Rosella, Sebastiano Miccolis, Sara Melzi, Simona Landonio, Carla Lovigu, Paolo Bonfanti, Tiziana Quirino Both prevalence and incidence of nephrotoxicity were low in pts receiving TFV in a non-selected clinical setting. Renal injury in pts receiving TFV seems associated with the presence of co-morbidities and with advanced HIV infection. |
| P155 | [P155] CHANGES IN CREATININE CLEARANCE OVER TIME IN A PATIENT COHORT ON TENOFOVIR AS PART OF COMBINED ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P155 Imali Fernando, Dan Clutterbuck Previous studies showed a link between significant nephrotoxic events in this patient population and variables of baseline renal insufficiency, diabetes and advanced immunosuppression. It may be queried therefore whether the relative scarcity of these predisposing factors in the Edinburgh cohort helped prevent any significant renal events. |
| P156 | [P156] RENAL FUNCTION IN PATIENTS TAKING TENOFOVIR AND NON-TENOFOVIR BASED ANTIRETROVIRAL REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P156 M M Rosenvinge, B A Chelliah, J Goldblatt, S T Sadiq, M R Pakianathan There was no significant increase in renal toxicity for patients taking tenofovir, although those on a non-tenofovir based regimen showed a greater improvement in CrCl. The clinical signficance of this can only be ascertained by longer term follow up. |
| P157 | [P157] RENAL SAFETY PROFILE OF TENOFOVIR DF (TDF)-CONTAINING COMPARED TO NON-TDF-CONTAINING REGIMENS IN ANTIRETROVIRAL-NAÏVE PATIENTS WITH MILD RENAL IMPAIRMENT OR HYPERTENSION AND/OR DIABETES MELLITUS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P157 S Staszewski, A Pozniak, J Gallant, E DeJesus, SS Chen, J Enejosa, A Cheng In antiretroviral-naïve pts with mild renal impairment at baseline, HTN and/or DM, treatment with TDF through 96 weeks was not associated with increased risk of renal dysfunction. |
| P158 | [P158] URINARY PROTEOME ANALYSIS BY CAPILLARY ELECTROPHROESIS COUPLED MASS SPECTROMETRY (CE-MS) FOR DETECTION OF TENOFOVIR-ASSOCIATED KIDNEY DAMAGE IN HIV PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P158 Georg MN Behrens, Ulrike Moebius, Ala Gurjanov, Harald Mischak, Reinhold E Schmidt, Stefan Wittke Tenofovir therapy was associated with pathological urinary polypeptide patterns independent of serum creatinin. CE-ME may aid in early diagnosis of tenofovir-associated kidney damage. |
| P159 | [P159] A 100% ATAZANAVIR UROLITHIASIS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P159 Jean-Yves Liotier, Jean Tomasini, Georges Kreplak, Marc Bary, Myriam Kirstetter Such types of kidney stones have already been reported, but are still not precisely known, and none apparently 100% atazanavir. Which lead us to write the present poster. |
| Adverse Effects - Other |
|
| P160 | [P160] IS OLDER AGE A RISK FACTOR FOR ANTIRETROVIRAL TOXICITIES? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P160 C A Sabin, C J Smith, T Hill, A N Phillips While older patients are more likely to discontinue treatment without viral failure and to develop some adverse events this may be due to a higher incidence of intercurrent medical problems rather than being drug-related. |
| P161 | [P161] SWITCHING AN NRTI TO TDF DUE TO NRTI TOXICITY IS SAFE AND EFFECTIVE IN BOTH SEXES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P161 Maria J Galindo, Celia Miralles, Maria J Perez-Elias, Rosario Palacios, Piedad Arazo, Maria L Alvarez, Santiago Moreno Switching and NRTI to TDF for NRTI-toxicities is safe and effective virologically and immunologically in both men and women and leads to improvements in the safety profile in many of the subjects. There were some differences in the treatment-limiting toxicities associated with NRTIs between men and women. |
| P162 | [P162] THE APTIVUS® COMPASSIONATE USE PROGRAM (CUP): SAFETY AND EFFICACY DATA FROM 3,920 PATIENTS IN THE CLINIC Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P162 Bruno Hoen, William Towner, Milos Opravil, Vincente Soriano, Michael Kraft The Aptivus® CUP provided access to TPV for HTE patients. No unexpected safety issues were seen. Virologic and immunologic findings were consistent with RESIST data. |
| P163 | [P163] ANTIRETROVIRAL TOXICITIES VERSUS INCREASING ACCESS TO ANTIRETROVIRAL DRUGS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P163 Janak K Maniar, Alok J Maniar Incidence of toxicity varied with cART component. ZDV remains important component of cART with manageable toxicity. Hypersensitivity skin reaction often necessitates omitting NVP. Lipodystrophy and or hyperlipidemia has restricted d4T use. CNS toxicities rarely required omitting EFV. ABC hypersensitivity is rare in this study. IRIS related TB is difficult to diagnose and manage. |
| P164 | [P164] ADVERSE DRUG REACTIONS IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY – A PROSPECTIVE STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P164 Vipindas Chenghat, MR Parthasarathy, Varadarajan, P Thirumalaikolundusubramanian, Ganesh Athappan This study throws light on the critical importance of regular follow up. As most of them hail from rural area, their family members and NGOs taking care of them were trained to look for adverse drug reactions and motivated to bring them immediately; which has helped us to identify side effects and provide adequate care in time, thus reducing drug related morbidity and mortality. |
| P165 | [P165] CLINICAL IMPORTANCE OF OCULAR IMMUNE RECOVERY SYNDROMES. A PROSPECTIVE OBSERVATIONAL STUDY IN HIV+ INDIVIDUALS STARTING HAART IN BOTSWANA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P165 Christina Meenken, S A Danner, P J Ringens, T K Mudiayi, G J van den Horn These preliminary results suggest that ocular immune recovery phenomena may occur rather frequently in patients starting HAART. 3-Months follow-up showed only mild to moderate inflammatory reactions. The question whether these phenomena are transient, or may cause serious harm (e.g. epiretinal membrane formation as has been reported from retrospective studies), necessitating cessation of HAART, can be answered after long term follow-up data become available from this study. |
| P166 | [P166] INCREASED HAEMOGLOBIN A2 PERCENTAGE IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION – DISEASE OR TREATMENT? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P166 Andrew A Benzie, Michelle J Wilkinson, Lorraine A Phelan, Barbara J Bain The increased haemoglobin A2 percentage observed in HIV-infected patients has been confirmed. It is partly but not entirely attributable to therapy, specifically zidovudine therapy. The percentage of haemoglobin A2 may be high enough to lead to mis-diagnosis of beta thalassaemia trait if there is a lack of awareness of this unexpected effect of HIV infection and its treatment. |
| P167 | [P167] PANCREATIC TOXICITY REVISITED IN THE HAART ERA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P167 Roberto Manfredi, Leonardo Calza Epidemiologic-pathogenetic studies are needed to assess the significance-outcome of HIV-associated pancreatic abnormalities in the HAART era. Gabexate-octreotide indications deserve controlled studies, assessing cost-effectiveness, too. Persisting of altered pancreatic enzymes is of relevant concern when continuing antiretrovirals in these p. |
| P168 | [P168] UNLIKELY BED FELLOWS? SEXUAL DYSFUNCTION, RECREATIONAL DRUG USE, DEPRESSION AND HIV Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P168 Daniel Richardson, Harpal Lamba, David Goldmeier Recreational drug use, depression, peripheral neuropathy, lipodystrophy and hepatitis co-infection with or without elevated oestradiol levels are possible aetiological factors in sexual dysfunction in HIV infected men. Sexual dysfunction may impact upon adherence to anti-retroviral therapy and must be addressed by physicians involved in HIV care. The high rate of recreational drug use is of concern as both recreational drug use and sexual dysfunction have been associated with unsafe sexual behaviour in men who have sex with men. |
| P169 | [P169] RESPONSES TO TUBERCULOSIS TREATMENT WITH DIRECTLY OBSERVED TREATMENT STRATEGY (DOTS) IN HIV-POSITIVE AND HIV-NEGATIVE PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN A NIGERIAN HOSPITAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P169 Modupe O Fatokun The simultaneous use of HAART and DOTS is associated with an increase in adverse effects although the patterns are similar in both groups. However, the treatment interruption patterns were not influenced by this noticeable increase in adverse effects. |
| Adherence, Resistance and Disease Monitoring - Adherence |
|
| P170 | [P170] SWITCHING FROM TWICE DAILY (BID) ABACAVIR (ABC) AND LAMIVUDINE (3TC) TO A FIXED DOSE COMBINATION (FDC) OF ABC/3TC TAKEN ONCE DAILY (QD) IMPROVES PATIENT ADHERENCE AND SATISFACTION WITH THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P170 Desmond Maitland, Akil Jackson, Jess Osorio, Sundhiya Mandalia, Graeme Moyle, Brian Gazzard Switching from ABC and 3TC BID to an all QD ABC/3TC FDC based regimen was associated with improved subject adherence with fewer missed doses and improved dose accuracy and patient satisfaction with therapy. |
| P171 | [P171] DIFFERENT ADHERENCE LEVELS DO NOT INFLUENCE ON CD4 CELL COUNT IN VERY LONG ANTIRETROVIRAL EXPERIENCED PATIENTS: BEAT STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P171 Carmina R Fumaz, Jose A Muñoz-Moreno, Maria J Ferrer, Raquel López-Blázquez, José Moltó, Eugènia Negredo, Guadalupe Gómez, Bonaventura Clotet Two thirds of p maintained optimal levels of adherence after more than 10 y on antiretroviral therapy. Different adherence levels did not influence on CD4 cell count. A third of p recognized suboptimal treatment’s adherence. However, drug concentrations were below LLQ in only 6% of p. Thus, monitoring drug concentration might not reflect patients’ behavior in daily life. |
| P172 | [P172] WHY DO PATIENTS CONTINUE ON A NON-BOOSTED PI REGIMEN? DATA FROM A COHORT OF 1012 NELFINAVIR (NFV)-TREATED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P172 A Antela, JM Antunez, E Ortega, P Viciana, T Martin Most of the reasons to maintain NFV are closely related to the confidence of patients and physicians on an effective, well tolerated regimen, adapted to patient’s lifestyle, despite the higher number of pills when compared to more recent options. Most patients preferred to continue on NFV when offered changing to other drugs. |
| P173 | [P173] PATIENT PERCEPTION ABOUT NFV-CONTAINING THERAPY: RESULTS IN A COHORT OF 1012 PATIENTS FROM SPAIN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P173 A Antela, A Rivero, JL Sirvent, M Linares, J Sola Most of patients on NFV felt comfortable with their regimen. High levels of good perception regarding satisfaction, quality of life, comfort and infection control were obtained in this cohort of NFV-treated HIV-infected patients. |
| P174 | [P174] A COMPARISON BETWEEN AACTG ADHERENCE QUESTIONNAIRE AND THE 9-ITEM MORISKY MEDICATION ADHERENCE SCALE IN HIV-PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P174 Björn Södergård, Margit Halvarsson, Johanna Brännström, Anders Sönnerborg, Mary P Tully MMAS may be superior to AACTG, due to less internal attrition. Association between MMAS and viral load was found, but not for AACTG, possibly due to lack of power. AACTG may be too complicated for this unselected HIV-infected population, and the item wording may have encouraged social desirability explaining the higher adherence estimate for that measure. |
| P175 | [P175] MAINTAINED GOOD TREATMENT RESULTS AT THE LARGEST OUTPATIENT HIV-CLINIC IN SWEDEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P175 Margit Halvarsson, Björn Södergård, Johanna Brännström Good treatment results are possible to obtain even in an unselected patient population. The treatment results for the clinic have consistently been this high since 2002. |
| P176 | [P176] WILLEY´S 2-ITEM READINESS ASSESSMENT USED IN A SWEDISH SAMPLE OF HIV-INFECTED PATIENTS WITH ANTIRETROVIRAL TREATMENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P176 Björn Södergård, Margit Halvarsson, Johanna Brännström, Anders Sönnerborg, Mary P Tully The patients had a high degree of readiness for treatment. An association between degree of readiness and viral load was found. |
| P177 | [P177] PATIENTS' TREATMENT SATISFACTION IMPROVES WITH SIMPLER AND BETTER TOLERATED ANTIRETROVIRAL REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P177 Peio López de Munáin, Daniela Rojas, Jorge Del Romero Patient’s perception and declared treatment compliance reinforce the current strategy in HIV therapy of switching to more convenient and better tolerated ARV regimens. |
| P178 | [P178] DIAGNOSTIC VALUE OF THE 2-ITEM SWISS HIV COHORT STUDY ADHERENCE QUESTIONNAIRE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P178 Ann E Deschamps, Sabina De Geest, Anne-Mieke Vandamme, Eric Van Wijngaerden The 2-item SHCS-AQ predicted VF only moderately at baseline. However, after a second exposure to the SHCS-AQ at T3 and knowing that they were monitored electronically, excellent results were obtained. The effect of this intervention merits further investigation. |
| P179 | [P179] IPANEMA COHORT: EVALUATION OF PATIENT PREFERENCES REGARDING OD OR BID DAILY DOSING IN HIV TREATMENT CONTAINING SQV/R AND THE IMPACT ON ADHERENCE AND CLINICAL RESPONSE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P179 E Pedrol, E Ortega, J Sanz, I Suarez-Lozano, T Martin, F Vera, E Ribera, J Pasquau, J Ruiz Although patients expressed preference for OD therapies, neither adherence nor efficacy was affected in this cohort by dosing regimen. After a mean of 1.4 years of treatment with SQV/r, adherence and efficacy were good without significant differences between the groups. |
| P180 | [P180] CORRELATES OF ARVS DRUG ADHERENCE: A CASE STUDY OF MOI TEACHING AND REFERRAL HOSPITAL ELDORET, KENYA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P180 Joseph Mutitu Distance from home to the health centre, occupation of the patient, level of income, family cohesiveness, level of patient education, patient perceived quality of the service rendered by the health workers and the method used in patient recruitment (i.e. either through VCT or PMTCT or DTC) are the main factors that affect drug adherence. |
| P181 | [P181] HIV INFECTION IN PEOPLE ELDER THAN 60 YEARS IN A SPANISH HOSPITAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P181 Roberto Oropesa, Victor Gonzalez-Valles, Jose Perez-Silvestre, Vicente Abril, Miguel Garcia-Deltoro HIV infection in elderly predominate in men with sexual transmission. Most of them had AIDS. Many patients have undetectable viral load and CD4+ were almost twice the baseline counts. It suggests a good HAART adherence. The scheme most used was D4T-3TC with EFV or PI. Curiously, IDV and NFV were more used than newer PI or those boosted with ritonavir. |
| P182 | [P182] Adherence to HAART assessed by pharmacy refill data: influence in virological and immunological response Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P182 Angela C Ventura, João B Pires, Anabela Madalena Adherence over 90% was associated with lower viral loads and increased rate of virological response; also with increase of CD4 + cells count and rate of immunological response. Antiretroviral adherence must be improved and monitored over time. |
| P183 | [P183] INJECTION SITE REACTIONS (ISR) AND SUCCESS OF HAART INFLUENCE CONTINUED USE OF ENFUVIRTIDE (T20) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P183 Martin Vogel, Eva Wolf, Kevin Ummard, Christiane Koegl, Jan-Christian Wasmuth, Guelcan Bicim, Arend Moll, Hans Jaeger Successful HAART may overcome discontinuation of T20 due to ISR. Nevertheless, ISR was an independent factor leading to discontinuation of T20. Whereas occurrence rate was similar, ISR intensity was more pronounced in pts who discontinued T20. |
| P184 | [P184] PROSPECTIVE STUDY ASSESSING INJECTION SITE REACTIONS, QUALITY OF LIFE AND ENFUVIRTIDE ADMINISTRATION PREFERENCE USING BIOJECTOR® VERSUS NEEDLES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P184 M Loutfy, M Harris, J Raboud, S Shen, C Kovacs, R Halpenny, S Scriver, M Hoad, D Fletcher, B Trottier, S Dufrense, F Smaill, A Rachlis, S Walmsley, R Lalonde, C Tsoukas, S Trottier, J Montaner The Biojector® was associated with less severe ISRs and increased QoL in patients taking ENF versus needles. Most patients preferred the Biojector®. |
| P185 | [P185] IDENTIFICATION OF SEXUAL HEALTH PROBLEMS IN PERSONS LIVING WITH HIV Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P185 J Morgenstern, D van Laeken, C Nöstlinger, R Borms, J Bogner, R Colebunders We conclude that SH problems are an important cause of a decreased QOL of PLWH. Health care teams taking care of PLWH need adequate counseling training. Improving SH should be an important aim of every HIV treatment/care program. In some countries the integration of SH care issues into HIV-care needs to be recognized to a larger extent. |
| P186 | [P186] ANXIETY IN HIV PATIENTS ON HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P186 Benedetto M Celesia, Luciano Nigro, Valeria Milioni, Rosario La Rosa, Sergio Mavilla, Fabio Bisicchia, Maria T Mughini, Arturo Montineri This data underline the opportunity of anxiety evaluation and psychological support in patients with advanced HIV infection, after therapeutic failure, mainly when they live in unsafe social status. |
| P187 | [P187] ADHERENCE TO HAART AND SATISFACTION FROM MEDICAL CARE PROVIDED: A SURVEY AMONG HIV INFECTED PATIENTS IN GREECE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P187 N Pitsounis, S Peristeraki, N Tsogas, N Mangafas, M Chini, A Lioni, A Skoutelis, P Nikolaides, P Gargalianos, G Panos, T Kordosis, V Paparizos, A Gikas, M Moschou, G Chrysos, G Koratzanis The majority of patients reported adherence to HAART and satisfaction with medical care provided. Approximately 1 out of 10 patients missed more than 2 doses every month. Almost 7 out of 10 patients having side effects from HAART reported deterioration in quality of life. 6 out of 10 patients were satisfied with the number of pills they were taking. |
| P188 | [P188] TREATING HIV IN EAST LONDON: FACTORS INFLUENCING THERAPY IN A DIVERSE POPULATION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P188 Jane Anderson, Fowzia Ibrahim, Cecilia Bukutu We report high levels of antiretroviral therapy use, unrelated to ethnicity, gender or sexual orientation, in a diverse inner city population. Religious belief has an important bearing on treatment decisions but there is also evidence of a pluralistic approach to therapy. |
| P189 | [P189] PROMOTING HEALTHY LIFESTYLE CHANGES IN A NURSE-LED HIV ROUTINE MAINTENANCE CLINIC Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P189 L Mathers, C Wilson, P McGinness, P Topping, C Glover, D Kennedy, A Seaton, A Winter, R Nandwani We have successfully reorganised our service to meet the needs of an expanding patient cohort by introducing a nurse-led routine maintenance clinic. This has improved patient choice by offering an evening clinic, enhanced our ability to promote healthier lifestyles, and has the potential to reduce demand on medical clinics by up to 900 clinic visits per year. |
| P190 | [P190] TRAVELLING WITH ART (ANTIRETROVIRAL THERAPY) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P190 Catherine C Smith By recognising and addressing the issues around travelling with ART, it is possible to provide pre-travel advice which enables HIV positive patients to reduce the risk of poor adherence to antiretroviral therapy during travel and to travel more confidently with their medication. |
| P191 | [P191] MEDICAL COSTS ASSOCIATED WITH NON-ADHERENCE TO HAART IN AN ITALIAN OBSERVATIONAL COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P191 A Ammassari, MP Trotta, M Merito, P Marconi, A d'Arminio Monforte, A Antinori In our study, ART non-adherence did not significantly affect total and ART costs, but increased considerably inpatient expenditures. |
| P192 | [P192] FACILITY-BASED SUPPORT GROUP: A VIABLE STRATEGY FOR IMPROVING ADHERENCE TO ARVS IN COMPREHENSIVE HIV CARE AND TREATMENT PROGRAMS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P192 Yakubu M Adamu To support treatment adherence and follow up of patients on ART, a facility-based PLHA support group can be the option that links the facility and the community and assists with rapid tracking of treatment defaulters. |
| P193 | [P193] SCALING UP DRUG ADHERENCE: A COMPARATIVE STUDY OF PATIENTS FROM NOMADIC AND FARMING COMMUNITIES IN KENYA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P193 Joseph Mutitu The nomadic way of life has a great influence on the rate of drug adherence. More specific strategies aiming at scaling up the level of drug adherence among nomadic communities should be implemented. |
| P194 | [P194] AN HIV-PATIENT HAS REFUSED TO PROCEED WITH HAART: REASONS, UPSHOTS, AND FURTHER STRATEGY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P194 Stella V Minaeva, Grigoriy F Moshkovich HAART improves quality of life, prolongs its duration, and prevents opportunistic infections. That is why it is very important to initiate HAART in time and save treatment adherence. |
| P195 | [P195] RELATIONSHIP BETWEEN TIME TO VIRAL LOAD SUPPRESSION AND FIRST MONTH ADHERENCE TO HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P195 R A Rode, B C Vrijens, A C Lange, K R Niemi, K J Wikstrom, R S Heuser, T J Podsadecki ARV-naïve HIV-1 infected subjects achieving optimal adherence during the first month of HAART are more likely to achieve VLS and do so more quickly than those who do not. |
| Adherence, Resistance and Disease Monitoring - Resistance |
|
| P196 | [P196] PHENOTYPIC AND GENOTYPIC DETERMINANTS OF TMC114 (DARUNAVIR) RESISTANCE: POWER 1, 2 AND 3 POOLED ANALYSIS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P196 S De Meyer, T Vangeneugden, E Lefebvre, H van Marck, H Azijn, I De Baere, B van Baelen, MP de Béthune BL TMC114 susceptibility was the strongest predictor of virologic response. TMC114 RAMs provide a useful tool to predict virologic response to TMC114 treatment. |
| P197 | [P197] BETTER TREATMENT RESPONSE (TR) TO TIPRANAVIR/r (TPV/r) COMPARED TO LOPINAVIR/r (LPV/r) IN PATIENTS WITH HIGHER LOPINAVIR (LPV) MUTATION SCORES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P197 S Walmsley, D Hall, J Sherer, C Boucher As LPV scores increased (>3), phenotypic resistance level increased more for LPV than TPV. Week 48 TRs were greater in patients taking TPV/r vs. LPV/r. In patients whose BL isolates were genotypically LPV sensitive but had >3 LPV score mutations, virologic responses were significantly better with TPV/r. |
| P198 | [P198] PREDICTED FUTURE EFFECTS OF LEVEL OF VIRAL LOAD (VL) SUPPRESSION BY THE 36TH WEEK Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P198 Kit N Simpson, Rukmini Rajagopalan, Brigitta Dietz Small difference in viral suppression at 36 weeks may have a large effect on the time a patient remains on the initial therapy because the hazard of viral rebound declines substantially over time for ARV-naïve patients. Physicians and patients should discuss trade-offs between ease of use and tolerability versus potency and durability before selecting the initial ARV regimen. Besides the impact on clinical outcomes, this decision has the potential to affect both short and long term health-related cost and quality of life. |
| P199 | [P199] STUDY 934: SIGNIFICANTLY LOWER FREQUENCY OF THE M184V MUTATION ON FTC + TDF + EFV COMPARED TO COMBIVIR + EFV AT WEEK 96 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P199 D J McColl, N A Margot, S M Chuang, S S Chen, A K Cheng, M D Miller Pts with virologic failure remained susceptible to multiple NRTIs, including TFV. Significantly fewer pts on FTC+TDF+EFV compared to CBV+EFV developed the M184V mutation by week 96. No pt developed K65R by week 96. |
| P200 | [P200] PREVALENCE OF PRIMARY RESISTANCE IN THERAPY-NAïVE PATIENTS IN GERMANY: COMPARISON OF DIFFERENT INTERPRETATION SYSTEMS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P200 Heribert Knechten, Britta Ranneberg, Jan van Lunzen, Gerd Faetkenheuer, Matthias Kirsch, Christian Höhn, Robert Ehret, Patrick Braun The prevalence of primary resistance analysed by Stanford db corresponded with results found in other studies. The distribution between the detected resistances to NRTIs, NNRTIs and PIs differed slightly with higher fractions for NRTIs. In contrast the prevalence of resistance-associated mutations using the Bennet algorithm was lower. However, data of prevalence of resistance depend on the algorithm used. The analyses of non-B subtypes (here 23%) becomes more important in Germany. |
| P201 | [P201] PREVALENCE OF PRIMARY RESISTANCE MUTATIONS IN NEWLY DIAGNOSED HIV PATIENTS IN MALAGA PROVINCE: STUDY MALAGA-2 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P201 Rosario Palacios, Isabel Viciana, Ivan Perez, Javier de la Torre, Fernando Salgado, Sonsoles Fernandez, Juan Roldan, Jesús Santos The prevalence of primary RM in pts with newly diagnosed HIV infection from Southeast Spain is similar as reported by others. We did not find a factor related with its presence. It is worthy the high prevalence of HIV subtype not B in Spanish population. There were few seroconverters and many cases with a late stage of disease among pts with newly diagnosed HIV infection. |
| P202 | [P202] VIRAL DYNAMICS AS PREDICTOR OF TREATMENT OUTCOME OF PATIENTS RECEIVING RESISTANCE TESTING-GUIDED SALVAGE HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P202 Valerio Tozzi, R Bellagamba, F Castiglione, A Amendola, F Forbici, C Gori, R D'Arrigo, A Bertoli, E Nicastri, G D'Offizi, J Ivanovic, MF Salvatori, MR Capobianchi, A Antinori, CF Perno, P Narciso In pts receiving GRT-guided salvage HAART, pvl changes between week 2 and 8 were predictive of virological failure. Virological failure was associated with a rapid appearance of emergent resistance-associated mutations. |
| P203 | [P203] A CLINICALLY VALIDATED MUTATION SCORE FOR RESISTANCE TO FOSAMPRENAVIR/RITONAVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P203 Bernard Masquelier, Lambert Assoumou, Diane Descamps, Laurence Bocket, Jacqueline Cottalorda, Annick Ruffault, Anne-Geneviève Marcelin, Laurence Morand-Joubert, Catherine Tamalet, Charlotte Charpentier, Gilles Peytavin, Zeina Antoun, Françoise Brun-Vézinet, Dominique Costagliola This clinically validated fAPV/r mutation score should be of interest for the clinical management of PI-experienced patients. |
| P204 | [P204] HIV REPLICATION CAPACITY AND GENOTYPE CHANGES IN PATIENTS UNDERGOING TREATMENT INTERRUPTION OR LAMIVUDINE MONOTHERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P204 N Gianotti, S Tiberi, S Menzo, A Danise, E Boeri, L Galli, M Clementi, A Lazzarin, A Castagna S. Raffaele In the E-184V Study, HIV RCR was associated with both viral rebound and CD4 cell decline. RCR was also associated with the de-selection of the RT 184V and 41L mutations. The de-selection of the 41L mutation was associated with the magnitude of viral rebound and the de-selection of the 184V mutation with the degree of CD4 cell decline. |
| P205 | [P205] LACK OF VIROLOGIC RESPONSE TO THE COMBINATION OF TIPRANAVIR/RITONAVIR + ENFUVIRTIDE IN TREATMENT EXPERIENCED HIV-INFECTED PERSONS WITH MULTI-DRUG RESISTANT VIRUS CAN BE PREDICTED BY THE PRESENCE OF TWO OR MORE OF SIX MUTATIONS FROM FIVE POSITIONS IN PROTEASE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P205 Rodger D MacArthur, Debra Richmond, Lawrence R Crane The presence of two or more mutations from a small subset of all mutations known to limit TPV/r activity reliably predicted lack of virologic response to an antiretroviral regimen containing TPV/r + ENF. |
| P206 | [P206] CHARACTERIZATION OF N(t)RTI RESISTANCE ASSOCIATED WITH THE RARE RT MUTATION K65N IN HIV-1 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P206 T Pattery, G Muyldermans, M-P de Béthune, S De Meyer, Y Verlinden, L Laenen, P Mc Kenna A search of Virco’s genotype database (243,608 samples) showed 33 samples (0.013%) with K65N and 32 samples (0.013%) with K65N as part of a mixture with other variants at position 65. Investigations are ongoing to understand if this mutation arises spontaneously or develops within the population due to previous exposure to specific N(t)RTI therapies. |
| P207 | [P207] EFFECT OF DRUG RESISTANCE ON THE EXPRESSION OF ACTIVATION MARKERS AND INTERLEUKIN-7 RECEPTOR ON CD4 AND CD8 CELL SUBSETS IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P207 Jean-Pierre Routy, Francois Mercier, Vincent Calvez, Thomas Klimkait, Francois Hamy, Mohamed-Rachid Boulassel Expression of cell activation and IL-7Ra on CD4 and CD8 subsets were not influenced by WT or DR variants. The presence of compensatory mutations might explain the absence of differences. Further studies are warranted with a larger population where cell activation, IL-7Ra and programmed death-1 will be assessed. |
| P208 | [P208] SUCCESSFUL ANTIRETROVIRAL SEQUENCING OF PATIENT-DERIVED HIV-1 ISOLATES CONTAINING A K65R MUTATION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P208 Wenoah A Veikley, David Anderson, Trevor N Hawkins Development of the K65R mutation was rare. Once the K65R occurred, a variety of successful subsequent regimens were constructed that showed long-term durability. |
| P209 | [P209] LIMITED CROSS-RESISTANCE TO TIPRANAVIR IN PATIENTS PREVIOUSLY TREATED WITH TWO OR MORE PROTEASE INHIBITORS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P209 V M Kohlbrenner, D B Hall, J D Baxter, C F Perno, D L Mayers TPV maintains significant antiviral activity (FC IC50 ≤4-fold) against majority of HIV-1 clinical isolates resistant to other PIs. High level resistance to TPV (>10-fold) is uncommon (<2.5%) in viruses from HTE patients who have taken >2 PIs. |
| P210 | [P210] GENOTYPIC RESISTANCE TO TIPRANAVIR/RITONAVIR (TPV/r) IN THE ITALIAN EAP BI 1182.16 STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P210 A Saracino, F Suter, G Di Perri, M Galli, A Cargnel, F Mazzotta, P Grossi, B Grisorio, G Pastore, C Tinelli, L Monno, G Angarano Our study suggests that current TPV-associated mutation list does not fully reflect the genotypic profile of TPV resistance and needs to be further verified. |
| P211 | [P211] V118I MUTATION AS MARKER OF ADVANCED HIV INFECTION AND DISEASE PROGRESSION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P211 M Zaccarelli, V Tozzi, P Lorenzini, F Forbici, P Narciso, F Ceccherini-Silberstein, MP Trotta, G Liuzzi, CF Perno, A Antinori The onset of V118I mutation after treatment failure is unfavourable for the patient and can be considered a marker of disease progression. A possible interpretation is that V118I mutation usually arises after the appearance of other NRTI mutations, such as TAM, to which it was found significantly associated, thus representing a further evolution of HIV towards an increased level of drug resistance. |
| P212 | [P212] DECLINE IN THE NUMBER OF PATIENTS SUSCEPTIBLE OF RESISTANCE TESTING: 2000-2006 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P212 Beatriz Hernandez, Maria J Perez-Elias, Carolina Gutierrez, Jose L Casado, Ana Moreno, Fernando Dronda, Carmen Page, Juan C Galan, Santiago Moreno The therapeutic regimes and strategies recommended nowadays have lowered the number of patients experiencing therapeutic failure and therefore the demand of HIV resistance testing. An important proportion of patients with therapeutic failure have already failed previously more than once. |
| P213 | [P213] EVALUATION OF 3 EXPERT SYSTEMS FOR GENOTYPIC ANALYSIS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P213 Franco Maggiolo, Annapaola Callegaro, Monica Airoldi, Veronica Ravasio, Giampietro Gregis, Fredy Suter The 3 ES were able to significantly predict the virologic outcome of genotypic-based HAART regimens. Their prediction capacity was similar. Their use may help clinicians in the interpretation of complex mutational patterns. |
| P214 | [P214] REDUCTION IN DRUG RESISTANCE PREVALENCE IN TREATMENT-EXPERIENCED PATIENTS: VARIED ESTIMATES ACCORDING TO EMPLOYED METHODOLOGIES IN A CLINICAL COHORT STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P214 S Di Giambenedetto, M Colafigli, C Pinnetti, M Prosperi, L Bracciale, A Bacarelli, J Schwarz, R Cauda, A De Luca All analyses showed a reduction of DR to all classes in recent years. Reduction was particularly evident when the treated population was used as denominator, given the reduction of virological failures. |
| P215 | [P215] SELECTION OF MUTATIONS IN TREATMENT-EXPERIENCED PATIENTS FAILING TDF-BASED REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P215 E Magiorkinis, D Paraskevis, C Haida, A Vassilakis, P Gargalianos, M Lazanas, V Paparizos, T Kordossis, A Antoniadou, G Panos, A Hatzakis Our findings revealed that additional novel mutations (K70E/G/N) can be selected by regimens that include TDF in treatment-experienced patients. The impact of those mutations on TDF phenotype should be investigated. |
| P216 | [P216] GENOTYPIC RESISTANCE IN HIV+ NAÏVE PATIENTS ENROLLED IN A 96-WEEK RANDOMIZED TRIAL COMPARING ABACAVIR (ABC) VS. STAVUDINE (D4T), BOTH COMBINED WITH LAMIVUDINE/EFAVIRENZ (3TC/EFV) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P216 E Ferrer, J Niubo, D Podzamczer, M Crespo, J Gatell, P Sanchez, J Sanz, S Veloso, J Llibre, P Barrufet, M Ribas, E Merino, J Lacasa, C Alonso, M Aranda, F Pulido, J Berenguer, ABCDE Study Team In this 96-week trial only 3% (7/227) had VF associated with the presence of RM. We observed a prevalence of overall RM at BL of 5.3%, and of only 1.3% of NNRTI-associated RM. The BL NRTI-RM detected were often not associated with VF. |
| P217 | [P217] KINETIC CHARACTERISATION OF PROTEASE INHIBITOR BINDING TO HIV-1 VARIANTS WITH DECREASED TMC114 SUSCEPTIBILITY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P217 I Dierynck, M De Wit, I Keuleers, J Vandersmissen, E Gustin, K Hertogs Decreased binding affinity to MDR variant enzymes explains the molecular mechanism of resistance to Pis. Further kinetic characterisation will explore the influence of individual mutations on TMC114 binding to HIV-1 protease. |
| P218 | [P218] DETECTION OF LOW FREQUENCY DRUG RESISTANT MUTATIONS IN ANTIRETROVIRAL-TREATED HIV-1C INFECTIONS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P218 Harriet Okatch, Vladimir Novitsky, Myron Essex Single genome sequencing allows for the detection of low frequency mutation below the threshold of 30% for bulk sequencing, allows early detection of these mutations for some samples and in addition can detect mutations otherwise missed by conventional methods of detection. |
| P219 | [P219] SELECTION OF L214F AFTER TENOFOVIR FAILURE: ROLE IN RESISTANCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P219 Carolina Gutierrez, Maria Jesus Perez-Elias, Carmen Page, Beatriz Hernandez, Jose Luis Casado, Ana Moreno, Fernando Dronda, Juan Carlos Galan, Santiago Moreno The mutation L214F is associated with tenofovir failure and could be contributing to resistance to the drug. As previous studies showed, the association of L214F and the patterrn of TAM 1 could be associated with a decrease in the viral response. |
| P219A | [P219A] OUTCOMES OF ANTIRETROVIRAL REGIMENS CONTAINING ABACAVIR (ABC) WITH TENOFOVIR (TDF) IN TREATMENT-EXPERIENCED PATIENTS: PREDICTORS OF RESPONSE AND DRUG RESISTANCE EVOLUTION IN FAILING PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P219A S Di Giambenedetto, C Torti, F Castelnuovo, N Manca, M Colafigli, M Prosperi, R Cauda, G Carosi, A De Luca Responses to TDF+ABC containing regimens in this cohort should be interpretaed in the light of the heavy treatment experience. Prior use of multiple regimens, of TDF and baseline M41L were associated with worse virologic responses; use of PI in the regimen predicted better responses. TAMs appeared to drive viral evolution toward the development of 74V instead of 65R. |
| P220 | [P220] COST-EFFECTIVENESS OF GENOTYPIC ANTIRETROVIRAL RESISTANCE TESTING IN HIV-INFECTED PATIENTS WITH TREATMENT FAILURE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P220 Pedram Sendi, Huldrych F Guenthard, Mathew Simcock, Bruno Ledergerber, Joerg Schuepbach, Manuel Battegay GRT in HIV infected patients with ART failure is a cost-effective use of scarce health care resources and beneficial to the society at large. |
| P221 | [P221] LONG-TERM EFFICACY OF SALAVAGE ANTIRETROVIRAL THERAPY GUIDED BY GENOTYPIC RESISTANCE TESTING Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P221 Arne Kroidl, Mark Oette, Stefanie Koch, Rolf Kaiser, Martin Däumer, Dieter Häussinger Salvage therapy guided by GRT using the geno2pheno tool may result in a durable virologic response. Moreover high percentages of patients undergo treatment adjustment after shorter periods. |
| P222 | [P222] GENOTYPIC RESISTANCE TESTING IN NEWLY DIAGNOSED HIV PATIENTS IN GLASGOW Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P222 A Ho, D Yirrell, A Winter, R Nandwani, A Seaton, R Fox The prevalence of primary resistance in our unit is similar that found elsewhere in the UK, and our results clearly demonstrate the benefit of routine baseline resistance testing. |
| P223 | [P223] PREVALENCE OF MUTATIONS IN INFECTIONS WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE BF IN ANTIRETROVIRAL EXPERIENCED AND NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P223 Patricia Patterson, Lorena Abusamra, Omar Sued, Alejandro Krolewiecki, Pedro Cahn Patients infected with subtype BF were clinically indistinguishable from patients with subtype B. Mutations for the reverse transcriptase and protease regions had similar distribution among groups, except the TAM L210W which was more prevalent in the subtype B group. Further studies should evaluate the predictive value of genotypic assays in subtype BF infections. |
| P224 | [P224] MEDICAL PROFESSIONALS’ ATTITUDES AND KNOWLEDGE ABOUT GENOTYPIC TESTING Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P224 Ramesh Babu Rayapu, S B Rani, K R Sandhya, Ayodhya K Ramaiah, R Sharath The Genotypic testing facilities are not available in many parts of India. Although the genotypic test is often used and relied upon but still few in medical profession have enough knowledge of resistance mutations. Hence there is a dire need to provide knowledge about resistance mutations and in genotypic testing to physicians treating PLW HIV/AIDS. It is necessary to create genotypic testing facilities abundantly. |
| P225 | [P225] IMPACT OF TAMS IN VIRAL RESPONSE OF A QUADRUPLE NRTI REGIMEN IN HIV-1 INFECTED PATIENTS WITH A MULTI-DRUG RESISTANT VIRUS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P225 A Bonjoch, JM Llibre, JA Iribarren, R López-Blázquez, E Negredo, MJ Galindo, C Miranda, P Domingo, B Clotet Therapy with TZV/TDF could maintain an acceptable immunological response with a mean drop of 1 log in VL at least up to 6 months in highly pretreated pts. A worse viral response were related to the coexistence of 67N and 41L mutations. While new agents become available to construct a feasible salvage this non-suppresive regimen appears a safe option. |
| P226 | [P226] IMPACT OF DIFFERENT TAMS ON OUTCOME OF A HAART REGIMEN WITH ABC+3TC+AZT (TRIZIVIR) AND TDF Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P226 Stephan Dupke, Thomas Berg, Bettina Hintsche, Christoph Mayr, Frank Schlote TZV+TDF is a simple and potent treatment option for moderately pretreated patients. L210W was identified as key mutation for non-response. In contrast to established algorithms the CTP-score enables prediction of combination therapy and might be a beneficial tool to predict response to TZV+TDF. Due to the small number of patients further evaluation is necessary. |
| P227 | [P227] RETROSPECTIVE STUDY FOR MUTATIONS ASSOCIATED WITH TREATMENT FAILURE TO TDF-BASED REGIMENS: IDENTIFICATION OF A NOVEL SITE AT CODON 138 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P227 E Magiorkinis, D Paraskevis, G Magiorkinis, C Issaris, P Gargalianos, M Lazanas, V Paparizos, T Kordossis, A Antoniadou, G Panos, A Hatzakis In addition to the previously described resistance mutations (M41L and D67N) associated with reduced response to TDF, a novel site (mainly E138A) was identified to be significantly associated with treatment failure to TDF-containing regimens. |
| P228 | [P228] DIFFERENT RESISTANCE PATTERNS SELECTED AFTER FAILURE TO FIRST ARV THERAPY IN A ROUTINE PRACTICE FRENCH COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P228 L Morand-Joubert, C Amiel, C Jacomet, P De Truchis, H Bideault, Y Levy, C Cheneau, B Bonnet, A Trylesinski, C Aubron-Olivier In this routine practice cohort, despite the early stage of treatment resistant virus was found frequently. |
| P229 | [P229] ANALYSIS OF THE INFLUENCE OF HIV-1 PROTEASE-SPECIFIC T-CELLS ON THE SEQUENCE OF HIV-1-PROTEASE AND THE DEVELOPMENT OF DRUG RESISTANCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P229 Sandra Muller, Birgit Schatz, Kathrin Eismann, Silke Bergmann, Michael Bauerle, Hauke Walter, Barbara Schmidt, Klaus Korn, Bernd Spriewald, Ellen Harrer, Thomas Harrer Our study demonstrates that the HIV-1-specific CTL response shapes the sequence of the PR. The interaction between CTL response and drug resistance mutations may have important clinical implications for to the understanding of drug resistance pathways and the design of therapeutic vaccines. |
| P230 | [P230] DIFFERENT DEVELOPMENT OF HIV DRUG RESISTANCE MUTATION PATTERNS IN SUBTYPE 06_CPX AFTER MOTHER-TO-CHILD TRANSMISSION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P230 Martin Stürmer, Amina Carlebach, Schlomo Staszewski, Hans W Doerr, Richard Linde, Christoph Königs Although infected with the same virus and treated with NFV, different DRMP developed in both patients. Whether the nucleoside backbone, course of viral suppression, or different host environment is responsible for this variability must be confirmed in larger studies. |
| P231 | [P231] FAILURE OF LOPINAVIR/RITONAVIR-CONTAINING REGIMEN WITH NEWLY SELECTED PI RESISTANCE MUTATIONS IN AN ANTIRETROVIRAL NAÏVE PATIENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P231 Stefanie Koch, Arne Kroidl, Mark Oette, Ruth Petch, Martin Däumer, Rolf Kaiser, Dieter Häussinger This is the second published case of an ART-naïve patient selecting PI mutations on an LPV/r-containing triple therapy. The occurrence of newly selected PI-mutations in combination with NRTI-mutations has led to the emergence of virological failure despite virtual phenotypic PI-susceptibility. |
| Adherence, Resistance and Disease Monitoring - Disease Monitoring |
|
| P232 | [P232] DISTRIBUTION OF VIRAL ANTIGEN DEPOSITS AND PRODUCTIVELY INFECTED CELLS IN LYMPHOID TISSUE IN DIFFERENT STAGES OF HIV SEROCONVERSION AND IN CHRONIC INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P232 H J Stellbrink, K Tenner-Racz, J van Lunzen, B Zöllner, P Racz, for the German Competence Network The pattern of virus production in lymphoid tissue during early seroconversion differs from that in late seroconversion and chronic infection. Virus production in germinal centers is still low at this stage, indicating that the optimal microclimate for HIV replication is established later during seroconversion. . . . |
| P233 | [P233] CEREBROSPINAL FLUID VIRAL LOADS REACH BELOW 2 COPIES/ML IN HIV-1 INFECTED PATIENTS WITH EFFECTIVE HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P233 Aylin Yilmaz, Bo Svennerholm, Lars Hagberg, Magnus Gisslén We could not demonstrate any persistent viral replication in the CSF of HIV-1 infected patients on effective HAART, rendering it unlikely that CSF acts as a viral reservoir with the risk of re-seeding HIV-1 to the periphery. |
| P234 | [P234] ADULTS WITH PERINATALLY ACQUIRED HIV-1 INFECTION: ADHERENCE, RESISTANCE AND DISEASE MONITORING Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P234 C Foster, S Portsmouth, S McDonald, S Fidler This small cohort illustrate the breadth of complex medical, psyhcosocial, ARV and adherence needs of young people with perinatally acquired HIV infection transfering to adult services. |
| P235 | [P235] NEWLY DIAGNOSED HIV INFECTION AT A REFERENCE CENTRE OF NORTHERN ITALY, 2004-2006 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P235 Roberto Manfredi, Leonardo Calza A national surveillance of HIV infection seems mandatory, to have a monitoring and plan educational-preventive measures. The increased sexual transmission, the rising immigrant rate, the frequency of AIDS presenters and concurrent STD, are of particular concern. |
| P236 | [P236] EPIDEMIOLOGY OF PRIMARY DRUG RESISTANCE IN CHRONICALLY HIV-INFECTED PATIENTS IN GERMANY: THE RESINA-STUDY 2001-2005 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P236 Mark Oette, Rolf Kaiser, Martin Däumer, Gerd Fätkenheuer, Jürgen K Rockstroh, Heribert Knechten, Dieter Häussinger The prevalence of primary HIV drug resistance was estimated at 9% in chronically infected HAART-naïve patients in the largest state of Germany, mostly due to NRTI-associated mutations. No risk factor for primary resistance could be identified. We found a moderate increase of prevalence almost reaching statistical significance. Thus, routine genotypic resistance testing should be performed before administration of first-line ART. |
| P237 | [P237] OUTBREAK OF SUBTYPE CLADE C HIV INFECTION AMONGST SCOTTISH HETEROSEXUALS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P237 Ciara Cunningham, David L Yirrell, Sheila O Cameron, D H Kennedy, R Fox, A Seaton, C Love, Rak Nandwani Documented clusters of heterosexually acquired HIV infection are rare. This cluster represents perhaps the earliest evidence of onward heterosexual transmission of clade C HIV within a group of U.K. born individuals. |
| P238 | [P238] NOCTE STUDY: BASELINE TREATMENT BELIEFS ARE MORE INFLUENTIAL THAN NUCLEOSIDE DOSE FREQUENCY FOR ADHERENCE TO EFAVIRENZ-BASED HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P238 Robert Horne, Vanessa Cooper, Grace Gellaitry, Bernard Vrijens, Anne-C Lange, Martin Fisher, David White Adherence to EFV-based HAART was not predicted by BID vs. QD dosing. Patients’ beliefs about HAART predicted persistence with HAART with implications for the design of evidence-based adherence interventions. |
| Community Initiatives |
|
| P239 | [P239] A DEDICATED MINORITY CLINIC FOR HIV PATIENTS – A STRATEGY TO ACHIEVE HIV TREATMENT SUCCESS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P239 D Jayaweera, M Robinson, H Archer, H Riviera Treatment outcomes at this clinic were similar among the Haitian population and other minorities. The data from this study suggest that availability of multilingual and culturally sensitive staff may improve clinical outcomes in US minority populations. Further investigation is warranted. |
| P240 | [P240] ROLE OF COMMUNITY PARTICIPATION AND NON GOVERNMENTAL ORGANISATIONS IN DRUG THERAPY FOR HIV PATIENTS – A SOUTH INDIAN SCENARIO Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P240 Vipindas Chenghat, MR Parthasarathy, R Prabhu, P Thirumalaikolundusubramanian An integrated approach of NGOs and community with Governmental agencies has resulted in better patient care. It is suggested to have similar approach for other chronic diseases. |
| P241 | [P241] COMMUNITY ENGAGEMENT FOR ANTIRETROVIRAL TREATMENT THROUGH PEOPLE LIVING WITH HIV IN IBADAN, NIGERIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P241 Obatunde O Oladapo, Oluwatoyin A Afenisumen Engaging PLWH and communities in providing treatment information promotes improved health-seeking behaviours, acceptance of ART and reduction of barriers to care and treatment. Providing effective community and individual education about ART including treatment adherence; managing treatment side effects and positive prevention results in stigma reduction in communities and health centres while ensuring greater cooperation among PLWH and the wider community. |
| P242 | [P242] INVOLVING PEOPLE WITH HIV IN RAISING DEMAND FOR HIV TREATMENT AND CARE IN IBADAN AND OGBOMOSO COMMUNITIES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P242 Obatunde O Oladapo, Oluwatoyin A Afenisumen, Oladokun O Olawunmi PLWH should be meaningfully involved in supporting provision of ART services through counseling and care services. Networking and collaboration initiatives involving PLWH ensure increased access to services; better clients follow-up and management. |
| P243 | [P243] IDENTIFYING CHALLENGES AND ADVANTAGES OF PEER EDUCATIONAL IN STIS AND HIV PREVENTION EDUCATION WITH PLWHA AND HIGH RISK YOUTH IN PAKISTAN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P243 Muhammad W Wasim, Rana A Gulzar Presentations at centers by peer educators have demonstrated that audiences over 12 years of age typically have only basic information about STIs and HIV. Confusion regarding the difference between HIV and STIs and the specifics of risk related behaviors generated interest in the presentations. |
| P244 | [P244] HIV/AIDS IN KATHMANDU: ROLE OF REHABILITATION CENTERS IN PREVENTION AND CARE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P244 Poonam Kandel This project reviewed the causes of HIV epidemic in Kathmandu and the positive influences of rehabilitation centers. Based on data from the evaluation, recommendations have been made to rehabilitation centers to expand the funding so that more number of HIV infected patients get anti-retroviral treatment and to increase the level of knowledge among the community members. |
| P245 | [P245] “TUKYOGEREKO-LETS TALK ABOUT IT”: THE POSITIVE MEN’S UNION EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P209 Richard Serunkuuma, William Mulindwa, Fatuma Namata Working with and supporting HSBs like the PHAs can meaningfully contribute to the positively acceptable shaping of the health care system for the benefit of HSPs, HSBs themselves and the general community. Anything excluding HSBs most especially PHAs, is equal to pushing away the globally advocated Universal Access to Treatment and other supplimentary services! |
| P246 | [P246] FRIENDS OF FUZEON Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P246 Karen F MacRae In conclusion support groups can play an important role in empowering individuals on Enfurvitide, participant verbal feedback has been positive in enhancing adherence, symptom control and psychological well being. |
| P247 | [P247] THE MIGRANT-AIDS-PROJECT: TEACHING IMMUNOLOGY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P247 Javier Arola Navarro, Matthias Wienold, Ahmet Kimil, Ramazan Salman, Matthias Stoll Education efforts address concepts uncommon to science-based medicine. These include lay health beliefs (e.g. “The stronger the better”, “Vaccines protect against infection”) and different medical traditions e.g. holistic medicine. Metaphors do not easily translate into different cultural contexts and highly skilled trainers are needed to explain models. |
| P248 | [P248] SHARING GROUP, BEHAVIOR CHANGE COMMUNICATION PROGRAM; CARE, SUPPORT AND TREATMENT IN SUPPORT GROUP CAN MINIMALISE RESISTANCE TO ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P248 Maulana Aries Setyawan SG not just pure focus in Group Discussion and Behavior Change Communication (BCC), but SG can support CST program include Antiretroviral. Because if we look it, SG can Support to minimalism Antiretroviral resistance case from PLWHA have been Antiretroviral therapy transmission to Public persons with risk. |
| P249 | [P249] GENDER INEQUALITIES, HEALTH RIGHTS AND VULNERABLE POPULATIONS AND PEOPLE LIVING WITH HIV/AIDS IN PAKISTAN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P249 Muhammad W Wasim, Rana A Gulzar, Nusrat G Yasmeen Training of young girls as peer educators agents of change is recommended. Fundamental human rights of all women girls infected or affected must underpin all responses to the epidemic. Education and awareness programs based on cultural/religious norms can stop risk of sexual exploitation and STIs/HIV/AIDS. |
| HIV Management In Resource-Limited Settings |
|
| P250 | [P250] CONSERVATION OF FIRST LINE ANTIRETROVIRAL TREATMENT WHERE THERAPEUTIC OPTIONS ARE LIMITED Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P250 Catherine Orrell, Guy Harling, Stephen Lawn, Linda-Gail Bekker, Robin Wood ART as a public health intervention in resource poor settings requires the clinical benefit of each regimen to be maximized. Here, regimen switches were only due to virological failure or toxicity. Over 95% of individuals remained on first-line ART using a combination of viral monitoring and a targeted adherence intervention. |
| P251 | [P251] SECOND LINE LOPINAVIR/RITONAVIR CONTAINING THERAPY IS EFFECTIVE WITHOUT MAJOR SIDE EFFECTS AFTER FAILING FIRST LINE NNRTI CONTAINING REGIMENS: 12 MONTHS FOLLOW-UP STUDY AT MULAGO HOSPITAL ADULT INFECTIOUS DISEASES CLINIC Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P251 Barbara Castelnuovo, Fred Lutwama, Patricia Mwebase, Andrew Kambugu, Moses Kamya Second line regimen including lopinavir/ritonavir is effective and safe in resource limited settings. |
| P252 | [P252] AIDS DEFINING ILLNESS (ADI) OCCURRING AFTER INITIATION OF GENERIC HAART IN SOUTHERN INDIA – CHENNAI HIV COHORT STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P252 N Kumarasamy, Anitha Cecelia, Bella Devaleenol, Tokugha Yepthomi, Suneeta Saghyam, P Balakrishnan, Suniti Solomon, Timothy Flanigan, Kenneth Mayer This study states that ADI occurs even after initiation of HAART. Appropriate chemoprophylaxis to prevent OIs should be used even after initiation of HAART. There is an urgent need for cost effective viral load monitoring to switch therapy early following failure to avoid clinical events in resource constrained settings. |
| P253 | [P253] EVIDENCE DOES NOT SUPPORT THE SOLE USE OF RAPID ORAL FLUID TESTS FOR HIV DIAGNOSIS IN RESOURCE-POOR SETTINGS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P253 Paul Collini, Angela Obasi In resource-poor settings with high rates of HIV in the general population, although likely to be popular, the negative predictive value of rapid oral tests would not be sufficiently high to avoid the need for confirmation with a second test. Such confirmation is also mandatory for positive tests. Rapid oral tests do not have sufficient accuracy to be used as confirmatory tests. On current evidence, any diagnostic HIV testing strategy would have to use at least one non rapid oral test or one blood test. |
| P254 | [P254] EVIDENCE-BASED CLINICAL DECISION-MAKING IN RESOURCE-POOR SETTINGS: WHOSE EVIDENCE AND HOW BEST CAN IT BE USED Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P254 Paul Collini, Angela Obasi Direct evidence to guide the HIV clinician in resource-poor settings is emerging and where lacking the use of less direct evidence can be highlighted. |
| P255 | [P255] DECENTRALIZED INTEGRATED MODEL OF ANTIRETROVIRAL SCALING-UP IN A SUBURBAN SETTING: THE PRETIVI PROJECT IN DOUALA, CAMEROON Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P255 Alessandro Soria, The PRETIVI Team A rapid scaling-up of ART when integrated in a decentralized public health structure is feasible and achieves good clinical and immunological results. Replicating this model of care could be a strategy to fill the gap in African access to ART. |
| P256 | [P256] A COMPARISON BETWEEN IMMUNOLOGICAL RESPONSE OF PROTEASE INHIBITORS AMONG ART-NAÏVE AND ART-EXPERIENCED PATIENTS IN BANGALORE, SOUTH INDIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P256 Kadappa Satish, G V Mallesh, RS Bhimasenarao, N Yadav, R A Murthy, N Praveen Immune-Response in the ART experienced patients with PI is persistent and comparable to Immune Response in ART naïve patients with PI. |
| P257 | [P257] MORTALITY AND FACTORS ASSOCIATED WITH DEATH IN 750 ADULTS RECEIVING FREE ART IN A TERTIARY CENTER IN NORTH INDIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P257 Ajay Wanchu, Pradeep Bambery, Subash Varma, Surjit Singh Higher body weight, clinical stage I or II & higher CD4 count at the start of therapy was associated with better chances of survival. There was no difference in age, sex, concomitant TB & nature of ART. Despite free medication, considerable delay in initiation of ART results in higher mortality. |
| P258 | [P258] GENDER DIFFERENCE IN IMMUNOLOGICAL RESPONSE TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) BASED REGIMEN IN HIV-1 INFECTED INDIAN PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P258 Ketan Patel, Atul Patel, Jagdish Patel, Rajiv Ranjan, Rakesh Sharma No gender difference in immunological response to NNRTI based cART in HIV-1 infected patient is observed in this cohort. Female gender is associated with higher incidence of acute toxicity with NNRTI. |
| P259 | [P259] EFFICACY OF CURRENT NUTRITIONAL MANAGEMENT OF SEVERE MALNUTRITION IN CHILDREN WITH HIV Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P259 Kwalombota M Kwalombota, Kusweje Victor Morbidity from severe malnutrition is increased in HIV infected children. Nutritional management in children with HIV is less efficacious as compared to HIV negative children. A more efficacious mode of treating malnutrition associated with HIV needs to be researched. |
| P260 | [P260] NEVIRAPINE VS. EFAVIRENZ BASED TREATMENT IN ART NAïVE PATIENTS IN INDIA: A COMPARISON OF IMMUNOLOGICAL RESPONSE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P260 Kadappa Satish, G V Mallesh, R S Bhimasenarao, N Yadav, R A Murthy, K N Praveen Our study shows that Nevirapine and Efavirenz have comparable immunological effectiveness in antiretroviral therapy naïve patients. |
| P261 | [P261] SHORT-TERM OUTCOME TO FIRST LINE ANTIRETROVIRAL REGIMEN IN A POOR RESOURCE COUNTRY: A PRELIMINARY REPORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P261 Olanisun O Adewole, Emmanuel A Anteyi, Ibrahim Wada, Olusegun Z Ajuwon, Temitayo T Adewole There are significant clinical and immunologic response to treatment on this regimen. However, improvements were marked at the first 6 months of treatment. This was not sustained till 12 months. This prelimnary results suggest a need for review of the present regimen in order to achieve a long lasting response. |
| P262 | [P262] TO STUDY THE COMPLIANCE LEVEL OF HEALTH CARE PROVIDERS IN FOLLOWING THE UNIVERSAL PRECAUTIONS IN THE TREATMENT OF HIV-AIDS PATIENTS, AND TO SEE WHETHER A TRAINING PROGRAMME ABOUT THE VARIOUS UNIVERSAL PRECAUTIONS IN THE CARE OF HIV-AIDS PATIENTS, PRODUCES ANY SIGNIFICANT CHANGE IN THE LEVEL OF THE COMPLIANCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P262 P M Babu, Rajesh Krishnamoorhty, Suresh N Khanna, Samith Thomas Training showed improvement in the compliance of the study group. But certain hospital factors were in short supply which had its effect on the compliance. This study also shows the lack in government interests to provide proper supplies of various patient care and precautionary commodities. |
| P263 | [P263] MANAGERIAL ISSUES OF ANTIRETROVIRAL THERAPY IN A TERTIARY REFERRAL CENTRE OF RESOURCE-LIMITED SETTINGS – MADURAI, INDIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P263 Vipindas Chenghat, MR Parthasarathy, R Prabhu, P Thirumalaikolundusubramanian Though managerial issues were on the rise, many of them were solved by strengthening public-private partnership, health education and provision of specialty health services of this institution to patients. |
| P264 | [P264] TRAINING ON UNIVERSAL PRECAUTIONS FOR HEALTHCARE PROVIDERS IS NECESSARY EVEN IN RESOURCE-LIMITED SETTINGS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P264 Rajesh Krishnamoorthi, PM Babu, S Thomas, SK Natrajan Workshops to train HCP about universal precautions significantly improve their knowledge about HIV/AIDS. HCP including physicians are not fully aware of universal precautions. This leads to stigma and denial of services to HIV/AIDS infected patients. A significant improvement is observed upon completion of these workshops even among HCP practicing at a tertiary level health care hospital. Our data show that even in resource limited settings, conducting trainings for HCP is necessary and effective. |
| P265 | [P265] POSSIBLE ROLE OF DISTANCE EDUCATION FOR IMPROVEMENT OF PHYSICIANS’ KNOWLEDGE CONCERNING ANTIRETROVIRALS AND HIV/AIDS THERAPY AND PREVENTION IN RESOURCE-POOR SETTINGS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P265 Vladimir V Rafalskiy, Irina V Andreeva DCME program is effective and inexpensive form of the dissemination of modern information about HIV/AIDS treatment and prevention, antiretrovirals updates etc. Electronic format allows to regularly update information and it is enough inexpensive form of CME and PGE. |
| P266 | [P266] INTERNATIONAL HIV/AIDS TRAINING COURSE FOR PHYSICIANS: THE MULTIPLYING EFFECT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P266 V Renggli, M Zolfo, R Colebunders, O Koole, V Huyst, L Lynen It can be concluded that offering a training course in the North to selected physicians working in developing countries is contributing to cover the high need of training for health care professionals in the field of clinical management of HIV/AIDS in low resource settings. |
| P267 | [P267] DATA ON SERVICES AVAILABLE TO HIV/AIDS PATIENTS IN TWO TERTIARY CARE HOSPITALS OF PESHAWAR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P267 Hamzullah Khan, Balqis Afridi, Abdul Jamil Medical services available in two tertiary care centres of Peshawar are not satisfactory. There is need for further actions, more collaboration, leadership, community involvement, UN assistance and government support. |
| Post-Exposure Prophylaxis |
|
| P268 | [P268] PEPSE – ARE WE MEETING THE STANDARD? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P268 A Currie, P Sarkar, Y Gourlay, R Nandwani, A Winter Although the numbers are small, this audit has shown that our PEPSE prescriptions are in line with current national guidance. We are just below the BASHH target of 90% being prescribed within 72 hours. We have identified exceptionally high default rates for PEPSE follow-up which has significant implications in this high-risk group and this needs to be addressed. |
| P269 | [P269] KNOWLEDGE AND PRACTICE IN POST-EXPOSURE HIV PREVENTION FOR MEDICAL STAFF IN MOSCOW Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P269 Alexey I Mazus, Galina Yu Pankova, Margarita V Lavrova, Alexandr A Goliusov, Yuriy V Martynov The retrospective and effective epidemiological analysis resulting from the epidemiological survey, has shown that the behavioral algorithm in case of occupational exposure to HIV must be learned and trained. |
| Clinical Pharmacology |
|
| P270 | [P270] DISEASE STATE MODEL FOR APRICITABINE IN TREATMENT NAÏVE HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P270 P Smith, A Forrest, J Sawyer This model characterized the dose-dependent antiviral response to ATC well and may be suited to prediction of response versus viruses with reduced drug susceptibility. |
| P271 | [P271] TROUGH CONCENTRATIONS IN HIV PATIENTS RECEIVING BOOSTED HARD-GEL CAPSULES (HGC) AND 500MG FILM-COATED TABLET (FCT) FORMULATIONS OF SAQUINAVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P271 L Dickinson, D Back, A Winston, S Khoo, M Boffito SQV FCT Ctrough was significantly higher than HGC Ctrough, which is consistent with a previous single sample TDM study (2). Higher SQV concentrations achieved with FCT and lower pill burden are clearly beneficial to patients. |
| P272 | [P272] EXPLORING THE FEASIBILITY OF DRIED BLOOD SPOTS FOR QUANTIFICATION OF LOPINAVIR, NEVIRAPINE AND EFAVIRENZ CONCENTRATIONS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P272 L Else, L Dickinson, M Schellenberger, S Khoo, D Back DBS sampling is a promising method for use in low income countries. However, there are practical issues that must be carefully managed including %recovery and long-term stability. Also, inter-subject variability in blood hematocrit and the presence of interfering constituents may affect the B/P ratio making it challenging to optimise drug concentrations from DBS. |
| P273 | [P273] APPROACHES TO THE ANALYSIS OF THERAPEUTIC DRUG MONITORING DATA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P273 Sara Gibbons, David Back, Marta Boffito, Mike Youle, Saye Khoo There are some important conclusions. Firstly, TDM data are inherently selective and will likely not reflect population data. Most clinicians request TDM for a specific reason rather than as a routine test. Secondly, the inherent danger of over-interpreting TDM data must be avoided. The present data DO NOT mean that 33% of clinic subjects on ATV/r are below the 10th centile, but show that some subjects on ATV/r will have suboptimal levels, irrespective of, for example, acid reducing agents. |
| P274 | [P274] STEADY-STATE PHARMACOKINETICS (PK) OF TENOFOVIR (TDF) AND FOSAMPRENAVIR (FPV) AFTER ONCE DAILY (QD) TDF WITH UNBOOSTED OR RITONAVIR (R)-BOOSTED TWICE DAILY (BID) FPV IN HEALTHY VOLUNTEERS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P274 A Luber, D Slowinski, M Andrews, K Olson, C Peloquin, G Pakes, K Pappa, M Shelton, D Condoluci Co-administration of FPV and FPV/r with TDF resulted in minor decreases in TDF exposures. The modest increase in APV Cmin that is observed is unlikely to be clinically important. |
| P275 | [P275] TIPRANAVIR GENOTYPIC INHIBITORY QUOTIENT PREDICTS 24-WEEK VIROLOGICAL RESPONSE TO TPV-BASED SALVAGE REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P275 Daniel Gonzalez de Requena, Stefano Bonora, Andrea Calcagno, Silvia Fontana, Marco Siccardi, Maria Grazia Milia, Antonio D'Avolio, Mauro Sciandra, Olivia Bargiacchi, Giovanni Di Perri TPV gIQ showed to predict VR at 24 weeks to TPV-containing salvage regimens better than TPV Ctrough or TPV- RMs alone. A possible TPV gIQ cut off value (11000) for reaching VR at week 24 was suggested. |
| P276 | [P276] PLASMA CONCENTRATIONS OF ATAZANAVIR IN HIV PATIENTS TREATED WITH REGIMENS INCLUDING NEVIRAPINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P276 Michael Kurowski, Antje Breske, Steffi Lehmann, Guido Kruse, Herbert Eskoetter In regimens including nevirapine and ATV/r the trough levels of NVP are comparable to values obtained with NVP alone. However, for ATV/r the trough levels are lower than historical controls or values from the prescribing information. To avoid too low plasma levels of ATV especially in treatment experienced pts therapeutic drug monitoring may be appropriate. |
| P277 | [P277] NO EFFECT OF TMC125 ON THE PHARMACOKINETICS OF ORAL CONTRACEPTIVES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P277 M Schöller-Gyüre, C Debroye, F Aharchi, B Woodfall, M Peeters, K Vandermeulen, R Hoetelmans No clinically relevant changes of the PK of EE and NE were observed when TMC125 was given concomitantly with Ortho-Novum® 1/35. No loss in contraceptive efficacy of OC is expected when TMC125 is coadministered. |
| P278 | [P278] PHARMACOKINETICS OF TMC125, WITH ATAZANAVIR (ATV) AND ATAZANAVIR/RITONAVIR (ATV/r) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P278 M Schöller-Gyüre, B Woodfall, T De Marez, G De Smedt, M Peeters, K Vandermeulen, R Hoetelmans The increase of exposure to TMC125 when coadministered with either ATV or ATV/r is considered not to be clinically relevant. However, due to the significant decrease of Cmin of ATV when given with TMC125, this combination should only be used if combined with low dose ritonavir. |
| P279 | [P279] CD4 CELLS INCREASE IN PATIENTS RECEIVING THE COMBINATION OF TDF/ddI-EC WITH OR WITHOUT A NNRTI Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P279 James D Scott, Madonna Mashburn, David Anderson, Robert K Bolan Our findings show that CD4 cells in our population receiving TDF/ddI-EC increased significantly regardless of whether their regimen was NNRTI-based or not. Virologic response was strong in patients receiving TDF/ddI-EC; but did not differ based on other components of the regimen. |
| P280 | [P280] EFV IN HIV-PATIENTS WITH UNDERLYING LIVER DISEASE: IMPORTANCE OF CONTINUOUS TDM Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P280 Antonios Katsounas, Hartwig Klinker, Peter Langmann ΔALT, ΔAST and ΔγGT in liver-disease-HIV-patients were not significantly different from values of liver-healthy HIV-patients with normal EFV-plasmalevels. Normal EFV-plasmalevels correlate to good responses. EFV in patients with liver disease using TDM seems save. |
| P281 | [P281] EFAVIRENZ INDUCTION OF THE UGT-1A1 REDUCES ATAZANAVIR-INDUCED HYPERBILIRUBINEMIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P281 Erik Mossdorf, Oliver Kummer, Stephan Kraehenbuehl, Manuel Battegay, Manuel Haschke, Luigia Elzi This case illustrates well a complex interaction between ATV and EFV which influences ATV induced hyperbilirubinemia. |
| P282 | [P282] PHARMACOGENETIC FACTORS ASSOCIATED TO VIROLOGICAL FAILURE AND/OR CNS TOXICITY IN PATIENTS TREATED WITH EFAVIRENZ Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P282 S Rodriguez-Novoa, P Barreiro, C de Mendoza, G Gonzalez, C Castellares, J Morello, I Jimenez, J Gonzalez, V Soriano Patients carrying the CYP2B6 TT genotype show less frequently virological failure under EFV therapy than patients with CT or CC. A greater exposure to EFV in these patients may explain this observation as well as their higher risk for developing CNS toxicities. No similar association with EFV plasma levels nor with clinical outcome were seen for 3435-Pgp genotypes. |
| P283 | [P283] DOSING FOSAMPRENAVIR IN CIRRHOTIC PATIENTS: POSSIBLE ROLE OF TDM Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P283 Francesca Gatti, Alessandro Matti, Paola Nasta, Arianna Loregian, Silvana Pagni, Saverio G Parisi, Luciano Biasi, Katiela Prestini, Massimo Puoti, Giorgio Palù, Giampiero Carosi In cirrhotic pts on FAPV 700mg BID Ct was above suggested minimum target concentration of 400 ng/ml in almost all NC pts but only in 2/5 C pts, both with a LS < 50 kPa; therefore in these pts TDM may be recommended. |
| P284 | [P284] CLINICAL EFFECTS OF THE ATAZANAVIR AND H2-BLOCKER INTERACTION ON CD4 COUNT AND VIRAL LOAD Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P284 Ian R McNicholl, Vanita A Parrish Despite a lower VL decrease in patients receiving once daily H2B with ATV, there does not appear to be a significant effect on CD4 count or VL. |
| P285 | [P285] INFLUENCE OF LIVER CIRRHOSIS ON ATAZANAVIR PHARMACOKINETICS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P285 Francesca Gatti, Paola Nasta, Arianna Loregian, Silvana Pagni, Alessandro Matti, Katiela Prestini, Luciano Biasi, Caterina Boldrin, Massimo Puoti, Giorgio Palù, Giampiero Carosi ATV Ct and AUC 0-24 are slightly higher in C pts; an inverse correlation between AUC pl and LS was found but number ofpts is too small to draw conclusions. |
| P286 | [P286] PHARMACOKINETICS OF LOPINAVIR AND RITONAVIR AFTER MULTIPLE DOSE ADMINISTRATION OF LOPINAVIR/RITONAVIR TABLET CO-ADMINISTERED WITH EFAVIRENZ Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P286 Cheri E Klein, Yan Cai, Yi-Lin Chiu, Sonja J Causemaker, Thao T Doan, Thomas J Podsadecki, Barry M Bernstein, George J Hanna LPV concentrations following LPV/r 400/100 mg tablet BID with EFV were generally well-predicted by a simulation model and are within the range of concentrations previously demonstrated to be efficacious. |
| P287 | [P287] PLASMA LOPINAVIR LEVELS IN A GROUP OF PREGNANT WOMEN ON LOPINAVIR, RITONAVIR, ZIDOVUDINE, AND LAMIVUDINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P287 Kaveh Manavi, Amy McDonald, Ali Al-Sharqui In our cohort, a proportion of pregnant women had sub-therapeutic plasma lopinavir level. Further investigations on the significance of this finding are required. |
| P288 | [P288] CROSSOVER, STEADY-STATE COMPARISON OF LOPINAVIR/RITONAVIR (LPV/R) PHARMACOKINETICS (PK) IN WOMEN OF COLOUR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P288 Ian R McNicholl, Polina German, Deborah Cohan, Cynthia Feakins, Francesca T Aweeka These data suggest higher PK variability in this population as compared to previously reported. |
| P289 | [P289] P-GLYCOPROTEIN IS INHIBITED BY LOPINAVIR AND LOW-DOSE RITONAVIR IN HIV-INFECTED PATIENTS AND IN HEALTHY MEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P289 Christoph Wyen, Gerd Fatkenheuer, Rob Aarnoutse, Wolfgang Hein, Farid Abdulrazik, Edgar Schoemig, David Burger, Uwe Fuhr, Alexander Jetter LPV + RTV inhibit the PGP activity in HIV infected patients and, already after a single dose, in healthy volunteers. |
| P290 | [P290] ACETAMINOPHEN PHARMACOKINETICS AND HEPATIC TRANSAMINASES ARE UNAFFECTED ON ATAZANAVIR/RITONAVIR COADMINISTRATION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P290 T Eley, E Chung, R Nettles, W Wu, X Xu, T Li, Y Wang, R Bertz At steady state, ATV/RTV has no significant effect on the PK of APAP; 90% CI for the AUC ratio was within 0.80-1.25. ATV/RTV does not affect APAP glucuronidation. APAP + ATV/RTV caused no significant increases in AST or ALT. |
| P291 | [P291] ATAZANAVIR AND RITONAVIR INCREASE PLASMA LEVELS OF MK-0518 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P291 G C Mistry, L A Wenning, S Merschman, J T Kost, W E Bridson, J A Stone, K M Gottesdiener, J A Wagner, M Iwamoto Multiple doses of ATV + RTV modestly increases plasma levels of MK-0518. MK-0518 is generally well tolerated when coadministered with ATV + RTV. |
| P292 | [P292] IMMUNOVIROLOGIC RESPONSE AND PHARMACOKINETICS OF RITONAVIR-BOOSTED ATAZANAVIR/FOSAMPRENAVIR IN HIV-1-INFECTED SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P292 O Viganò, O Bargiacchi, P Di Vincenzo, G Di Perri, M Galli, S Bonora, S Rusconi The combination of ATV and FPV boosted by RTV resulted in a sustained immunovirological response. This association showed adequate Ctrough values of both drugs, well above the minimum effective concentrations (150 ng/mL for ATV and 400 ng/mL for FPV). Moreover, GIQ values also showed to be above proposed cut-offs (ATV-GIQ: 200; FPV-GIQ: 250), confirming this parameter as a good predictor of virological response in PI-treated patients. |
| P293 | [P293] EFFECT OF BOOSTED SAQUINAVIR ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RACEMIC METHADONE IN OPIATE-DEPENDENT PATIENTS ON STABLE METHADONE MAINTENANCE THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P293 C Jamois, M Riek, A Patel, P Smith, R Morrison, C Schmitt We conclude that the decrease in R-methadone exposure seen with SQV/r 1000/100mg bid coadministration is not clinically relevant. No signs or symptoms of methadone withdrawal were observed during the study conduct and the triple combination was well tolerated. |
| P294 | [P294] PHARMACOKINETIC INTERACTION BETWEEN TMC114, A NEW PROTEASE INHIBITOR, AND METHADONE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P294 V Sekar, M El Malt, E De Paepe, T Stevens, M De Pauw, T Vangeneugden, E Lefebvre, W van den Brink, R Hoetelmans No a-priori adjustment of methadone dosage is required with TMC114/r co-administration, as the effect on the active R-methadone exposure was small and withdrawal symptoms were rare. |
| P295 | [P295] PHARMACOKINETIC INTERACTION BETWEEN TMC114, A NEW PROTEASE INHIBITOR, AND THE SELECTIVE SEROTONIN REUPTAKE INHIBITORS, PAROXETINE AND SERTRALINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P295 V Sekar, E De Paepe, T De Marez, M De Pauw, T Vangeneugden, E Lefebvre, R Hoetelmans Co-administration of paroxetine or sertraline with TMC114/r was generally well tolerated. Similar results are expected for TMC114/r 600/100 mg bid (dose recommended for treatment-experienced patients). If clinically warranted, sertraline or paroxetine may be co-administered with TMC114/r. Although previous studies have failed to show a correlation between plasma concentration of selective serotonin reuptake inhibitors (SSRIs) and antidepressant response, clinical monitoring is recommended and dose titration of the SSRI may be indicated when sertraline or paroxetine is co-administered with TMC114/r. |
| P296 | [P296] LACK OF SEX DIFFERENCES IN ONCE-DAILY LOPINAVIR/RITONAVIR (LPV/r) PHARMACOKINETIC (PK) PROFILE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P296 I Ofotokun, S Chuck, M Palau, J Binongo, E Acosta, J Lennox · Steady state LPV/r PK was similar in HIV+ men vs. HIV+ women. · DBM profile was similar for QD vs. BID dosing. · No correlation observed between LPV Cmax and DBM. |
| P297 | [P297] INFLUENCE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY WITH NELFINAVIR ON ENDOTHELIAL CELL-DERIVED MICROPARTICLES IN HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P297 Oleksii M Korzh, Genadiy I Kotchuev, Olena O Pavlova These findings suggest that activated platelets and oxidized LDL induce EDMP generation, and that elevated EDMPs may be a sign of vascular injury in HIV-1-infected patients receiving HAART containing nelfinavir. |
| P298 | [P298] SIGNIFICANCE OF PLASMA THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR LEVELS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P298 Iryna Korzh, Inga Fedotova These data suggest that increased plasma level of TAFI may be involved in the mechanism of vascular endothelial damage in HIV-1-infected patients receiving HAART. |
| P299 | [P299] RIFAMPIN (RIF) MODESTLY REDUCES PLASMA LEVELS OF MK-0518 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P299 M Iwamoto, L A Wenning, S Y Liou, J T Kost, E Mangin, K M Strohmaier, T C Marbury, J Stone, K M Gottesdiener, J A Wagner MK-0518 co-dosed with RIF is generally well tolerated. Plasma levels of MK-0518 are modestly decreased when co-dosed with RIF. |
| P300 | [P300] LACK OF A PHARMACOKINETIC INTERACTION OF MK-0518 ON MIDAZOLAM (MDZ) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P300 M Iwamoto, L A Wenning, M D Troyer, J I Ventura, J T Kost, E Mangin, K M Strohmaier, E P DeNoia, J Stone, K M Gottesdiener, J A Wagner MK-0518 co-dosed with MDZ is generally well tolerated. Plasma levels of MDZ are not affected by MK-0518, which implies that MK-0518 is not an inducer or inhibitor of CYP3A4, and that MK-0518 would not be expected to affect the pharmacokinetics of other drugs metabolized by CYP3A4. |
| P301 | [P301] A PILOT, COMPARATIVE STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE MONOTHERAPY ADMINISTERED WITH AND WITHOUT FOOD Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P301 Santiago Moreno, Antela Antonio, Carolina Gutierrez, Beatriz Hernandez, Maria J Perez-Elias, Fernando Dronda, Ana Moreno, Jose L Casado, Carmen Page, Maria Pumares, Rosa Pedrol, Juan C Galan In this pilot study, the administration of food did not have any effect on the plasma drug levels or the antiviral activity of enteric coated capsules of ddI. |
| P302 | [P302] CLINICAL IMPACT OF ANTIRETROVIRAL/ANTIEPILEPTIC DRUG INTERACTIONS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P302 Ysobel Gourlay, Alison H Thomson, Ray Fox This case illustrates the variation in drug therapy and dosing which is required in an HIV patient presctibed AED and emphasises the role of drug concentration analysis in the monitoring of treatment. |
| P303 | [P303] EXPANDING THE ROLE OF SPECIALIST PHARMACY SERVICES IN THE MANAGEMENT OF HIV PATIENTS IN GLASGOW Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P303 Y Gourlay, K Brown, B McNulty, F Brown, J Mochan, A Winter, R Nandwani, A Seaton, A Currie, R Fox We have successfully developed our specialist pharmacy service to meet the needs of an expanding patient cohort by introducing a pharmaceutical care plan which enhances patient care, improves communication between pharmacists and clinicians, and saves money. |
| P304 | [P304] USE OF GASTRIC ACID-REDUCING AGENTS IN HIV-INFECTED PATIENTS TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY – A SWISS PATIENT SURVEY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P304 Frédéric Lajaunias, Joerg Beron The proportion of Swiss HIV patients on HAART using gastric acid modifying drugs appears to be at the same level as reported for Germany, Spain or the USA. It is important to recognize that half of the patients obtain their drugs without prescription. Assessment of concomitant drug use by physicians might be important to avoid negative drug interactions. |
| HIV-Related Infections, Co-Infections and Malignancies - non-specific |
|
| P305 | [P305] THE SPECTRUM OF MALIGNANCIES IN THE ERA OF HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P305 Oliver Friedrich, Martin Vogel, Jan-Christian Wasmuth, Esther Voigt, Ulrich Mey, Carolynne Schwarze-Zander, Juergen K Rockstroh, Ulrich Spengler Whereas opportunistic infections and related mortality have decreased considerably after the introduction of HAART, HIV-related malignancies are remaining therapeutic challenges in the health-management of HIV-infected patients. |
| P306 | [P306] INPATIENTS IN THE POST HARRT ERA 2004-5; PREDICTORS OF PROLONGED ADMISSIONS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P306 Jonathan Cartledge, Charlotte Newey, Paul Benn, Simon Edwards, Ian Williams, Rob Miller AIDS related admissions are still common in HIV positive patients. Infection and respiratory diseases predominate. Factors predictive of prolonged length of stay can be identified on admission which is key for discharge planning. |
| HIV-Related Infections, Co-Infections and Malignancies - HBV |
|
| P308 | [P308] VIROLOGICAL CHARACTERISTICS OF HEPATITIS B VIRUS (HBV) IN HBV/HIV CO-INFECTED PATIENTS AND PREDICTORS OF LAMIVUDINE RESISTANCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P308 B Ramos, M Núñez, L Martín-Carbonero, J Sheldon, P Barreiro, P Labarga, C Castellares, A Ruiz-Sancho, J García-Samaniego, V Soriano When possible LAM monotherapy should be avoided in HBV/HIV-coinfected patients with HBV-A, in whom either peginterferon and/or tenofovir or entecavir, should be preferred. While tenofovir could be ideal in patients requiring HAART, entecavir might be the best option when antiretrovirals are not required. |
| P309 | [P309] THREE-PILL QD EFV+ddI-BASED HAART IS AS EFFECTIVE AND WELL TOLERATED IN HBV AND/OR HCV CO-INFECTED AS IN NON-CO-INFECTED PATIENTS FOR INITIAL (I), SIMPLIFICATION (S) AND RESCUE (R) THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P309 H Knobel, J Hernandez-Quero, P Domingo, E Ribera, B Vendrell, O Serrano, J Perez-Molina Although Co+ Pts showed more risk factors for Tx failure at BL, EFV+ddI-based HAART was equally effective in both groups. Overall incidence of AR and liver toxicity was also similar and a rare cause of Tx D/C. |
| P310 | [P310] HEPATITIS B VIRUS, HEPATITIS C VIRUS AND HUMAN IMMUNE DEFICIENCY VIRUSES CO-INFECTIONS IN PATIENTS RECEIVING ANTIRETROVIRAL DRUGS AT DR. GEORGE MUKHARI HOSPITAL, SOUTH AFRICA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P310 Azwidowi Lukhwareni, Morore K Mphahlele, Takalani E Ramulifho, Jeffrey M Mphahlele, Olga M Mzileni Results indicate that HBV/HIV co-infection is high and HCV infections remain at 2%, and therefore a need for monitoring HBV infections during HIV lamivudine containing therapy is significant as active/chronic infections or re-activation can be affected by lamivudine. |
| P311 | [P311] SEARCH OF OCCULT HEPATITIS B IN A COHORT OF HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P311 Giovanni Cenderello, Federica Toscanini, Pasqualina De Leo, Marco Anselmo, Giuseppe Ferrea Our study shows that HIV pts rarely hide HBV occult infection. HIV pts present a previous HBV infection and a lack of immune function that could be facilitating factors for this infection. Probably an ARV therapy based on drugs which are active on HIV and HBV could inhibit HBV replication. Although much more research is needed our report could justify the reduced rate of HBV occult infection. |
| HIV-Related Infections, Co-Infections and Malignancies - HCV |
|
| P312 | [P312] SAFETY ASSESSMENT OF LOPINAVIR/RITONAVIR (LPV/r) IN HIV+ AND HEPATITIS C (HCV) CO-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P312 P Cote, C Cooper, JG Baril, C Kovacs, M Caseiro, S Haider, S Vezina, D Rouleau, R Foccacia, M Poliquin, N Ackad, N Longo, J Sampalis HIV/HCV patients treated with (LPV/r SGC) experience significant immunological improvement and HIV-VL decrease with minimal perturbation of baseline HCV-VL. Hepatotoxicty incidence was low. Clinically relevant lipid abnormalities observed with combination antiretroviral therapy where not observed. HCV, lipid and antiretroviral therapy interaction merits further study. |
| P313 | [P313] FACTORS ASSOCIATED WITH PROGRESSION OF LIVER FIBROSIS IN HIV/HCV CO-INFECTED PATIENTS: INFLUENCE OF ANTIRETROVIRALS AND METABOLIC DISTURBANCES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P313 Pablo Barreiro, Pablo Labarga, Andrés Ruiz-Sancho, Carol Castellares, Juan González-Lahoz, Vincent Soriano CD4 T-cell depletion is associated with ALF in HIV+ patients with chronic hepatitis C. Insulin resistance and liver steatosis, as reflected by higher glucose and triglyceride levels in subjects with ALF, might contribute to faster progression of liver fibrosis in HIV/HCV coinfected patients. The specific role of PI, which may cause hyperlipidemia and insulin resistance, on liver fibrosis, warrants further investigation. |
| P314 | [P314] CRITICAL ROLE OF RIBAVIRIN FOR THE ACHIEVEMENT OF EARLY VIROLOGICAL RESPONSE TO HCV THERAPY IN HCV/HIV CO-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P314 B Ramos, M Nunez, A Rendon, MA Berdún, E Losada, I Santos, S Echevarria, A Ocampo, C Miralles, P Arazo, P Barreiro, M Romero, P Labarga, C Castellares, L Martin-Carbonero, J Garcia-Samaniego, V Soriano Prescription of high RBV doses enhances the EVR to HCV therapy in HCV/HIV-coinfected patients, with results approaching those seen in HCV-monoinfected ones. |
|
|
|
| P316 | [P316] HEALTHCARE ACCESS AND FOLLOW UP ADHESION FOR DRUG USERS AND PRECARIOUS POPULATION; CONTRIBUTION OF FIBROSCAN®: AN OBSERVATIONAL STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P316 Marc Bary, Karine Asselah, Jacques Lherm, Arafa Boukhemair, Didier Touzeau This examination is non invasive, gives immediate results strengthens the therapeutic alliance and allows an objective assessment of the liver fibrosis extent which is not impaired by extra hepatic conditions. This information thus added to clinical and biological picture allow not waiting for the stressing verdict of liver biopsy. The therapeutic collaboration between the patient and the physician is strengthened. Good results, such as the decrease of liver stiffness, encourage alcohol abstinence and treatment compliance. In conclusion, FibroScan® could be used as a first line examination for liver disease like ECG for heart disease. |
| P317 | [P317] LIMITED VALUE OF ALANINE AMINOTRANSFERASE LEVELS IN THE MANAGEMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P317 Beatriz Hernandez, Fernando Dronda, Ana Moreno, Carmen Quereda, Maria J Perez-Elias, Jose L Casado, Santiago Moreno ALT levels are not useful in the management of chronic hepatitis C in HIV infected patients: up to 17% of patients with no liver disease have abnormal levels, and up to 41% of patients with normal levels have severe liver damage. |
| P318 | [P318] DETECTION OF HIV/HCV CO-INFECTION MARKERS IN BLOOD AND SALIVA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P318 Alexey I Mazus, Alexandr Ya Olshanskiy, Elena L Golokhvastova, Eugeniy V Ivannikov, Nataliya G Litvinova, Timur P Bessarab Saliva can be used for HIV diagnostics but not for HCV diagnostics. |
| P319 | [P319] PREVALENCE, ETIOLOGY AND STAGE OF LIVER CIRRHOSIS IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P319 Carol Castellares, Pablo Labarga, Pablo Barreiro, Leticia Galindo, Rebeca Casado, Javier Garcia-Samaniego, Juan Gonzalez-Lahoz, Vicente Soriano LC is quite prevalent among HIV+ patients with chronic hepatitis C, particularly if HBV coexists. Chronic hepatitis B alone does not increase the risk for cirrhosis, most likely due to the use of specific effective antivirals. FibroScan® may allow to easily recognise subclinical cirrhosis and designing appropriate therapeutic. |
| P320 | [P320] PREVALENCE AND THERAPEUTIC SIGNIFICANCE OF ANTI-INTERFERON ANTIBODIES IN HCV/HIV CO-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P320 Belen Ramos, Andres Ruiz-Sancho, Julie Sheldon, Carlos Toro, Pilar Rios, Vicente Soriano Anti-IFN Ab were identified in only 2/40 HCV/HIV-coinfected patients who failed previous HCV therapy. Both subjects subsequently failed re-treatment with peg-IFN + RBV. In contrast, none of the 7 patients who reached SVR with re-treatment developed anti-IFNα Ab. These preliminary data do not support an important role of anti-IFN Ab as cause of lack of response to HCV therapy in HCV/HIV-coinfected patients. |
| P321 | [P321] EFFICIENCY AND SAFETY OF THERAPY OF HCV-HIV CO-INFECTED PATIENTS WITH PEG-INTERFERON α-2A AND RIBAVIRIN IN COMPARISON WITH INTERFERON α-2A AND RIBAVIRIN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P321 Luybov M Ivanova, Alexei V Kravchenko, Natalya Yu Gankina, Semen L Maksimov, Eugeniy V Ivannikov, Elena L Golohvastjva The Preliminary data testify to high efficiency of therapy HCV-infection with IFN-α-2a and RBV at the patients with the HIV-infection who are not receiving HAART. Treatment Peg-IFN was more effective. Research proceeds. Final results will be received by November, 2006. Bearableness of treatment was satisfactory. |
| P322 | [P322] NEURO-PSYCHOLOGICAL DISTURBANCES IN HIV/HCV CO-INFECTED AND HCV MONO-INFECTED PATIENTS ELIGIBLE TO RECEIVE PegIFNα Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P322 P Nasta, S Antonelli, A Matti, F Gatti, C Zeni, S Compostella The median number of NPS are significantly greater in HIV/HCV pts than HCV mono-infected. In HIV/HCV co-infection setting, a multidisciplinary approach, also with more sofisticated test (MMPI-2), shoud be implemented. Future trial on preventive approach with antidepressants could be investigated. |
| P323 | [P323] HIV-HCV CO-INFECTION – TIME TO ACT? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P323 Saurabh R Jindal, Pankaj Golegaonkar, Dattatray Saple The relatively low levels of HCV prevalence in the study seem to indicate low prevalence among the heterosexual HIV patients. This prevalence is similar to those reported in blood donors (0.285%) in western India. The current point of time where the prevalence amongst the heterosexual population is low, may serve an ideal window of opportunity for interventions and measures to prevent the explosion of HCV in heterosexual population in India. |
| P324 | [P324] SUSTAINED CLEARANCE OF HCV AFTER IMMUNOLOGIC RESTORATION SYNDROME IN AN HIV-HCV CO-INFECTED PATIENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P324 Philippe Genet, Philippe Renard, Tahar Touahri, Laurence Courdavault, Françoise Leturdu We finaly concluded to a clearance of HCV virus secondary to an immunologic restoration. Other hypothesis could be ruled out: toxic hepatitis was improbable due to recovery of hepatic biology despite the continuation of treatments. An hepatitis secondary to another viral infection was ruled out and could not explain the clearance of HCV virus. |
| HIV-Related Infections, Co-Infections and Malignancies - Opportunistic Infections |
|
| P325 | [P325] TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS IN HIV AND MALARIA CO-INFECTION IN KAMPALA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P325 Hakim Sendagire, Mark Kaddumukasa, William Buwembo, Judith Orikyiriza, Patrick Kakeeto, Gote Swedberg, Philippa Musoke, Fred Kironde There was no evidence of in-vivo cross-resistance, instead co-trimoxazole prophylaxis seems to reduce on the malaria episodes in HIV patients and shows a trend towards improving treatment outcomes. |
| P326 | [P326] PREVALENCE AND INCIDENCE OF GBV-C INFECTION IN HIV PATIENTS: DEPENDENCE ON HIV VIRAL LOAD Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P326 Carolynne Schwarze-Zander, Markus Neibecker, Carolin Welzel, Hans-Dieter Nischalke, Esther Voigt, Martin Vogel, Jan-Christian Wasmuth, Ulrich Spengler, Jürgen K Rockstroh Co-infection with GBV-C in HIV patients is common. Newly detection of GBV-C RNA was significantly associated with decrease of HIV viral load. Whether detection of GBV-C RNA is due to newly acquired GBV-C infection or consequence of decrease of HIV viral load competing for the same target cells merits further study. In our cohort loss of GBV-C had no deleterious effect on HIV disease. |
| P327 | [P327] COMPARABLE ANTIBIOTIC RESISTANCE PROFILES IN PNEUMOCOCCI ISOLATES FROM HIV-POSITIVE VERSUS -NEGATIVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P327 Christoph Stephan, Gudrun Just-Nuebling, Pramod M Shah, Errol Babacan, Schlomo Staszewski HIV patients were younger and in a less advanced stage of their pneumococcal disease at time of diagnosis. We could not confirm emergeing pneumococcal resistance in HIV patients. Local recommendations for community-acquired, typical pneumonia should include ß-Lactam-Antibiotics. |
| P328 | [P328] A CONTAGIOUS CORONAVIRUS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P328 Alisdair A MacConnachie, Terry C Collins, R Andrew Seaton, Dermot H Kennedy Coronavirus RTI in patients with HIV may be severe enough to require prolonged hospital admission and extensive investigation due to immunosuppression and the broad differential diagnosis. |
| P329 | [P329] RESOLUTION OF POMPHOLYX WITH COMBINATION ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P329 Alisdair A MacConnachie, Catherine C Smith The recognised treatments of pompholyx often involve immunesuppression. It is therefore interesting that in our case, a man already immunocompromised, resolution occurred only after immune reconstitution. This presumably indicates the more complex nature of the underlying pathogenesis. |
| P330 | [P330] A NORTH DUBLIN INNER CITY EXPERIENCE OF HIV/MYCOBACTERIAL CO-INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P330 Eimear Brannigan, Nicholas S Chew, Brendan Keogh, Margaret Hannan, Gerard Sheehan, John Lambert Over an 18-month period, the incidence of culture-proven mycobacterial infection was 0.06% within the local general population. The incidence of mycobacterial infection within our HIV cohort was 2%. Given that mycobacterial infection was a HIV indicant diagnosis in 60% of co-infected patients in our study, all patients presenting with mycobacterial infection should be tested for HIV infection. |
| P331 | [P331] OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY IN THE GLASGOW HIV COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P331 Helena A White, Emma Bell, Lindsay Semple, R Andrew Seaton OHPAT is a cost-effective, efficacious therapeutic option for patients with HIV. It may contribute to consolidating care for AIDS-defining infections, but also aid in management of other non-HIV related infections, and non-infectious complications of HIV or its therapy. |
| P332 | [P332] FAVORABLE TREATMENT OF HIV-ASSOCIATED CRYPTOCOCCUS NEOFORMANS MENINGITIS, FOLLOWED BY AN EMERGING AMPHOTERICIN B-RESISTANT CRYPTOCOCCUS LAURENTII CNS INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P332 Roberto Manfredi Clinicians should consider that cryptococcosis may still occur, although a dual, subsequent infection by C.neoformans and C.laurentii is very infrequent. The eradication of C.neoformans does not guarantee that another Cryptococcus spp could occur subsequently. Moreover, susceptibility studies are mandatory for C.laurentii treatment. To assess whether antimycotic treatment-prophylaxis against C.neoformans may help to select resistant C. laurentii strains, is strongly needed. |
| P333 | [P333] COMPARISON OF CLINICAL FEATURES AND SURVIVAL OF CRYPTOCOCCOSIS IN HUMAN IMMUNODEFECIENCY VIRUS (HIV)-POSITIVE AND HIV-NEGATIVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P333 Ubonvan Jongwutiwes, Sasisopin Kiertiburanakul, Somnuek Sungkanuparph Serum cryptococcal antigen and India ink preparation are more helpful for the diagnosis in HIV-positive patients. Mortality rate is high in both HIV-positive and HIV-negative patients. The relapse rate is higher in HIV-infected patients but can be reduced by ART. |
| P334 | [P334] INVESTIGATION OF RECOVERY PATTERNS OF CRYPTOCOCCOSIS IN AIDS PATIENTS UNDER DIFFERENT ANTI-CRYPTOCOCCAL DRUG THERAPIES AT MULAGO HOSPITAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P334 Michael Mukiibi, John Kateregga Both Fluconazole and the combination of Amphotericin B and Flucytosine are markedly effective against cryptococcal meningitis. The fall in the recovery rate for the patients on the combination at 6-8 weeks could be attributed to non adherence to treatment by these patients. The increase in the lymphocyte numbers could be attributed to the fact that T- lymphocytes increased on treatment. The increase in neutrophil and monocyte numbers could be due to the fact that they are phagocytic cells which normally increase in disease. |
| P335 | [P335] TRENDS IN HUMAN PAPILLOMAVIRUS (HPV) INFECTION AMONG HIV-POSITIVE WOMEN BEFORE THE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (PRE-HAART) AND HAART ERA IN A NIGERIAN CLINIC Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P335 Olanrewaju O Onigbogi There has been a significant rise in the incidence of HPV since the introduction of HAART. This may be due to the longer survival of HIV-infected patients, surpassing the latency period for the anogenital malignancies. Care providers should be more vigilant for HIV-associated malignancies as patients live longer in this part of the world. |
| P336 | [P336] RHINOPHARYNGEAL CARCINOMA AND A CONCURRENT LYMPHOPROLIFERATIVE DISORDER, BOTH ASSOCIATED WITH UNDERLYING HIV-EPSTEIN-BARR VIRUS COINFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P336 Roberto Manfredi, Leonardo Calza Our p suffered from 2 distinct malignant and pre-malignant disorders, with some intriguing pathogenetic associations mainly linked to EBV, but also HIV and related immunodeficiency, and perhaps the chronically inhaled cocaine as a local pathogenetic co-factor. Both squamous carcinoma and lymphoproliferative disorder of the nasopharynx are more frequent in the immunocompromised host, and deserve further pathogenetic studies, to clarify the shared-addictive role of some viral-environmental risk factors, in the pathogenesis of nasopharyngeal carcinoma, especially when concurrent HIV-EBV infection are present. |
| P337 | [P337] BLOOD ELECTROLYTES IN PATIENTS WITH TUBERCULOUS MENINGITIS: COMPARISON OF RESULTS IN SUBJECTS WITH OR WITHOUT HIV INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P337 Nuria Tornador, Bernardino Roca Tuberculous meningitis, in patients with HIV infection, was more common in men, but in patients without HIV infection was more common in women. Tuberculous meningitis occurred at a younger age in patients with HIV infection than in patients without HIV infection. Blood electrolytes were similar in patients with or without HIV infection. |
| P338 | [P338] VISCERAL LEISHMANIASIS IN HIV-INFECTED PATIENTS IN THE HAART ERA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P338 Nuno Marques, Rosa Sá, Joaquim Oliveira, Filomena Coelho, José Saraiva da Cunha, António Meliço-Silvestre At present VL is not included among AIDS-defining illness. However, its clinical and epidemiological features in HIV-infected pts may suggest its inclusion. |
| P339 | [P339] THALIDOMIDE TREATMENT FOR REFRACTORY HIV-ASSOCIATED COLITIS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P339 J N Jarvis, L Johnson, E Wilkins, P Hay These cases add to the limited data suggesting thalidomide is effective and safe in the treatment of HIV associated colitis, and also suggest thalidomide treatment may have long-term benefits, persisting after discontinuation of therapy. |
| P340 | [P340] RAPIDLY PROGRESSIVE NECROTISING INFLAMMATORY PANSINUSITIS: POSSIBLE INVASIVE FUNGAL INFECTION IN A NEUTROPENIC HIV-POSITIVE PATIENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P340 R O'Connell, S Tariq, M Murphy A clinical diagnosis of invasive fungal disease was made in the absence of laboratory evidence. At 3 months, iv ceftazidime, tobramycin and liposomal amphotericin continue with marked clinical improvement and cessation of hard palate destruction. |
| HIV-Related Infections, Co-Infections and Malignancies - Tuberculosis |
|
| P341 | [P341] LIMITED IMPACT OF IFN-γ TESTING AND TB CHEMOPROPHYLAXIS OF HIV POSITIVE PATIENTS ON TB INCIDENCE IN SOUTH EAST LONDON Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P341 E Hamlyn, K Childs, L Campbell, R Barker, P Easterbrook, F Post Whereas potentially useful for the diagnosis of patients with HIV/latent TB, widespread IFN-γ testing and chemoprophylaxis of HIV+ patients is unlikely to have a major impact on TB control in SE London. |
| P342 | [P342] CENTRAL NERVOUS SYSTEM TUBERCULOSIS: A REVIEW OF 34 CASES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P342 C Afonso, N Janeiro, P Pacheco, A Mello, R Badura, F Antunes No significative differences were found between the two groups of patients. CSF demonstrated high variability in cellular count and, surprisingly, neutrophilic predominance in the majority of cases. No correlation was found between mortality and HIV infection or with severity of disease at presentation. |
| P343 | [P343] TUBERCULOSIS IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P343 Farahnaz Almasi Coinfection of tuberculosis and HIV is a well known entity. It’s incidence in our patients was 14% which is important and preventable by chemoprophylaxis. More than 50% of cases suffered from pulmonary tuberculosis and 60% of them had positive sputum smears which shows importance of tuberculosis in HIV infected patients as a public health treatening infection. |
| P344 | [P344] IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME OF TUBERCULOSIS AMONG HIV-INFECTED PATIENTS RECEIVING ANTITUBERCULOUS AND ANTIRETROVIRAL THERAPY IN A NORTH DUBLIN INNER CITY HOSPITAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P344 Nicholas S Chew, Eimear Brannigan, Catherine Nugent, Gerard Sheehan, John Lambert The incidence of IRIS was 25% in the study period. IRIS was more likely to occur when ART was initiated within 6 weeks of MTB treatment and in those with extra-pulmonary MTB infection. All IRS cases were mild and responded to conservative measures. |
| P345 | [P345] HIV, TB, AND RADIOBACTER CO-INFECTION: A CASE REPORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P345 Christina Radcliffe, Kaveh Manavi Following treatment with augmentin, the abdominal symptoms improved substantially. The lymphadenopathy partially improved. We believe that this is the first case report of radiobacter lymph node infection and TB infection co-existing in one patient. This is an important case as it highlights an emerging pathogen. Clinicians must be aware of the need to look for more than one infection in HIV positive patients. |
| P346 | [P346] TUBERCULOSIS MANAGEMENT IN DEVELOPMENT INITIATIVES INTERNATIONAL (DII) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P346 James Mayanja Improve data capture system with empahsis on TB. Intesify sensitization of staff and clients on TB at the work place. Procure better quality protective devices for lab staff. Improve feedback mechanisms especially on referred patients. Refer patients you cannot manage well especially MDR TB cases. TB Management willcontinue to be a major area of focus for many years to come in order to reduce morbidity and mortality among DII centre clients. |
| P347 | [P347] A RETROSPECTIVE STUDY OF PATIENTS WITH ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS ADMITTED IN INTERNAL MEDICINE SERVICE IN ALGARVE (PORTUGAL) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P347 José Arduán, Carlos Cabrita, Elena Rios, Paula Fonseca, Pastor S Silva Despite the increase in the patients observed in the acquired immunodeficiency consult (currently, 990 active patients), the percentage of re-hospitalised patients in the past years has reduced, due to HAART and the opening of Outpatient Clinic. Tuberculosis continues to be the most common diagnosis in the hospitalisation, due to this high prevailing pathology in Portugal. Despite noticing a progressive increase in the past few years on the hospitalisation caused by cardiovascular diseases, mellitus diabetes and secondary dislipidemy to HAART, as well as chronic hepatitis disease (by HIV/HVC co-infection) and neoplasies, the number is not significant. |
| P348 | [P348] RE-EMERGING TUBERCULOSIS. ASSESSMENT OF POTENTIAL CORRELATIONS WITH HIV AND OTHER RISK FACTORS, AND BETWEEN IMMIGRANTS AND RESIDENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P348 Roberto Manfredi, Sergio Sabbatani Our 12-y experience sheds light on 2 different T profiles. Local p are often elderly with frequent concurrent disorders and specific risk factors for T, a more frequent HIV infection, and a predominant involvement of sites other than pulmonary, while immigrants are represented by younger p, who develop prevalent lung localization. |
| HIV-Related Infections, Co-Infections and Malignancies - Other |
|
| P349 | [P349] KAPOSI’S SARCOMA IN HIV-INFECTED PATIENTS: CLINICAL REPORT OF 23 CASES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P349 Nuno Marques, Helena Alves, Orlando Marques, José Saraiva da Cunha, António Meliço-Silvestre KS mainly occurred in a male population with a very low immunity status and that were HAART naïve. Pts who developed KS while receiving HAART began treatment with low CD4+ counts. The mortality rate was considerable and treatment with HAART plus chemotherapy was effective (complete or partial remission) in the majority of pts. |
| P350 | [P350] IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH KAPOSI’S SARCOMA. A CASE REPORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P350 E Savio, G Perez, S Cabrera, J Medina The abrupt change in the evolution of the KS after starting HAART concomitant with the increase of the CD4 count is consistent with IRIS. The physicians should be aware of the possibility of KS IRIS |
| P351 | [P351] RELATIONSHIP BETWEEN HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND PERIPHERAL BLOOD MONONUCLEAR CELLS APOPTOSIS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P351 G P Stanczak, J Kowalska, A Ignatowska, T Dyda, J Higersberger, P Pulik, E Firlag- Burkacka, J J Stanczak, A Horban Positive effect of viral replication inhibition by NRTIs was in part depressed by proapoptotic activity of the drugs;PIs antiapoptotic mechanism of the drugs was determined. Suppression of HIV-1 induced apoptosis due to decrease of viral load is affected by toxicities caused by ART. Annexin V-PE assay is reliable and useful for apoptosis studies. |
| P352 | [P352] CHARACTERISTICS OF NON-HODGKIN’S LYMPHOMAS IN HIV PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P352 Roberto Oropesa, Victor Gonzalez-Valles, Jose Perez-Silvestre, Francisco Garcia-Gonzalez, Vicente Abril, Ana Blasco, Mireia Gil, Emilio Ballester, Enrique Ortega Less than half of patients were taking HAART at the moment of diagnosis despite low CD4 counts and previous AIDS criteria in majority of patients. NHL occurring in HIV-infected persons are almost exclusively of the B-cell type with histologic patterns representative of aggressive forms. The prognosis is significantly worse than that observed in the general population. |
| P353 | [P353] FAST PROGRESSION TO AIDS IN PATIENT WITH AUTOIMMUNE POLYENDOCRINOPATHY TYPE I Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P353 Paola Piano, Francesco Ortu, Paolo Serra, Maria Serrau, Paolo E Manconi KS may be seen at any stage of HIV infection even in the presence of a normal CD4+ T cell count. If we consider symptoms of an acute HIV Syndrome on July 2004, we come to conclude that our patient developed a very fast progression to AIDS. We believe that APECED could play an important role on the clinical HIV history of the patient. |
| P354 | [P354] GONORRHOEA, CHLAMYDIA AND SYPHILIS ARE COMMON IN MEN WHO HAVE SEX WITH MEN (MSM), NEWLY DIAGNOSED WITH HIV IN STOCKHOLM, SWEDEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P354 Ulla-Karin Hallgren, Ivar Qvarnstrom, Fredrik Pettersson, Gun Malmlov, Svante Nielsen, Goran Bratt, Anders Karlsson Venhälsan There is an ongoing spread of HIV in parallell to other STIs among MSM in Stockholm. Gonorrhoea, Chlamydia and syphilis occur frequently at HIV-diagnosis, are often asymptomatic and might be of importance for the spread of HIV. In partner notification, the patient should always be tested for all STIs in all locations, regardless which infection he is traced for. MSM with a history of syphilis have a high risk of becomming HIV-infected. |
| P355 | [P355] OUTBREAK OF SYPHILIS BUT NOT OF ACUTE HEPATITIS C AMONG HIV-INFECTED HOMOSEXUAL MEN IN MADRID Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P355 Andres Ruiz-Sancho, Pablo Barreiro, Carol Castellares, Belen Ramos, Maite Gutierrez, Juan Gonzalez-Lahoz, Vicente Soriano Syphilis remains an important public health problem among HIV-infected individuals engaged in sexual risk behaviours, mainly MSM, despite attending regularly HIV clinics and being on HAART. In the recent outbreak of syphilis among MSM in Madrid, the incidence of acute hepatitis C remains low compared to other European large cities. However, it may become an emerging problem in the near future if a “founder” effect occurs from an HCV/HIV-coinfected MSM engaged in risky practices. |
| P356 | [P356] QUARTERLY SYPHILIS TESTING IS VERY COST-EFFECTIVE FOR A LATINO HIV COMMUNITY CLINIC Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P356 Daniel D Pearce Routine quarterly syphilis screening of HIV patients was greater than 2.5 times less costly in finding a positive RPR and an RPR of interest than the standard of care methods employed by the adjacent GMC. Since the strategy of checking RPR quarterly was quite cost-effective in the HIV clinic we recommend a more frequent periodic screening strategy than annually be considered for all US HIV clinics. |
| P357 | [P357] DECREASE OF BONE MINERAL DENSITY AND PLASMA LEVELS OF RANKL, OPG AND TRAIL IN HIV-1 ANTIRETROVIRAL-NAÏVE INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P357 Marco Borderi, Francesco Chiodo, Davide Gibellini, Maria Carla Re, Fabio Vescini This study indicated that in HIV-1 positive patients: i) the up-regulation of TRAIL and OPG is significantly detectable; ii) high RANKL plasma levels are correlated with reduction of lumbar BMD; iii) a low OPG/RANKL ratio is related to low BMD values. RANKL may act on HIV-1 related BMD decrease in the presence of low OPG/RANKL ratio suggesting an interesting mechanism for osteoporosis/osteopenia in the course of HIV-1 infection. |
| P358 | [P358] TROPICAL SPASTIC PARAPARESIS IN A PATIENT WITH HIV-1 INFECTION: FIRST CASE REPORTED FROM GREECE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P358 Vassilios Papastamopoulos, Ioannis G Baraboutis, Panagiota Stasinopoulou, Georgiou Ourania, Skoutelis T Athanasios In HTLV-I infected patients, the risk of developing TSP is quite small. Nevertheless, coinfected patients are more likely to develop neurological disease than HIV-1 monoinfected patients. This is the first case of HIV-1/HTLV-I coinfection in Greece and the first case of TSP irrespective of HIV status. |
| Paediatric Infections |
|
| P359 | [P359] VIRAL LOAD BLIPS IN HIV-INFECTED CHILDREN FROM THE CHIPS COHORT: WHAT DO THEY MEAN? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P359 D Shingadia, K J Lee, D Pillay, A S Walker, G Tudor-Williams, M Sharland, A Judd, D M Gibb Blips are relatively common among children on HAART, occurring more frequently in those starting HAART at younger ages, on PI (mostly NFV) or 2nd-line, and after longer suppression. They do not appear to impact CD4, CD8 or risk of subsequent virological failure; natural variation, assay effects and adherence may all play a role. |
| P360 | [P360] EMERGING MULTI-DRUG RESISTANCE IN CHILDREN WITH PERINATALLY ACQUIRED HIV-1 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P360 C Foster, N Mackie, P Seery, S Walters, G Tudor-Williams, H Lyall Perinatally infected children with MDR HIV living in the UK urgently require access to novel salvage therapies to survive. |
| P361 | [P361] EFFICACY OF TIPRANAVIR ORAL SOLUTION CO-ADMINISTERED WITH LOW DOSE RITONAVIR (TPV/R) IS SIMILAR IN ALL AGE GROUPS OF CHILDREN AND TEENAGERS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P361 C Giaquinto, G Notheis, M Della Negra, A Jelaska, J Mikl Azienda TPV/r therapy resulted in virological responses in children aged 2-18 years at Week 48. TPV/r is a promising potent therapeutic option for ARV experienced children and teenagers of all ages. |
| P362 | [P362] SEXUAL BEHAVIOUR OF HIV-INFECTED ADOLESCENTS IN THE UK Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P362 Rashida Ferrand, Elizabeth Kirkpatrick, Nahum de Esteban, Eva Jungmann HIV-infected adolescents are a socially vulnerable group and are practising unsafe sex. There is significant risk of transmission of resistant HIV strains. Ongoing assessment of sexual activity should be an integral part of HIV care services for young people. Provision of sexual health services including contraceptive services to HIV-infected adolescents needs to be improved. |
| P363 | [P363] LATE PRESENTATION OF HIV INFECTION AMONG ADOLESCENTS IN ZIMBABWE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P363 Rashida Ferrand, Filda Bwakura, Hilda Mujuru, Ruedi Luthy, Robert Miller, Elizabeth Corbett HIV-infected adolescents were profoundly immunosuppressed, stunted and living in precarious circumstances. The high prevalence of stunting infers infection early in life and the equal sex distribution and high incidence of parental and sibling mortality are consistent with long-term survival after vertical transmission. Further research into burden, aetiology, and psychological needs of adolescents with symptomatic HIV disease is needed. |
| P364 | [P364] FIVE-YEAR OUTCOME IN 19 HIV-1-POSITIVE CHILDREN TREATED WITH 2 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS + NELFINAVIR AS FIRST LINE PROTEASE INHIBITOR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P364 Bernd Buchholz, Steffen Hien, Matthias Beichert, Matthias Dürken, Walter Nützenadel Anti-retroviral therapy with NFV as first line PI in combination with 2NRTI was well tolerated and the antiviral activity was excellent for 3 years, but decreased thereafter. |
| P365 | [P365] TDM OF EFAVIRENZ AS A TOOL OF ADHERENCE IN HIV-INFECTED CHILDREN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P365 Raffaella Rosso, Antonio Di Biagio, Chiara Dentone, Ernestina Repetto, Alessandra Mularoni, Paola Villani, Claudio Viscoli Our small data highlights the importance of TDM as simple and effective tool for monitoring adherence, above all in children, where clinicians usually understimate their compliance. |
| P366 | [P366] PREDICTED PHARMACOKINETICS OF LOPINAVIR AFTER MULTIPLE DOSE ADMINISTRATION OF LOPINAVIR/RITONAVIR TABLET TO PEDIATRIC PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P366 Wei Liu, Cheri E Klein, Kennan C Marsh, Lisa E Hernandez, Barry M Bernstein, George J Hanna These simulations suggest that there is a limited range of pediatric BSA for which the intact tablet provides clinically appropriate LPV exposure. As the tablet should not be crushed or broken, the development of a pediatric strength tablet is warranted to provide dosing flexibility for this population |
| P367 | [P367] ROUTINE ADDITION OF HIGH-DOSE CO-TRIMOXAZOLE TO THE TREATMENT OF SEVERE PNEUMONIA IN YOUNG INFANTS IN HIGH PCP-BURDEN RESOURCE-LIMITED COUNTRIES MAY BE HELPFUL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P367 V K Pandey Interestingly a 13.7% drop in mortality was noted by routine use of high-dose cotrimoxazole in target group; but not statistically significant. Recommendation to add cotrimoxazole routinely to treatment of severe pneumonia in infants <6 months in high HIV prevalence settings may be of value but needs further studies. |
| P368 | [P368] EARLY PROTEASE INHIBITOR-SPARING TRIPLE THERAPY IN VERTICALLY HIV-1-INFECTED INFANTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P368 Marc Hainaut, Dimitri Van der Linden, Tessa Goetghebuer, Véronique Schmitz, Philip Maes, Edwige Haelterman, Jack Levy Early initiation of treatment with 3 reverse transcriptase inhibitors appeared to be highly effective and well tolerated in this cohort of vertically HIV-1-infected infants. Parental adherence is crucial to the effectiveness of therapy. |
| P369 | [P369] FACTORS WHICH INFLUENCE VACCINATION EFFECTIVENESS IN HIV-INFECTED CHILDREN ON ART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P369 Agnieszka Oldakowska, Magdalena Marczynska, Malgorzata Szczepanska-Putz Intensive hepatitis B vaccination protocol used resulted in protective antibody levels in 76% of patients, comparing to less than 50% after measles vaccination. Time since last vaccination, age of the beginning of HAART (for both vaccines) and additionally for HBV vaccination CD4% at evaluation and have been identified as important influences. |
| P370 | [P370] LONGITUDINAL ASSESSMENT BY QUANTITATIVE ULTRASONOGRAPHY IN HIV INFECTED CHILDREN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P370 Raffaella Rosso, Arianna Parodi, Chiara Torrisi, Antonio Di Biagio, Manuela Izzo, Emanuele Malfatto, Marina Vignolo, Claudio Viscoli We assume that this result is partly due to a delay in development that happens in pts; antiretroviral exposure and lipodystrophy can determine a worse bone quality in pts. |
| P371 | [P371] SALVAGE THERAPY IN PERINATALLY ACQUIRED HIV INFECTION: FIRST UK EXPERIENCE OF TMC114 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P371 A Bamford, C Foster, NE Mackie, H Lyall, S Walters, G Tudor-Williams TMC114 and T20 with optimised background therapy has successfully been used as salvage therapy in adult patients. This case illustrates the need for paediatric pharmacokinetic data, and access to novel therapies to achieve salvage. |
| P372 | [P372] URGENT NEED FOR PEDIATRIC ANTIRETROVIRAL THERAPY IN RURAL INDIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P372 Victoria Wilkins, Ann Melvin, Fr Raja, M Ganesh, NM Samuel We have identified extremely vulnerable pediatric HIV/AIDS population in Warangal District. 35% of these children qualify for ART by WHO guidelines. Bulk of funding for HIV/AIDS in India goes to adults in urban centers. It is crucial that provision of antiretroviral therapy in India be extended to pediatric, rural & semi-rural populations. Will allow children to return to school. We are developing ART strategies that are appropriate for pediatric populations in India. |
| P373 | [P373] BARRIERS TO THE DEVELOPMENT OF A PEDIATRIC FORMULATION OF SAQUINAVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P373 Maria Bachynsky, Martin Infeld, Wantanee Phuapradit, Navnit Shah, Neil Buss, Lucille Donatacci Research continues into the bioavailability and palatability of opened SQV mesylate capsules and ritonavir in sugar syrup or other vehicles in adult volunteers. If results are positive, a pediatric study using this approach is planned. |
| P374 | [P374] IS THERE A NEED FOR A DEDICATED WEBSITE FOR HIV-POSITIVE ADOLESCENTS LIVING IN THE UK? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P374 Eva M Jungmann, Katia Prime, Caroline Foster Preliminary results of this survey of young people living with HIV showed excellent access to the internet but little use of it to gain information about HIV. There is a need to facilitate access to useful youth-friendly information on the internet on all aspects of living with HIV including antiretroviral therapy and self-management. |
| Mother-to-child Transmission |
|
| P375 | [P375] TRANSMISSION OF CELL FREE HIV-1 RNA THROUGH BREAST FEEDING: A PILOT STUDY IN CHENNAI, INDIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P375 R Radhakrishnan, S Mini Jacob, S Kavitha Daniel, NM Samuel This is the first follow up study undertaken in India to estimate cell free HIV-1 RNA in plasma and breastmilk. It was observed that mothers with high levels of CFV in their breast milk and plasma upto 6 months were more likely to transmit HIV-1 through breastfeeding. Further studies are needed to prove that the high CFV in plasma and breast milk increase the breast feeding transmission. |
| P376 | [P376] DIFFERENT RATES OF EARLY VIRAL LOAD REDUCTION WITH NEVIRAPINE OR LOPINAVIR/RITONAVIR-BASED COMBINATION ANTIRETROVIRAL THERAPIES IN PREGNANT WOMEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P376 Charlotte Bell, Noreen Desmond, Graham P Taylor Although time to first on-therapy viral load was slighty shorter for women on nevirapine this was not statistically signicant. Despite more advanced disease (based on CD4 cell counts) HIV viraemia declined more rapidly in women taking nevirapine than in those taking Kaletra. This may have implications for when to start therapy in pregnancy and for long-term outcomes. |
| P377 | [P377] HIV IN PREGNANCY: EXPERIENCE FROM A LONDON TEACHING HOSPITAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P377 Shalini Andrews, Mark R Pakianathan, Phillip Hay 40% were diagnosed with HIV for the first time in pregnancy. 32% of these had CD4<200. We significantly improved screening for sexually transmitted infections. More women used combination therapy and had viral load <50 but this was not associated with more vaginal deliveries. This study emphasises the importance of antinatal screening for HIV. |
| P378 | [P378] PLACENTAL TRANSFER OF LOPINAVIR, SAQUINAVIR, AND RITONAVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P378 Katharina Weizsaecker, Cornelia Feiterna, Jan P Siedentopf, Michael Kurowski, Joachim W Dudenhausen Our results confirm minimal placental transfer of protease inhibitors. Even though our numbers are small, LPV seems to cross the placenta more readily than SQV. While LPV concentrations were far below those recommended for antiretroviral activity, possible toxic and teratogenic effects on the fetus have to be considered. We could also confirm consistently low maternal LPV levels at delivery in women receiving a standard dose of 800/200 mg/d LPV/r. |
| P379 | [P379] THERAPEUTIC DRUG MONITORING (TDM): IS IT OF CLINICAL UTILITY IN HIV+ PREGNANT WOMEN? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P379 Rachel J Caswell, Sheema Doshi, Saye H Khoo, Masa Chaponga, Mary Poulton, Jan Welch, Sarah Gibbon, Candice McDonald, John S Lambert TDM showed varying trough levels on both 3 and 4 BD doses; TDM assisted in clinical management. Further analysis of VL/CD4/race/weight/infant infection in relation to TDM are ongoing. |
| P380 | [P380] NEVIRAPINE USE DURING PREGNANCY: DATA FROM THE ITALIAN TARGET COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P380 E Chiesa, S Fiore, MA Forleo, N Palai, M Fasolo, F Sabbatini, C Tibaldi, F Vichi, T Bini, E Ferrazzi, A d'Arminio Monforte H. Busto In our experience NVP use in pregnancy is not related to higher incidence of toxicity or adverse pregnancy outcomes. AEs occurr mostly in naïve patients, who should be closely monitored. |
| P381 | [P381] A RETROSPECTIVE REVIEW OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN EAST LONDON Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P381 Nicola Lomax, Liat Sarner, Lynne Sivyour, Jane Anderson We have demonstrated that in the majority of pregnancies in this cohort (98%) medical interventions are successful in preventing MTCT of HIV, however there are a small number of complex cases where there is still a real risk of MTCT. In such cases, multidisciplinary team work, early case planning and assessment of the risks is crucial to support these women in an attempt to prevent HIV transmission. |
| P382 | [P382] USE OF ANTIRETROVIRAL THERAPY IN PREGNANCY – HOW HAVE THE BHIVA GUIDELINES CHANGED OUR PRACTICE? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P382 Kimberley M Forbes, Simon Limb, Jennifer Swan, Penelope Thomas We have observed an increase in the use of PIs, conceptions on established ART, vaginal deliveries and the use of non AZT containing regimes. Both the use of Zidovudine monotherapy and the numbers of emergency cesarean sections have fallen over the study period. |
| P383 | [P383] PHARMACOKINETICS (PK), SAFETY, TOLERABILITY AND EFFICACY OF BOOSTED SAQUINAVIR 500MG FILM COATED TABLETS IN A REGIMEN OF 1000/100MG BID PLUS 2 NUCLEOSIDE ANALOGUES (NRTIS) IN HIV+ PREGNANT WOMEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P383 MY Tung, M Boffito, S Taylor, JM Short, SE Gibbons, D Back, W Khan, DA Hawkins SQV/r was well tolerated by the majority of women during pregnancy with no cases of mother-to-child transmission. SQV 500mg tablet PK assessments suggest that effective SQV exposures are delivered throughout the day using SQV/r 1000/100mg bid. |
| P384 | [P384] HEMOGLOBIN AMONG HIV-1-INFECTED PREGNANT WOMEN IN RURAL INDIA ACCORDING TO ANTIRETROVIRAL PROPHYLAXIS REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P384 Shoba Dharmarajan, NM Samuel, Parameshwari Srijayanth, James Bethel, Hannah Vanhook, Mini Jacob, Viju Junankar, Doreen Collin, Jennifer Read Rural Indian women who received ZDV for MTCT prophylaxis were less likely to be anemic at 2moPP than women who did not receive such prophylaxis. These results support the safety of ZDV prophylaxis in this population. |
| P385 | [P385] PARTICULARITIES OF MOTHER-TO-CHILD HIV TRANSMISSION IN GIURGIU COUNTY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P385 Paul Marinescu, Loredana Manolescu, Camelia Sultana, Simona Ruta Because preventing HIV transmission from mother to child imply knowing the HIV status of the pregnant woman we strongly recomand testing to all pregnat women and we signal that the introduction of HIV testing in pregnant women may reveal a new face of HIV infecion in our county. |
| P386 | [P386] SEVERE NEUTROPENIA AMONG HIV-1-EXPOSED INFANTS ACCORDING TO MATERNAL ANTIRETROVIRAL PROPHYLAXIS REGIMEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P386 Mini Jacob, Parameshwari Srijayanth, Shoba Dharmarajan, NM Samuel, Doreen Collins, Sonia Stoszek, Viju Junankar, James Bethel, Jennifer S Read Neutropenia at birth was relatively common among these infants of HIV-1-infected mothers, irrespective of ARV Pr regimen, but was transient and without clinical sequelae. |
| P387 | [P387] INTRACYTOPLASMATIC SPERM INJECTION (ICSI) FOR HIV COUPLES: OUR RESULTS WITH TESTED NEGATIVE CRIOPRESERVED SPERM SAMPLES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P387 Francesca Vichi, Claudio Blé, Claudia Livi, Elisabetta Chelo, Francesco Mazzotta HIV serodiscordant couples who undergo IVF-ICSI to avoid disease transmission experience good rates of success, but also encounter complications from assisted reproductive technology similar to traditional patients. |
| P388 | [P388] THE CLINICAL OUTCOME OF PROPHYLAXIS OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN SERBIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P388 Spaso M Andjelic, Bojan V Vasic, Relja R Lukic, Gordana J Dragovic Results from our PMTCT Center showed that intravenous usage of AZT during delivery and Cesarean Section reduces entirely the risk of MTCT of HIV. |
| P389 | [P389] ANTIRETROVIRAL RESISTANCE MUTATIONS AMONG HIV-POSITIVE PREGNANT WOMEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P389 James Mayanja Genotyping mutations associated with AZT resistance were seen i in 20% of pregnant women with increasing plevalence during the observation period and an association with length of drug exposure. ARV resistance to multiple agents were rare among pregnannt women in this cohort. Continued serveillance is going on as is the analysis of genotyping and the subsequent clinical course among infected children. |
| P390 | [P390] PREVALENCE AND FACTORS AFFECTING HUMAN IMMUNODEFICIENCY VIRUS SEROSTATUS DISCLOSURE AMONG PREGNANT WOMEN RECEIVING PREVENTION OF MOTHER-TO-CHILD TRANSMISSION SERVICES IN DAR ES SALAAM, TANZANIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P390 Annette A Almeida, Majigo V Mtebe, Japhet Z Killewo, Protas O Ndayanga The major barrier to disclosure is fear of negative outcomes however; multiple partners, loss of marriage and religion (Muslim) contribute to poor disclosure of HIV serostatus. |
| New Treatments and Targets |
|
| P391 | [P391] SWITCHING TO SAQUINAVIR 500MG-BASED REGIMENS MAINTAINS ANTIRETROVIRAL EFFICACY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P391 Tabitha Mahungu, Jayne Ballinger, Leonie Swaden, Colette Smith, Mike Youle, Margaret Johnson S500/r-based regimens are well tolerated in both treatment-naïve and treatment experienced patients. Switching experienced patients from S200 to S500 does not lead to virological rebound. |
| P392 | [P392] SAFETY AND ANTIVIRAL ACTIVITY OF THE NOVEL CCR5 ANTAGONIST APLAVIROC IN COMBINATION WITH ZIDOVUDINE+LAMIVUDINE IN HIV-INFECTED THERAPY NAÏVE SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P392 Judith Currier, Adriano Lazzarin, Joerg P Kleim, Helen Steel, Judith Millard, Tab Bonny, The ASCENT Study Team While target plasma concentrations of APL were achieved, the antiviral activity of APL as part of a triple drug regimen did not appear to be comparable to COM+EFV. However, the occurrence of idiosyncratic hepatotoxicity precluded further investigation of APL. |
| P393 | [P393] SELECTIVE SUPPRESSION OF R5 HIV-1 BY THE NOVEL CCR5 ANTAGONIST MARAVIROC (MVC) IS ASSOCIATED WITH MAINTENANCE OF CD4 CELL COUNTS IN ANTIRETROVIRAL-EXPERIENCED PATIENTS (PTS) INFECTED WITH DUAL/MIXED-TROPIC (D/M) HIV-1 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P393 Elna van der Ryst, Howard Mayer, James M Goodrich, Karen Turner, John F Sullivan, Paul Simpson, Mike Westby Selective suppression of R5 variants by MVC in pts with a D/M phenotype is not associated with CD4 cell decline and may differ from those where an X4 phenotype emerges “naturally”. |
| P394 | [P394] SAFETY AND ANTIVIRAL ACTIVITY OF THE NOVEL CCR5 ANTAGONIST APLAVIROC IN COMBINATION WITH LOPINAVIR/RITONAVIR IN HIV-INFECTED THERAPY NAÏVE SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P394 Patrick Yeni, Anthony LaMarca, Sam Madison, Garrett Nichols, Judith Millard, Deb McCarty, Tab Bonny, The EPIC Study Team While not powered to show significant differences between treatments, a trend towards less activity of the dual combination of APL+LPV/r than COM+LPV/r was seen. The occurrence of idiosyncratic hepatotoxicity precluded further study of APL. |
| P395 | [P395] EFFICIENCY AND SAFETY OF PHOSPHAZID IN CIRCUIT OF HAART IN HIV-INFECTED TREATMENT-NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P395 Alexei V Kravchenko, Natalya Yu Gankina 2 circuits HAART, including PhAZT (2 NRTI + NNRTI or PI), at HIV-infected treatment-naïve pts were equally effective. 27% of pts have stopped treatment within the first 6 months of therapy, but only in one case as a result of the adverse event. In other cases cancellation HAART has been caused by refusal of pts of treatment, because of return to intravenous introduction of drugs. |
| P396 | [P396] ANTI-PLATELET ACTIVATING FACTOR (PAF) EFFECTS OF HAART: A NEW INSIGHT IN THE DRUG THERAPY OF HIV INFECTION? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P396 A B Tsoupras, M Chini, A Lioni, N Tsogas, C A Demopoulos, S Antonopoulou, M C Lazanas Several anti-HIV drugs and their combinations exhibit antagonistic effect against PAF-induced platelet aggregation. They also inhibit the de novo biosynthetic route of PAF. The promising in vitro results need to be further studied and confirmed by in vivo tests, in order to optimize the efficacy of HAART. |
| P397 | [P397] EFFICACY OF NEW ZINCATE MACROCYCLIC POLYAMINES IN BLOCKING HIV-1 CXCR4-TROPIC ISOLATES IN VITRO Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P397 M Lo Cicero, F Sirianni, S Ferramosca, A Scozzafava, M Galli, C T Supuran, S Rusconi Considering their in vitro high antiviral activity in infections mediated by both FI-sensitive and -resistant isolates, these 4 zincate macrocyclic polyamines represent a new promising class of co-receptor inhibitors that warrant further investigation for future use in clinical practice. |
| P398 | [P398] STUDY OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) VARIANTS OBTAINED BY LONG-TERM PASSAGING IN PRESENCE OF NEWLY SYNTHESIZED 4-HYDROXYCOUMARINS (4-HC) WITH ANTI-HIV ACTIVITY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P398 Sevda Raleva, Albena Iordanova, Yana Gradinarova, Alexey Savov, Raina Gavazova, Liliana Froloshka, Petya Genova, Ilia Manolov, Daniela Dundarova, Radka Argirova 2-LTR rings are described to be typical for HIV-1 integrase mutants. The mutation(s) observed were not reversible after 17 passages without IM-7 pressure. The mutant(s) obtained are subjected to further analysis. |
| P399 | [P399] EVALUATION OF AQUEOUS EXTRACT OF BABOOL PODS FOR IN VITRO ANTI-HIV ACTIVITY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P399 Tabassum A Khan, Pratima A Tatke, Satish Y Gabhe The aqueous extract of Acacia nilotica pods possess a significant inhibitory activity against the viral enzyme Reverse Transcriptase. These results provide a rationale for conducting bioactivity-guided fractionation of the aqueous extract of Acacia nilotica pods and structure elucidation of the active molecules. |